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Abstract 
The rise in antimicrobial resistance combined with the decline in antibiotic 
discovery has put antibiotic therapy at risk. As a result, there is an urgent 
need for new antibiotics. Microbial secondary metabolites are a major 
source of industrially and medically significant compounds. Most of the 
antibiotics used in the clinic are derived from secondary metabolites 
produced by streptomycetes. Even though streptomycetes were thought to 
be mined to exhaustion, advances in genome sequencing and genome 
mining has revealed the presence of the untapped wealth of secondary 
metabolite encoding biosynthetic gene clusters harboured in their genomes. 
Developing strategies to awaken these silent gene clusters along with 
understanding the biosynthesis of these natural products is therefore of 
great importance. 
 
In this work, five gene clusters were targeted in S. albus S4 to generate a 
new heterologous host, which is hoped to aid in the research efforts for new 
antimicrobials. Activation of silent gene clusters hold great potential in the 
discovery of new and useful compounds. The genome of S. albus S4 
harbours many silent gene clusters. In this study, pleiotropic approaches 
were used to switch on the production of an antibacterial compound(s) in S. 
albus S4. Bioinformatic analyses of the spectral data obtained from the 
chemical extracts identified surugamides within the chemical extract. As 
surugamide A was previously reported to have antibacterial activity, its 
bioactivity profile was further investigated. Surugamides belong to the family 
of non-ribosomal peptides. Non-ribosomal peptides constitute a major class 
of natural products with diverse activities ranging from antibacterials to 
immunosuppressants. Atypical to canonical non-ribosomal peptide 
synthetase systems, the surugamide gene cluster lacks a cis-acting release 
mechanism responsible for the release of the cyclic and linear peptides it 
encodes the production for. In this work, a trans-acting standalone release 
factor was identified and its in vitro activity was also investigated.  
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Chapter 1 Introduction 
1.1 A brief history of the discovery of antibiotics  
The discovery and use of antibiotics is rightfully considered to be one of the 
greatest medical accomplishments of all time. The clinical availability of 
these therapeutics led to dramatic reductions in morbidity and mortality 
rates, enabling giant leaps in modern medicine. Without the treatments that 
we have in place through antibiotics, many of the medical achievements 
such as surgery and organ transplantations that we take for granted today, 
would not be possible (Rubin, 2007; Lewis, 2013). Though the term antibiotic 
is associated with the modern era, there is historical evidence of ancient 
civilisations using naturally available sources such as plants and moulds for 
the treatment of infections (Awad et al., 2012). Surprisingly, traces of the 
modern antibiotic tetracycline was even detected in the skeletal remains of 
an ancient Sudanese tribe that date as far back as 350 A.D, with the rate of 
infectious diseases recorded in this population as low (Bassett et al., 1980; 
Nelson and Levy, 2011). Detection of tetracycline in this group was not an 
isolated event, with skeletal samples from the Roman period in the Dakhleh 
Oasis in Egypt also revealing traces of tetracycline (Cook et al., 1989). 
Therefore, contrary to the thought that the exposure to and use of antibiotics 
are confined to the modern ‘antibiotic era’, there are historic examples of the 
use of antimicrobials in ancient civilisations (Bassett et al., 1980; Cook et al., 
1989; Aminov, 2010; Awad et al., 2012; Gould, 2016).  
 
The beginning of the modern ‘antibiotic era’ is associated with the names of 
Paul Ehrlich (1854 – 1915) and Alexander Fleming (1881 – 1955) (Rubin, 
2007; Valent et al., 2016; Gould, 2016). Ehrlich’s work on investigating 
pathogen specific antibacterial properties of dyes led to the discovery of 
arsenic-based Salvarsan, which despite its side effects, was the first modern 
chemotherapeutic agent to be employed and was used in the treatment of 
syphilis- an incurable disease at the time (Bosch and Rosich, 2008; Valent et 
al., 2016). Following on from Ehrlich’s work on the effect of azo dyes on 
microbes, Josef Klarer and Fritz Mietzsch synthesised 
sulfonamidochrysoidine to demonstrate its antibacterial potential (Rubin, 
2007). It was then through the efforts of Gerhard Domagk who demonstrated 
the in vivo efficacy of this sulfa drug in a murine model of Streptococcus 
- 2 - 
pyogenes systemic infection that it was marketed as Prontosil in 1935 to 
treat streptococcal and staphylococcal infections (Rubin, 2007). Further work 
carried out on Prontosil revealed its sole active component to be 
sulfanilamide, a known moiety at the time but not as an antibacterial, 
bringing sulfonamide drugs to the frontline (Rubin, 2007). 
 
The serendipitous discovery of penicillin by Fleming from the filamentous 
fungus, Penicillium notatum in 1928, and the demonstration of its in vivo 
antibacterial efficacy by Florey and Chain and later, the industrialisation of 
penicillin production in the 1940s, marked the beginning of the Golden Age 
of antibiotic discovery (Fleming, 1929; Chain et al., 1940; Fernandes, 2006; 
Rubin, 2007). The discovery platform introduced by Selman Waksman, a soil 
microbiologist, in the 1940s led to the discovery of majority of the antibiotic 
classes in use today and contributed to this rich period of discovery (Lewis, 
2013). Waksman’s discovery platform involved screening soil derived 
actinomycete bacteria for antimicrobial activity against an indicator organism 
by looking for the presence of zones of inhibition in growth on overlay plates 
(Schatz et al., 1944). The term ‘antibiotic’ was coined in 1941 by Waksman 
and was used to describe any microbial product that antagonised the growth 
of another microbe. Today, any natural, synthetic or semi-synthetic 
compounds that can target and oppose microbial growth are referred to as 
antibiotics (Rubin, 2007; Clardy et al., 2009; Aminov, 2010; Davies and 
Davies, 2010). Waksman’s discovery of the aminoglycoside streptomycin in 
1944 from the soil dwelling actinomycete Streptomyces griseus and the 
efficacy of streptomycin in the treatment of tuberculosis spurred on research 
efforts worldwide for the discovery of new antibiotics (Schatz et al., 1944; 
Rubin, 2007). Waksman’s bioactivity-guided screening platform brought the 
phylum Actinobacteria into the limelight as prolific antibiotic producers and 
as a result, they were extensively mined for new antibiotics (Zaffiri et al., 
2012). The discovery of many antibacterial classes in use today such as the 
b-lactams, tertracyclines, aminoglycosides and glycopeptides ensued during 
this rich period of discovery (Davies and Davies, 2010; Nelson and Levy, 
2011; Lewis, 2013).  
 
With the discovery and implementation of antibiotics, significant progress 
was made in managing infectious diseases (Clardy et al., 2009). Most 
antibiotics in use today are derived from natural products or secondary 
metabolites produced by bacteria and fungi (Davies and Davies, 2010; 
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Lewis, 2013). These small molecules are termed secondary metabolites as 
they are considered to be non-essential for the survival of the producing 
organism but often confers upon the organism many survival advantages 
such as by increasing the nutrient availability (e.g. siderophores) or providing 
the organism with competitive or defensive advantages (e. g. via antibiotics) 
(Davies and Davies, 2010). The evolution of these secondary metabolites 
with high specificity for single targets makes them highly medically desirable. 
These natural products have been the primary source of majority of the 
drugs in the clinic today (Clardy et al., 2006; Butler and Buss, 2006; 
Newman and Cragg, 2012).  
1.2 Actinobacteria  
Actinobacteria represent one of the largest taxonomic units among the major 
lineages currently recognised within the domain Bacteria. They are Gram-
positive, high G+C, filamentous bacteria (Ventura et al., 2007; Barka et al., 
2016). Actinobacteria are mostly comprised of environmental bacteria and 
are found in a wide range of habitats: soils, marine, rhizosphere and highly 
arid environments (Barka et al., 2016). Bacteria belonging to this phylum are 
a major component of the microbial population within the soil. (Hopwood, 
2007; Ventura et al., 2007; Miao and Davies, 2010; Thaker et al., 2013; Liu 
et al., 2013; Barka et al., 2016). Many secondary metabolites produced by 
actinomycetes have a broad spectrum of activities that are clinically and 
economically relevant. Their bioactivities range from antibacterial 
(streptomycin, chloramphenicol), to antifungal (nystatin) to antiviral 
(tunicamycin) to anticancer (doxorubicin, bleomycin), to antiparasitic 
(avermectin) to immunosuppressive (rapamycin) properties (Chaudhary et 
al., 2013). Genera of Actinobacteria such as Streptomyces, Salinispora, 
Amycolatopsis and Saccharopolyspora are talented producers of natural 
products and account for over two-thirds of all the clinically relevant 
antibiotics and anticancer drugs in use today (Ventura et al., 2007; Miao and 
Davies, 2010; Davies and Davies, 2010; Barka et al., 2016). Within the 
Actinobacteria phylum, streptomycetes account for over 70% of all the 
antibiotics produced (Bibb, 1996; Awad et al., 2012). Only the Streptomyces 
genus will be further explored in this chapter.  
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1.3 Streptomyces 
Streptomycetes are sporulating saprophytes, which are ubiquitous in soils 
worldwide and are competitive inhabitants of aquatic and marine 
ecosystems (Challis and Hopwood, 2003). They are non-motile, and as a 
consequence, are exposed to many stressful conditions (Challis and 
Hopwood, 2003). The production of complex secondary metabolites that 
possess antibacterial, antifungal, anti-parasitic, antiviral or other bioactive 
properties for self-preservation are believed to contribute to their remarkable 
success in the soil (Bibb, 1996; Challis and Hopwood, 2003; Awad et al., 
2012). These developmentally complex bacteria generally produce the 
antibiotics in a growth phase dependent manner when they switch from their 
vegetative growth phase to aerial growth phase in response to detection of 
signals such as nutrient depletion or other environmental stress signals 
(Figure 1) (Bibb, 1996; Challis and Hopwood, 2003; Chater, 2006; Hopwood, 
2007; de Lima Procópio et al., 2012).  
 
Under favourable conditions and nutrient availability, a spore germinates to 
give rise to germ tubes (Figure 1a). The germ tubes grow by tip-extension 
and branching hypha via mycelial growth to form the vegetative mycelia 
(Flärdh and Buttner, 2009). The branching thread-like hyphae that form the 
vegetative mycelium in the soil coupled with the secretion of hydrolytic 
enzymes such as cellulases and xylanases aid them in scavenging for and 
accessing the nutrients in soil (Flärdh and Buttner, 2009). In response to 
signals such as nutrient limitation, the production of secondary metabolites is 
initiated along with morphological differentiation, whereby the vegetative 
hyphae are broken down and non-branching aerial hyphae break the surface 
tension and grows into the air. The aerial hyphae then form aseptate tip 
compartments, which then septate synchronously to form unigenomic spore 
chains (Chater, 2006; Chater and Chandra, 2006; Flärdh and Buttner, 2009).  
They produce complex secondary metabolites such as antibiotics in the 
oldest vegetative mycelium while exospores are produced from the 
specialised aerial hyphae to aid dispersal and colonization of new 
environments (Bibb, 1996; Flärdh and Buttner, 2009; Liu et al., 2013). 
 
A further refined model of development has been reported for the stages 
prior to the formation of aerial mycelium and sporulation in streptomycetes 
(Figure 1b) (Yagüe et al., 2013). A transitory compartmentalised mycelium 
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(MI) initiates development where a fraction of the MI undergoes highly 
ordered programmed cell death (PCD) (Manteca et al., 2006; Yagüe et al., 
2013). The remaining viable cells differentiate into multinucleated second 
mycelium (MII) where septa are scarce. MII forms the vegetative substrate 
mycelia and undergoes another round of PCD (Yagüe et al., 2013; Yagüe et 
al., 2016). The remaining viable MII hyphae continues to grow until the  
rodlet layer is assembled providing the surface hydrophobicity necessary for 
its escape into air as aerial mycelium (Figure 1b) (Yagüe et al., 2013). 
Secondary metabolism typically occurs in the MII phase (Yagüe et al., 2013; 
Rioseras et al., 2014).  
 
In nature, streptomycetes produce the antibiotics in small amounts during 
their transition stage into the aerial phase at the expense of the nutrients 
available from the breakdown of the vegetative hyphae (Bibb, 1996; Flärdh 
and Buttner, 2009). It is likely that the antibiotics produced help defend their 
food source from other soil microbes (Chater, 2006; Flärdh and Buttner, 
2009). Both morphological differentiation and secondary metabolism are 
also governed by the availability of nutrients such as carbon, phosphorous, 
nitrogen and trace elements and thus, many of the genes that are involved in 
both processes are often interlinked (McCormick and Flärdh, 2012; Yagüe et 
al., 2013). Therefore, morphological differentiation and the production of 
antibiotics in streptomycetes are intrinsically linked (Chater, 2006; Flärdh 
and Buttner, 2009; Liu et al., 2013). For example, sigma factors and 
regulatory components encoded by the bld and whi genes are known to be 
involved in both the regulation of morphological differentiation and 
secondary metabolism  (Bibb, 1996; Chater, 2006; Flärdh and Buttner, 2009; 
Rodríguez et al., 2013). 
 

























Figure 1 The developmental life cycle of streptomycetes. 1a) Under 
favourable conditions, a spore germinates to give rise to germ tubes. 
The germ tubes grow by tip-extension and branching hypha via 
mycelial growth to form the vegetative mycelia. Morphological 
differentiation and the production of secondary metabolites are initiated 
upon detection of some signals including the A-factor, SapB and SapT. 
The vegetative hyphae are then broken down and multi-genomic aerial 
hyphae are produced along with the production of secondary 
metabolites. The aerial hyphae then grow by tip extension and septate 
synchronously to give rise to uninucleiodal spores. The spores are 
then dispersed again and the process repeats (Bibb, 1996; Flärdh and 
Buttner, 2009). 1b) A refined model for the development stages prior to 
the formation of aerial mycelia on solid medium. MI, first 
compartmentalised mycelium; PCD, programmed cell death and MII, 
second multinucleated mycelium (Figure 1a- (Schlimpert et al., 2016); 
Figure 1b-(Yagüe et al., 2013)). 
1a) 
1b) 
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This relationship between morphological differentiation and secondary 
metabolite production is well studied and understood in Streptomyces 
griseus. The autoregulatory factor or A-factor, a hormone like γ-
butyrolactone signalling molecule, produced in S. griseus in a growth-phase 
dependent manner, induces streptomycin production and sporulation 
(Horinouchi and Beppu, 1993; Ohnishi et al., 2005). The γ-butyrolactones 
are widely produced in streptomycetes, but their roles are species-specific 
(Takano, 2006; Flärdh and Buttner, 2009). For example, in the model 
organism of the genus, Streptomyces coelicolor, γ-butyrolactones play a key 
role in regulation of antibiotic biosynthesis but do not seem to be associated 
with differentiation (Takano, 2006; Flärdh and Buttner, 2009). S. griseus 
lacking A-factor is unable to produce streptomycin or spores, but with the 
addition of A-factor at a concentration of 10
-9 
M, is able to regain its wild-type 
phenotype (Horinouchi and Beppu, 1992; Flärdh and Buttner, 2009). The A-
factor in S. griseus exerts its effect on differentiation via the master 
regulator, AdpA- a transcriptional activator of the AraC family. During the 
vegetative growth phase, ArpA (the A-factor receptor protein) blocks adpA 
transcription by acting as a repressor leading to the accumulation of A-factor 
(Yamazaki et al., 2004; Ohnishi et al., 2005). This accumulation of A-factor 
leads to the de-repression of expression of adpA and the activation of the 
AdpA regulon sub-sequentially. AdpA directly targets genes that encode 
important proteins involved in morphological differentiation (Yamazaki et al., 
2004; Ohnishi et al., 2005). These proteins include SSgA- a protein with 
essential roles in sporulation and septation, σ
AdsA
- an exocytoplasmic sigma 
factor that is key in the formation of aerial mycelium and the response 
regulator AmfR, which initiates the SapB biosynthetic operon expression. 
The induced AdpA also activates a number of genes involved in the 
biosynthesis of streptomycin via the activation of strR encoding a pathway-
specific activator of biosynthetic genes involved in streptomycin production 
(Yamazaki et al., 2004; Ohnishi et al., 2005; Flärdh and Buttner, 2009). Both 
differentiation and the production of S. griseus characteristic secondary 
metabolite streptomycin is blocked upon the loss of A-factor (Yamazaki et 
al., 2004; Flärdh and Buttner, 2009).  
 
Early genetic mapping in the model actinomycete, S. coelicolor A3(2), gave 
evidence that the biosynthetic genes involved in the production of any 
specific secondary metabolite are clustered together on the chromosome or 
plasmids (Kirby et al., 1975; Rudd and Hopwood, 1979). The molecular 
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analyses, which followed revealed these clusters to be large (often tens of 
kb) and that they usually include several operons (Bentley et al., 2002; 
Chater, 2006). This knowledge along with the development in technology 
allowed the study of antibiotic biosynthesis regulation at the molecular level, 
shedding further light on the interplay between antibiotic production and 
morphological differentiation (Bentley et al., 2002; Chater, 2006).  
 
Most of the antibiotics in use today are derived from the secondary 
metabolites produced by this remarkable genus of microorganisms (Barka et 
al., 2016). These compounds exert their antimicrobial activities in many 
ways. The common mechanisms of antibacterial action are discussed in the 
next section. 
 
1.4 Common mechanisms of action of antibacterial 
compounds 
Antibacterial compounds work by either killing the bacteria (bactericidal) or 
by the arresting their growth (bacteriostatic). They achieve this by targeting 
and interfering with the bacterial cell wall synthesis, cell membrane, DNA 
synthesis, transcription, translation or the folate pathway (Figure 2) (Wright, 
2010). These mechanisms of action are discussed in this section.  
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1.4.1 Interference with cell wall synthesis 
Agents that interfere with the bacterial cell wall synthesis work by inhibiting 
peptidoglycan (PG) synthesis (Kohansky et al., 2010). Bacterial cells are 
enclosed by PG layers. The mechanical rigidity conferred by this layer of cell 
wall is critical for the bacterium’s survival in environmental conditions that 
may result in the alteration of the existing osmotic pressures (Scheffers and 
Pinho, 2005). The latter steps in the biosynthesis of the cell wall include the 
synthesis of PG subunits made of N-acetylglucosamine linked to N-
acetylmuramic acid with an attached pentapeptide. The subunit is 
transferred across the cytoplasmic membrane to the cell exterior or the 
periplasmic space (Scheffers and Pinho, 2005). The polymerisation of these 
subunits along with their incorporation into the PG layer is achieved via the 
action of the penicillin binding proteins (PBPs), which are responsible for the 
transglycosylation and transpeptidation reactions (Scheffers and Pinho, 
2005). Transglycosylases are involved in the formation of glycosidic bonds 
between the sugars to extend the glycan strands of existing PG monomers 
while the transpeptidases are involved in the cross-link formation between 
adjacent peptide chains while cleaving the two terminal D-alanines in the 
process to form the mature lattice-like PG layer (Scheffers and Pinho, 2005).  
 
The cell wall targeting antibacterial agents work by inhibiting the transport of 
peptidoglycan monomers in the cytosol across the cytoplasmic membrane, 
blocking the formation of peptide cross links by inhibiting the transpeptidase 
or by blocking both the transpeptidase and transglycosylases enzymes 
(Kohansky et al., 2010; Bakheet and Doig, 2015). Two antibacterial classes 
that work by interfering with the cell wall synthesis are β-lactams and 
glycopeptides (Kohansky et al., 2010). β-lactams function by blocking the 
transpeptidation activity of the PBPs. The β-lactam antibiotics share a 
common core made up of a 4-membered cyclic amide ring, which shares 
structural similarity with the PBP substrate D-Ala-D-Ala backbone. As a 
result, the β-lactams are able to bind to the transpeptidase active site and 
block its ability to form the peptide cross-links (Kohansky et al., 2010; Zeng 
and Lin, 2013).  Glycopeptides, on the other hand, work by binding to the D-
Ala-D-Ala at the carboxy terminus of the growing PG thereby blocking 
transglycosylation and transpeptidation through steric hinderance (Kang and 
Park, 2015).  
- 11 - 
1.4.2 Interference with the cell membrane integrity 
Compounds that target the cytoplasmic membrane cause disruption of the 
bacterial cell membrane and as a result, alter the permeability of the cell 
components (Hancock and Chapple, 1999). The bacterial cell membrane 
plays a key role in the survival of the bacteria as it provides selective 
permeability to maintain cellular homeostasis (Epand et al., 2016). Gram-
negative bacteria possess an additional outer membrane rich in 
lipopolysaccharides that are unique to them, imposing an additional layer of 
protection (Epand et al., 2016). The inner monolayer of the outer membrane 
of these bacteria as well as both layers of the cytoplasmic membrane in both 
Gram-positive and Gram-negative bacteria contain the lipid components: 
phosphatidylglycerol, phosphatidylethanolamine and cardiolipin (Epand et 
al., 2016). The polymyxin group of antibiotics exert their antibacterial activity 
against Gram-negative bacteria by binding to lipid A, which is the anchor for 
lipopolysaccharides in the outer membrane, thereby disrupting the 
permeability barrier (Galizzi et al., 1975; Yu et al., 2015; Epand et al., 2016).    
 
1.4.3 Disruption of DNA replication  
Modulation of chromosomal supercoiling through type II topoisomerase 
mediated strand breakage and re-joining is critical for DNA synthesis (van 
Eijk et al., 2017). During DNA replication, two bacterial topoisomerase II 
enzymes- DNA gyrase and topoisomerase IV play essential roles in 
modifying the topology of DNA by controlling the negative and positive 
supercoiling of DNA or by removing knots and tangles during the replication. 
Both DNA gyrase and topoisomerase IV are tetramers composed of two 
subunits each (two GyrA and two GyrB subunits for DNA gyrase and two 
ParC and two ParE subunits for topoisomerase IV) (van Eijk et al., 2017). 
Both DNA gyrase and topoisomerase can modulate the DNA topology by 
generating a transient double stranded break in the double helix, which they 
can then re-ligate. Even though both enzymes follow a similar mechanistic 
way of functioning, their physiological functions vary. DNA gyrase is capable 
of introducing negative supercoils into the DNA while topoisomerase IV 
plays a role in decatenating and removing the knots in DNA (van Eijk et al., 
2017). The quinolone class of antibacterial compounds work by targeting 
DNA gyrase and topoisomerase IV by forming a DNA-topoisomerase-
quinolone complex and strand breaks. If the SOS response and other DNA 
repair mechanisms fail to repair the breaks, it leads to eventual cell death 
(Hooper, 2001; Aldred et al., 2014).  
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1.4.4 Interference with transcription and translation  
The process of synthesising RNA from its template DNA is mediated by the 
enzyme RNA polymerase. In bacteria, a single type of RNA polymerase is 
responsible for all transcription (Ma et al., 2016). Agents that target 
transcription exert their mode of action by binding to the RNA polymerase 
and inhibiting transcription (Kohansky et al., 2010). The rifamycin group of 
antibacterial compounds work by binding to the actively subscribing DNA 
bound RNA polymerase and inhibiting the DNA dependent transcription 
(Floss and Yu, 2005; Kohansky et al., 2010). Many antibacterial compounds 
also work by binding to the bacterial ribosomal subunits and interfering with 
the translation process. The bacterial ribosome is composed of two 
ribonucleoprotein subunits, the 30S subunit, which contains 20 proteins as 
well as the 16S rRNA chain and a large 50S subunit, which consists of 34 
proteins and the 23S and 5S rRNA chains (Mccoy et al., 2011). The 
ribosome together with various other factors are responsible for mRNA 
translation over three steps: initiation, elongation and termination. 
Antibacterial compounds that target the ribosome targets one the following 
three sites: the 30S decoding site, which is responsible for the codon-
anticodon recognition, the peptidyl transferase centre on the 50S subunit or 
the peptide exit channel on the 50S subunit (Kohansky et al., 2010; Mccoy et 
al., 2011). For example, macrolide antibiotics work by blocking the exit 
tunnel of the peptide on the 50S subunit. Aminoglycosides on the other hand 
bind to the 30S decoding site and interfere with codon recognition and 
translocation, and allow the incorporation of incognate amino acids into the 
growing peptide chain (Kohansky et al., 2010; Mccoy et al., 2011).  
 
1.4.5 Disruption of the folate pathway 
Key steps of the folate synthesis pathway are targeted by antibiotics such as 
sulfonamides, which in turn affect nucleotide synthesis, the building blocks of 
DNA and RNA (Murima et al., 2014). Folate is a crucial precursor in the 
biosynthesis of purines, pyrimidines and amino acids. Dihydrofolate 
reductase has an important role in maintaining the cellular pool of 
tetrahydrofolate, an important cofactor required for the synthesis of amino 
acids, purines, S-adenosylmethionine and formyl-methionine. Dihydrofolate 
reductase can therefore act as a target (Murima et al., 2014; Bourne, 2014). 
Another enzyme involved in the folate pathway is dihydropteroate synthase. 
Dihydropteroate synthase is responsible for the production of 7,8- 
dihydropteroate by catalysing the condensation of 6-hydroxymethyl-7,8-
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dihydropterin pyrophosphate with para-aminobenzoic acid (pABA). 
Sulfonamide compounds are analogues of pABA and can act as alternative 
substrates and competitive inhibitors of pABA and result in dead-end 
products (Bourne, 2014; Murima et al., 2014) . 
 
Use of any effective therapeutic agent in the clinic is compromised by the 
potential development of resistance to that agent (Davies and Davies, 2010). 
The evolution of resistance in microbes to most of the front-line antibiotics is 
an urgent matter at hand. The widespread use of antibiotics combined with 
poor stewardship has led to an antibiotic resistance crisis (Davies and 
Davies, 2010). The resistance crisis has in turn put antibiotic therapy in great 
jeopardy (Wright, 2010; Silver, 2011; Livermore, 2011). 
1.5 Mechanisms of antibacterial resistance   
Resistance to antibacterial compounds is achieved mostly via the following 
general mechanisms: i) modifications of the compound itself, ii) target 
modification and/or bypass, iii) global cell adaptive processes and iv) 
prevention from reaching the target either by preventing entry or through 
efflux (Figure 2) (Dever and Dermody, 1991; Tenover and Georgia, 2006; 
Wright, 2010; Munita and Arias, 2016). Alteration of the compound is 
achieved by enzymes that can modify it in such a fashion that it is no longer 
able to interact with the target, or by destroying the compound itself (Munita 
and Arias, 2016). There are many kinds of modifying enzymes that have 
been reported. Regardless of what they are, the modifications are often 
correlated with a higher bacterial minimal inhibitory concentration (MIC) 
usually owed to steric hindrances that lower the avidity of the compound for 
its target (Munita and Arias, 2016). For example, aminoglycoside modifying 
enzymes are able to covalently modify the amino or hydroxyl groups of an 
aminoglycoside molecule and is reportedly the predominant mechanism of 
aminoglycoside resistance worldwide (Munita and Arias, 2016). Destruction 
of the compound to completely render it ineffective is another highly 
successful bacterial resistance strategy. β-lactamases are an important 
example of this where these enzymes are able to hydrolytically cleave the β-
lactam ring, which is essential for the antibacterial action of the compound 
(Dever and Dermody, 1991; Wright, 2010; Munita and Arias, 2016).  
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Changes in target sites are achieved through target protection or target 
modification. An example of target protection is the tetracycline resistance 
determinants TetM and TetO, where both of these proteins are able to 
interact with the ribosome in a GTP-dependent manner to dislodge 
tetracycline to allow protein synthesis to resume (Donhofer et al., 2012; 
Munita and Arias, 2016). Modifications of the target sites may be owed to i) 
mutations in the target site encoding gene (e.g. rifampin resistance), ii) 
bypass or replacement of the target so that new targets now exist to achieve 
a function similar to that of the original target (e. g. vancomycin resistance in 
enterococcus), and/or iii) enzymatic modification of the target (e.g. macrolide 
resistance through methylation of the ribosome) (Wright, 2010; Munita and 
Arias, 2016). The rifamycin antibiotic rifampin works by binding to a rifampin 
binding pocket on the RNA polymerase (encoded by the gene rpoB) blocking 
elongation of the RNA. Rifampin resistance is observed through single point 
mutations in the rpoB gene, which modifies the target and results in a 
decreased affinity of rifampin for its target (Campbell et al., 2001; Munita and 
Arias, 2016). The glycopeptide vancomycin works by interfering with the 
bacterial cell wall synthesis by binding to the terminal D-Ala-D-Ala residues 
of the PG chain preventing further incorporation of the PG subunits leading 
to cell death. Vancomycin resistance is primarily achieved through the van 
gene cluster that is capable of encoding the production of proteins, which 
can remodel PG by replacing the D-Ala-D-Ala to D-Ala-D-lactate/D-serine, 
thereby lowering the affinity of vancomycin to its target (Miller et al., 2014; 
Munita and Arias, 2016). Macrolide resistance is observed through a 
biochemical change via the ribosomal methylation by an enzyme encoded 
by the erm genes (Leclercq, 2002).  
 
Global cell adaptations enable the bacterium to cope with and adapt to 
stressful conditions whereby complex mechanisms are developed in order to 
maintain pivotal cellular process. An example of bacterial resistance that is 
achieved through global cell adaptations is against daptomycin (Munita and 
Arias, 2016). The calcium dependent lipopeptide antibiotic daptomycin 
exerts it antibacterial activity by modifying the bacterial cell membrane 
homeostasis by interfering with its associated phospholipids (Tran et al., 
2015). Daptomycin shares functional and structural similarity to the cationic 
antimicrobial peptides that are produced by the innate immune system. 
Resistance to daptomycin is associated with critical changes in the bacterial 
cell physiology brought about by adaptive changes in the cell wall and cell 
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membrane homeostasis (Tran et al., 2015). Limiting the influx of compounds 
to prevent it from reaching its target is another mechanism of antibacterial 
resistance. This is especially important in Gram-negative bacteria where the 
compounds have to penetrate the outer membrane and/or the inner 
cytoplasmic membrane to exercise its bioactive properties (Wright, 2010; 
Munita and Arias, 2016). Efflux pumps are a mechanism of resistance, which 
affects a wide array of antibacterial classes. They are bacterial machineries 
that are able to extrude the antibacterial compounds out of the cell, which in 
turn results in antibacterial resistance (e. g. tetracycline resistance in E. coli) 
(Wright, 2010; Munita and Arias, 2016).  
 
Antibiotic-producing microbes in nature have always been inherently 
resistant to the antibiotics they themselves produce (Davies and Davies, 
2010). However, the man-made selection pressure in the environment for 
antibiotic resistance has been so strong that the magnitude of resistance 
found in the environment is rapidly changing. The antibiotic resistance gene 
pool, as a result of this selective pressure, has become more accessible to 
microbes (Levy and Marshall, 2004; Alekshun and Levy, 2007; Munita and 
Arias, 2016).  
1.6 The emergence and impact of antibiotic resistance 
A microbiological point of view defines resistance as the state in which an 
isolate has a mechanism of resistance making it less susceptible to an 
antimicrobial agent when compared to other members of the same species 
that lack resistance mechanisms (Cantón and Morosini, 2011). In a clinical 
setting, antibacterial resistance generally refers to the pathogenic bacterial 
population that was originally susceptible to the compound of interest but 
has now become resistant and as a result, the clinical criteria of cure is not 
reached (Turnidge and Paterson, 2007; Munita and Arias, 2016). The 
acquisition or evolution of resistance in microbes to most of the front-line 
antibiotics is a pressing matter that is acknowledged by the highest levels of 
government as a significant threat to global health. The World Health 
Organization considers this crisis to be ‘one of the biggest threats to global 
heath today’ (Davies and Davies, 2010; WHO, 2018).  
 
The overuse and misuse of antibiotics since its deployment has played a 
major role in the evolution of antibiotic resistance (Ventola, 2015). Horizontal 
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gene transfer between bacteria on mobile genetic elements such as 
plasmids have contributed to this greatly where bacteria are able to transfer 
the resistance encoding genes between different species (Ventola, 2015). 
Resistance can also arise through spontaneous mutations (Ventola, 2015; 
Hwang and Gums, 2016). Under the increased selection pressure the 
resistance genes and the hosts that are selected for thrive and multiply and 
spreads it to other hosts and locations (Davies and Davies, 2010). 
Inappropriate prescription and the extensive use of antibiotics in agricultural 
purposes have also contributed significantly to the emergence of resistance 
(Davies and Davies, 2010; Ventola, 2015; Hwang and Gums, 2016). 
Infections caused by microbial agents that were once under control are now 
increasing in incidence due to multi-drug resistance. The most alarming 
examples, and arguably the most costly in regards to morbidity and 
mortality, concern bacteria (Levy and Marshall, 2004; Davies and Davies, 
2010). 
 
The increase in multi-drug resistant (MDR) pathogenic bacteria have 
compromised the treatment of many infectious diseases (Tanwar et al., 
2014). MDR bacteria disrupt disease control by increasing the possibility of 
the dissemination of the resistant pathogens while lowering the efficiency of 
the treatment itself leading to a prolonged infection time in the patient 
(Tanwar et al., 2014). Hospitals across both the developed and the 
developing world are faced with many challenges, epitomized especially by 
a group of pathogens referred to as the ‘ESKAPE’ pathogens (Louis B. Rice, 
2008; Boucher et al., 2009). The ESKAPE group of pathogens include 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter 
species (Louis B. Rice, 2008). These pathogens are common causes of life-
threatening nosocomial infections. They are becoming more and more 
prevalent and becoming increasingly resistant to most or all of the antibiotics 
used in the clinic limiting therapeutic options while increasing morbidity and 
mortality rates (Louis B. Rice, 2008; Boucher et al., 2009).  
 
Enterococci are opportunistic pathogens that can cause highly infectious 
diseases. They are a leading cause of bacteraemia and urinary tract 
infections. The plasticity of their genomes allow them to acquire resistance 
to many antibacterial compounds, which is concerning, particularly 
vancomycin resistant enterococci (Santajit and Indrawattana, 2016; Esposito 
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and De Simone, 2017). The vancomycin resistance in enterococci is 
primarily associated with E. faecium with the prevalence of vancomycin 
resistant E. faecium being especially worrisome. Aminoglycoside resistance 
among enterococci worldwide has also been a cause of concern (Santajit 
and Indrawattana, 2016; Esposito and De Simone, 2017). Staphylococcus 
species caused infections have traditionally responded well to penicillin, 
however resistance emerged soon after the introduction of penicillin in the 
clinic with the synthesis of penicillinases enzymes in S. aureus.  The 
production of β-lactamases in S. aureus strains increased drastically in the 
following years (Green et al., 2012). To counteract this resistance, 
methicillin, a semi-synthetic penicillin derivative, was introduced into the 
clinic. However, as with penicillin, resistance against methicillin followed 
soon after with the appearance of methicillin resistant S. aureus (MRSA) 
(Green et al., 2012). MRSA is a leading cause of skin and soft tissue 
associated infections acquired in hospitals, placing a significant burden on 
the health care system globally (Green et al., 2012).   
 
Klebsiella pneumoniae is a member of the of the Enterobacteriaceae family 
and is major causative agent of both community and hospital derived 
infections (Santajit and Indrawattana, 2016). The infections they cause 
include sepsis, pneumonia and urinary tract infections and are associated 
with high rates of morbidity and mortality. The rapidly accumulating multi-
drug resistance determinants against β-lactams, aminoglycosides and 
fluoroquinolones in K. pneumoniae is a cause of major concern worldwide 
(Santajit and Indrawattana, 2016). A. baumanii is another major causative 
agent of nosocomial infections including ventilator associated infections and 
urinary tract infections. The emergence of carbapenemase producing A. 
baumanii that can resist colistin and imipenem has been concerning as the 
combination of the resistance encoding genes allow them to evade the 
activity of most antibacterial compounds (Santajit and Indrawattana, 2016). 
P. aeruginosa is an opportunistic pathogen that is found in the normal gut 
microbiota. Even though the carriage rate of P. aeruginosa is fairly low in the 
general population, in health care settings, they can cause life threatening 
nosocomial infections, especially in immunocompromised patients. P. 
aeruginosa resistant to carbapenems, aminoglycosides and fluoroquinolones 
adds to resistance crisis (Santajit and Indrawattana, 2016). The opportunistic 
infections caused in immunocompromised patients by MDR Enterobacter 
spp add further concern as these strains are resistant to almost all of the 
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available antibiotics (Santajit and Indrawattana, 2016; Esposito and De 
Simone, 2017).  
 
The rise in the number of hospital infections caused by P. aeruginosa, A. 
baumannii and K. pneumoniae that are resistant to all or most antibiotics is 
particularly worrisome as they are Gram-negative bacteria (Levy and 
Marshall, 2004; Slama, 2008; Davies and Davies, 2010). The outer 
membranes of Gram-negative bacteria act as a semi-impermeable barrier to 
amphipathic molecules, which is problematic as most drugs tend to be 
amphipathic in order to cross the cytoplasmic membrane and be soluble 
(Lewis, 2013). Thus, the treatment of Gram-negative bacteria especially with 
the rise of multi-drug resistance has placed a significant burden on 
healthcare systems globally. The sheer importance of antimicrobials in the 
treatment of infections cannot be understated and with multi-drug resistance 
on the rise, continued discovery and development of new antimicrobial 
compounds is of utmost importance  (Davies and Davies, 2010; Lewis, 
2013). 
 
Furthermore, it was put forward by researchers that soil might be an 
exhausted antibiotic source and the many different antibiotics discovered 
during the Golden Age of antibiotic discovery were termed the ‘low hanging 
fruit’ (Wright, 2010; Silver, 2011; Livermore, 2011; Katz and Baltz, 2016). 
The repeated rediscovery of the same antibiotics contributed significantly to 
this bottleneck (Silver, 2011). The withdrawal of big pharmaceutical 
companies from antibiotic discovery due to the failures in combinatorial 
chemistry, target based screening from genome sequences for new 
antimicrobial compounds combined with the poor profitability of antibiotics 
led to the closure of many drug discovery programmes, which has served to 
exacerbate the antimicrobial resistance crisis (Projan, 2003; Fernandes, 
2006; Li et al., 2009; Coates et al., 2011). As a result, the world is now 
facing the possibility of a pre-antibiotic era highlighted especially with the 
emergence of resistant strains on the rise (Hopwood, 2007).  
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 1.7 Secondary metabolites: a continuing source of 
antimicrobials 
Tailoring of existing antibiotic classes that allowed the production of 
improved versions of antibiotics has proved to work to a certain extent 
(Silver, 2011). One such example is Augmentin, which is a penicillin 
antibiotic made by the addition of clavulanic acid, a β-lactamase inhibitor, to 
amoxicillin (White et al., 2004). During the last 30 years, there was interest in 
the pharmaceutical companies to develop analogues of the antibiotic as 
tailoring of existing antibiotics is much cheaper and less risky than finding 
novel classes (Coates et al., 2011). In any case, natural products remain 
and continue to be the lead molecules required for the development of novel 
antibiotics. Their complexity, structural diversity and notably, their selective 
and specific bioactivity along with the untapped wealth of secondary 
metabolites awaiting to be discovered emphasise this (Cragg and Newman, 
2013). 
 
1.7.1 Genome mining and silent gene clusters 
Sequencing and annotation of the S. coelicolor A3(2) genome paved the 
way for its rational mining and allowed the identification of many silent or 
cryptic pathways (Bentley et al., 2002). S. coelicolor was only known to 
produce four or five specialized metabolites prior to its genome being 
sequenced. However, upon obtainment of its genome sequence, a further 18 
biosynthetic gene clusters (BGCs) were identified (Bentley et al., 2002). The 
isolation of a novel natural product following this discovery, the iron chelator 
coelichelin, in S. coelicolor ushered in a new era of genome mining for 
chemical entities in microbes (Bibb, 1996; Challis and Ravel, 2000; Bentley 
et al., 2002). Genome mining is based on the identification of secondary 
metabolite BGCs in the genome sequence based on their homology to 
known secondary metabolite BGCs (Bachmann, 2014). With the next 
generation sequencing technologies available, and the relatively easy and 
inexpensive access to genome sequence data, it was revealed that many 
microbes contain blueprints for synthesising many more secondary 
metabolites. As a result, genomics and genome mining has revolutionised 
the search for novel secondary metabolites (Bachmann, 2014; Genilloud, 
2018).  
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Bioinformatic tools are able to detect and predict the secondary metabolite 
BGCs with homologies derived from known secondary metabolite BGCs 
based on detection strategies such as the type of pathway, hidden Markov 
models and conserved motifs. Computational tools such as antiSMASH 
(antibiotics & Secondary Metabolite Analysis Shell) can identify and predict 
known classes of secondary metabolite BGCs in the genome (Medema et 
al., 2011). AntiSMASH is also able to provide comprehensive functional 
annotations of non-ribosomal peptide synthetase (NRPS) and polyketide 
synthase (PKS) systems identified and can predict the possible chemical 
structures of the compounds predicted to be produced by these 
megaenzymes (Medema et al., 2011). Non-ribosomal peptides (NRPs) and 
polyketides (PKs) are two large families of structurally diverse compounds 
with biologically important activities (Fischbach and Walsh, 2006). The more 
in-depth understanding of the biochemical programming and the substrate 
specificity on a molecular basis of these two systems have made powerful 
tools in making these predictions for novel modular NRPS and PKS system 
products as well as paving way towards the rational engineering of such 
systems (Challis, 2008a; Challis, 2008b). Being able to predict the structural 
features and physio-chemical properties of the secondary metabolites 
encoded by the pathways help avoid the rediscovery of known compounds 
along with shedding light on ways to engineer these pathways (Ziemert et 
al., 2016). 
 
As with S. coelicolor, many microbes that were otherwise thought to be 
mined to exhaustion were shown to have the potential to produce many 
more secondary metabolites (Bachmann, 2014). These silent BGCs 
identified are not expressed under standard laboratory growth conditions 
(Rutledge and Challis, 2015). Bioinformatics predicted several of these gene 
clusters likely to encode novel products with complex structural features 
(Challis, 2008a; Rutledge and Challis, 2015). Genome mining of numerous 
Streptomyces spp. has revealed the presence of many such silent pathways 
with the potential for the biosynthesis of new and complex chemical entities. 
On average, Streptomyces genomes harbour about 30 secondary metabolite 
BGCs and most of these are silent under standard laboratory conditions 
(Ziemert et al., 2016). Many of these silent BGCs are predicted to encode 
the production of new and complex chemical entities (Chaudhary et al., 
2013; Harvey et al., 2015). Therefore, these silent pathways and their 
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potential for the production of novel antibiotics point towards an exciting new 
age for antibiotic discovery (Challis, 2008b; Rutledge and Challis, 2015). 
 
The activation of silent BGCs has therefore attracted significant interest from 
researchers across the globe. The two main approaches in trying to awaken 
these silent pathways are by using either pleiotropic approaches or cluster-
specific approaches (both of which are explored further in Chapters 3 and 4). 
Pleiotropic approaches include strategies such as varying growth conditions, 
co-cultivation, addition of elicitor molecules while gene cluster-specific 
approaches include overexpression/deletion of cluster-specific regulators, 
gene knockout studies and heterologous expression. While pleiotropic 
approaches are largely consisted of trial and error efforts, cluster-specific 
approaches utilise the genome sequencing information to provide a more 
directed and controlled approach towards activating these BGCs. The 
exponential growth in bioinformatics has aided researchers in the efforts in 
the discovery of new and useful natural products by prioritising silent gene 
clusters (Rutledge and Challis, 2015). As opposed to the traditional 
bioactivity guided screening, genome mining has the theoretical potential to 
eliminate chances of rediscovering the same compounds (Bachmann, 2014). 
Genome mining has also played a role in furthering the knowledge in the 
divergence of BGCs across various lineages (Genilloud, 2018). Additionally, 
it has also shed light into understanding the roles of secondary metabolites 
in their endogenous contexts with their roles in interspecies, intergeneric as 
well as inter-kingdom associations such as their roles in communication, 
antibiosis and symbiosis (Bachmann, 2014). 
1.8 Aims and objectives 
Heterologous expression of BGCs is an effective strategy in the activation of  
silent BGCs, over-expression of BGCs as well as in engineering natural 
product variants (Ongley et al., 2013). Therefore, having a readily available 
suite of heterologous hosts is invaluable in the continued discovery and 
development of new and useful natural product derived compounds. One of 
the aims of this study is to generate a chromatogram-simplified 
Streptomyces albus S4 heterologous host. S. albus is one of the most 
frequently used heterologous hosts because of its fastidious growth and 
genetic tractability (Seipke, 2015). These properties along with the potential 
S. albus S4 possess to produce a wide array of secondary metabolites 
motivated the endeavour to create an S. albus S4 heterologous host strain. 
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S. albus S4 was originally isolated from the nests of the higher attine ant 
species Acromyrmex octospinosus, an unexplored niche (Seipke, 
Crossman, et al., 2011; Seipke, Barke, et al., 2011). These leaf cutting ants 
employ antibiotic producing actinomycetes to protect their fungal cultivar 
from other invading fungi (Barke et al., 2010; Seipke, Barke, et al., 2011). S. 
albus S4 is known to produce the antifungal compounds candicidin and 
antimycin. However, it does not  produce any antibacterial agents when 
cultivated under standard laboratory conditions, but bioinformatic analysis of 
its genome sequence revealed that it has the potential to produce 
compounds with antibacterial properties (Seipke, Crossman, et al., 2011; 
Seipke, 2015). This study aims to use pleiotropic approaches to activate the 
production of an antibacterial compound(s) in S. albus S4, identify and 
chemically characterise the activated antibacterial compound and to further 
investigate its antimicrobial profile.  
 
NRPs are a large family of structurally complex and diverse natural products, 
often with remarkable biologically and therapeutically relevant activities. 
They are synthesised by large multifunctional mega enzymes called NRPSs 
with a modular, assembly line like synthetic logic (Martínez-Núñez and 
López, 2016; Süssmuth and Mainz, 2017). Each module plays a role in the 
peptide elongation and usually, a C-terminally located thioesterase (TE) 
domain facilitates the hydrolytic release or macrocyclisation of the mature 
peptide (Süssmuth and Mainz, 2017). The surugamide (sur) BGC encodes 
the production of the cyclic octapeptide surugamide A (SA) and the linear 
decapeptide surugamide F (SF) (Ninomiya et al., 2016). The sur BGC is 
made up four NRPSs (surABCD) arranged in an operon where surAD 
encodes the production of SA and surBC encodes the production of SF 
(Ninomiya et al., 2016). Contrary to the norm, this NRPS system lacks a cis-
acting TE domain responsible for the release of these peptides from the 
assembly line (Takada et al., 2013; Ninomiya et al., 2016; Kuranaga et al., 
2018). Therefore, this study also aims to understand the assembly line 
release of SA and SF. As NRPs are an important source of medically 
relevant compounds, understanding alternative mechanisms of release will  
be important in expanding the synthetic biology toolbox available for 
engineering NRP synthesis.  
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Chapter 2 Materials and Methods 
2.1 Strains and plasmids  
Bacterial strains, plasmids/cosmids used and constructed in this study are 
listed in Table 2.1.1 and 2.1.2 respectively.  
 
Table 2.1.1 Strains used and generated in this study 
Strain  Description Reference 
E. coli strains   
XL10-Gold  General cloning host, stocks 
normally maintained in XL10-Gold 
cells. TetrΔ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 endA1 supE44 thi-
1 recA1 gyrA96 relA1 lac Hte [F´ 






Non-methylating host to allow the 
conjugal transfer of DNA into 
Streptomyces (dam, dcm, hsdM); 
KanR, CamR) 
(MacNeil et al., 
1992) 
GB05-red Recombineering proficient host; 
araC-BAD-γβαA: lambda red operon 
and recA under PBAD promoter 
inserted at the ybcC locus 
(Fu et al., 2012) 
BL21(DE3) Host for heterologous protein 
expression; F– ompT dcm lon hsdSB 
(rB-, mB - ) gal λ(DE3 [lacI ind1 sam7 
nin5 lacUV5-T7 gene 1]) 
Agilent 
Technologies 
E. coli BW25113  Derivative of E. coli K12 strain 
BD792; indicator strain used in 
antibacterial assays 










Derivative of the Staphylococcus 
strain 8325-4; indicator strain used 






M. luteus Indicator strain used in antibacterial 
assays  
(Wieser et al., 
2002) 
Candida strains   
C. albicans  Candida albicans CA-6; indicator 
strain used in antifungal assays 





S. albus S4 Streptomyces albus S4 wildtype (Barke et al., 
2010) 
S4 ΔantΔcan S. albus S4 mutant in the production 
of antimycin and candicidin  
(Seipke, Barke, 
et al., 2011) 
S4 
ΔantΔcanΔsur 
S. albus S4 mutant in the production 
of antimycin, candicidin and 
surugamide A 
This study 
S4 Δ5 S. albus S4 mutant with a complete 
deletion of the antimycin BGC and 
mutations within the candicidin, 
surugamide, albaflavenone and 
fredericamycin BGCs 
EH, Seipke, This 
study 
S4 Δ5-cin2 S. albus S4 Δ5 heterologous 
expression strain for cinnamycin 
Seipke, 
unpublished 
S4 ΔsurE S. albus S4 surE mutant, AprR This study 
S4 ΔsurF S. albus S4 surF mutant, AprR This study 
S4 ∆surE attB 
φBT1::pIJ10257-
surE 
S. albus S4 surE mutant 
complemented with surE expressed 
from the ermE* promoter; AprR, 
HygR 
This study 
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Table 2.1.2 Cosmids and plasmids used and created in this study 
Cosmid/plasmid Description Reference 
Cosmids   
Supercos1 Cosmid backbone for S. albus S4 
Cos994; CarbR, KanR 
Stratagene 
Cos994 Supercos1 derivative spanning the 
surugamide gene cluster from surF to 
surB; CarbR, KanR; (DT159, DT160) 
This study 
Cos994-ΔsurE Cos994 derivative with surE deletion 
(DT161, DT162); CarbR, KanR, AprR 
This study 
Cos994-ΔsurF Cos994 derivative with surF deletion 
(DT167, DT168); CarbR, KanR, AprR 
This study 
Plasmids   
pCRISPomyces-
2 
Streptomyces CRISPR/Cas9 editing 
vector, AprR 




Surugamide spacer sequence (BbsI 
site, EHS9, EHS10) and HDR arms 






Albaflavenone spacer sequence (BbsI 
site, EHS4, EHS5) and HDR repair 






Fredericamycin spacer sequence (BbsI 
site, EHS7, EHS8) and HDR repair 




pIJ773 REDIRECT PCR template for the (Gust et al., 
S4 ∆surF attB 
φBT1::pIJ10257-
surF 
S. albus S4 surF mutant 
complemented with surF expressed 
from the ermE* promoter; AprR, 
HygR 
This study 
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aac(3)IV + oriT cassette 2002) 
pET28a Commercial protein expression vector; 
KanR 
Novagen 
pET30a Commercial protein expression vector; 
KanR 
Novagen 
pDB-His-MBP Commercial protein expression vector; 
KanR 
Gifted by Dr 
Mike Webb 
pET28a-surE pET28a derivative containing surE 
cloned into the NdeI and XhoI sites or 





pET28a derivative containing surE 
subcloned from pIJ10257-surE into the 
NdeI and HindIII sites; KanR 
This study 
pET30a-surE pET30a derivative containing surE 
cloned into the NdeI and XhoI sites; 




pDB-His6-MBP derivative containing 
surE cloned into the NdeI and XhoI 




pDB-His6-MBP derivative containing S. 
albus S4 surE cloned into the NdeI and 
XhoI sites; KanR (DT206, DT213) 
This study 
pIJ10257 pMS81 derivative containing ermE*p, 
integrates into the 
φBT1 attB site in Streptomyces; HygR 
(Hong et al., 
2005) 
pIJ10257-surE pIJ10257 derivative containing the surE 
coding sequence cloned into the NdeI 
and HindIII sites; HygR; (DT210, 
DT211) 
This study 
pIJ10257-surF pIJ10257 derivative containing the surF 
coding sequence cloned into the NdeI 
and HindIII sites; HygR; (DT208, 
DT209) 
This study 
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pIJ10109 Cinnamycin BGC containing vector, 
integrates into the Fc31 att site 
(Widdick et al., 
2003) 
pUZ8002 Encodes the conjugation machinery for 
the mobilisation of plasmids and 
cosmids from E. coli to Streptomyces; 
KanR 
(MacNeil et al., 
1992) 
2.2 Growth media, antibiotics and culture conditions 
E. coli strains were cultivated on Lennox agar (LA) or broth (LB) media 
(1000 mL dH20, 10 g tryptone, 5 g yeast extract, 5 g NaCl + 15 g agar) for 16 
h at 37 °C. Streptomyces strains were propagated on mannitol-soya flour 
(MS) medium (1000 mL tap water, 20 g mannitol, 20 g soya flour, 20 g agar) 
for 7 days at 30 °C unless otherwise stated. Antibacterial agents were added 
to the media when necessary at the following concentrations: carbenicillin, 
100 μg/mL (Formedium); nalidixic acid, 25 μg/mL (Applichem Panreac); 
apramycin, 50 μg/mL (Sigma); kanamycin, 50 μg/mL (Sigma); 
chloramphenicol, 25 μg/mL (Formedium); hygromycin B, 50 μg/mL 
(Invitrogen). LA or LB with no NaCl was used with hygromycin B.  
2.3 Molecular biology techniques 
2.3.1 Extraction of plasmid and cosmid DNA 
A bacterial cell pellet was obtained by the centrifugation of 3 - 5 mL of the 
bacterial culture that had been incubated while shaking at 220 rpm at 37 °C 
for 16 h. Cosmid or plasmid DNA extraction was carried out according to the 
manufacturer’s instructions using either the QIAprep miniprep kit (Qiagen) or 
the Monarch® plasmid miniprep kit (New England Biolabs). The 
concentration and purity of DNA was assessed using a P300 
nanophotometer (NanoPhotometer Pearl; Implen, Munich, Germany). 
 
2.3.2 Genomic DNA isolation from Streptomyces 
A bacterial cell pellet was obtained by the centrifugation of 10 mL of 
Streptomyces culture that had been incubated while shaking at 220 rpm in 
LB for 48 h at 30 °C. Genomic DNA extraction was carried out according to 
established protocols (Kieser et al., 2000). Essentially, the bacterial cell 
pellet was resuspended in 200 μL of buffer (50 mM Tris-Cl, pH 8.0, 10 mM 
EDTA, 100 µg/mL RNase A) and incubated with lysozyme (Sigma) at a final 
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concentration of 10 mg/mL for 1.5 – 3 h at 37 °C. Following the incubation, 
SDS and NaCl were added to a final concentration of 1% and 1.25 M, 
respectively and incubation continued on ice for a further 10 mins. The 
resultant sample was extracted twice with an equal volume of phenol: 
chloroform: isoamylalcohol 25: 24: 1 (Applichem Panreac). The sample was 
ethanol precipitated by adding ethanol (Sigma) at 2.5 times the volume of 
the sample followed by incubation at -20 °C for at least 30 mins. The sample 
was then centrifuged for 15 mins at 16,000 x g and the resulting DNA pellet 
washed with 500 μL of 70% ethanol. The pellet was air dried for 30 – 60 
seconds before resuspending in 100 μL of water. The concentration and 
purity of DNA was assessed using a nanophotometer. 
 
2.3.3 Amplification of DNA by polymerase chain reaction (PCR) 
Oligonucleotide primers were purchased from Integrated DNA Technologies 
(Leuven, Belgium) (Appendix Table A1). PCR reactions were carried out in a 
T100 Thermal Cycler (Bio-Rad). Q5 High-Fidelity DNA Polymerase (New 
England Biolabs) was used for the PCR amplification of restriction site 
containing inserts used in this study. Thermal cycling conditions consisted of 
initial denaturation at 95 °C for 30 seconds followed by 26 cycles of: 
denaturation at 98 °C for 10 seconds, annealing for 30 seconds and 
extension at 72 °C for 30 seconds/kb, which was then followed by a final 
extension cycle at 72 °C for 2 mins. Optimal annealing temperature was 
calculated using the NEB Tm calculator. GoTaq G2 DNA polymerase 
(Promega) was used in diagnostic PCR reactions and the thermal cycling 
conditions consisted of: initial denaturation at 95°C for 2 mins followed by 26 
cycles of denaturation at 95 °C for 30 seconds, annealing for 30 seconds, 
and extension at 72 °C for 60 seconds/kb, which was then followed by a final 
extension cycle at 72 °C for 5 mins. Optimal annealing temperatures were 
calculated using the Thermo Fisher Scientific Tm calculator. The resultant 
amplicons from the PCR reactions were visualised using agarose gel 
electrophoresis (2.3.4).  
 
2.3.4 Agarose gel electrophoresis and DNA extraction 
Agarose gel electrophoresis was used to determine the presence and size of 
PCR products or to separate and purify DNA. Samples were run alongside a 
1 kb plus DNA ladder (New England Biolabs). Generally, 1% agarose gels 
made up in 1 x TAE buffer were used. GoTaq buffer containing PCR 
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reactions or DNA samples containing 1/5 volume 6x loading buffer were 
generally run at 100 V for 30-45 mins. To image the gels, Gene-Genius Bio-
Imaging-System (Syngene) using the GeneSnap Program (Syngene) was 
used. For extraction of DNA, agarose gels were visualised using a UV 
transilluminator. The DNA bands of interest were cut out and transferred to a 
microcentrifuge tube. DNA extraction was carried out using the QIAquick gel 
extraction kit (Qiagen) according to the manufacturer’s instructions.   
 
2.3.5 Cosmid screening  
Cos994 was identified by screening a previously constructed S. albus S4 
cosmid library (Seipke et al., 2014) using the primer set DT159 and DT160, 
which targeted an internal fragment of surF. To establish the sequence of 
the insert, the cosmid was insert-end sequenced using primers RFS184 and 
RFS185 and the resulting reads were manually mapped to the S. albus S4 
genome using Artemis (Seipke, Crossman, et al., 2011; Seipke, Barke, et 
al., 2011; Carver et al., 2012). 
 
2.3.6 Sanger sequencing  
The integrity of cloned DNA, cosmid inserts and confirmatory PCR products 
was verified by DNA sequencing using Genewiz (Takeley, Essex, UK) or 
GATC Biotech (Eurofins). The sequence data was then aligned with the 
reference sequence using the ‘A plasmid editor’ tool (ApE; Davies, 
University of Utah Biology Department). 
 
2.3.7 Restriction digests and ligation reactions 
Restriction enzymes were purchased from New England Biolabs and the 
digests were carried out according to the manufacturer’s protocols. 
Following restriction digest of the vector, an alkaline phosphatase, CIP (New 
England Biolabs) was used to dephosphorylate the 5´ and 3´ ends of the 
digested vector as specified by the manufacturer. Ligations were carried out 
with the restricted and gel purified vector and insert using T4 DNA ligase 
(New England Biolabs) following the manufacturers instructions. Typically, 
ligations were carried out at room temperature overnight before transforming 
chemically competent XL10-Gold cells. 
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2.3.8 Transformation of E. coli  
Transformation of chemically competent E. coli was achieved by adding 
~100 ng of DNA or an entire ligation mix to 100 µL of chemically competent 
cells followed by incubation on ice for 20 min before heat shocking at 42 °C 
for 30 – 60 seconds and a further 2 min of incubation on ice. Eight hundred 
microliters of LB was added to the transformation mix followed by 1 h 
recovery incubation at 37 °C. Electroporation of E. coli was achieved by 
adding ~100 ng of DNA and 100 µL of electro-competent cells to a 2 mm 
gap electroporation cuvette (GeneFlow) followed by electroporation with a 
2.5 kV pulse for 5 ms using the Gene Pulser Xcell (Biorad) electroporation 
system. Following electroporation, 800 µL of LB was added, transferred to a 
microcentrifuge tube and incubated whilst shaking at 37 °C for 1 h before 
plating onto LA with the appropriate antibiotics. 
 
2.3.9 Intergeneric conjugation of Streptomyces  
Intergeneric conjugation of Streptomyces was carried out according to an 
established protocol (Kieser et al., 2000). Essentially, the plasmid or cosmid 
of interest was first transformed into the de-methylating E. coli strain 
ET12567/pUZ8002. A single transformant was then grown overnight in 10 
mL LB with the appropriate antibiotics. Two hundred microlitres of the 
overnight culture was used to make a 20 mL LB subculture containing all the 
antibiotics and allowed to grow until OD600nm was ~0.4. The 10 mL overnight 
culture and the 20 mL subculture were then pooled together and centrifuged 
to obtain the cell pellet. The pellet was washed twice with LB to remove 
antibiotics before resuspending in 1 mL of LB and mixing it with 200 µL of 
Streptomyces spores. The mixture was pelleted and resuspended in 300 µL 
of LB and then plated on MS agar with no selection and incubated at 30 °C 
for 16 – 18 h. Following this period of incubation, the plates were overlaid 
with 1 mL of sterile water containing nalidixic acid (500 µg/mL final 
concentration) and the desired antibiotic (final concentration: apramycin, 
2500 µg/mL; hygromycin, 3750 µg/mL)  
 
2.3.10 Generating spore stocks 
Transconjugants picked from the conjugation plate were colony purified to 
generate single colonies on MS agar containing the appropriate antibiotics. 
Single colonies were then picked to cultivate a sporulated lawn. Following 7 
days of growth at 30 °C, 2 mL of 20% glycerol was added to the plate and a 
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sterile cotton bud was used to dislocate the spores and another 1 mL of 20 
% glycerol was added. The resulting spores were collected and stored at -80 
°C.  
2.3.11 ReDirect Recombineering  
The Streptomyces mutants S4 ΔsurE and S4 ΔsurF were generated 
following the ReDirect PCR targeting protocol (Gust et al., 2002). The 
ReDirect apramycin cassette was amplified from pIJ773 using DT161, 
DT162 for the replacement of surE on Cos994 to generate Cos994-ΔsurE; 
DT167and DT168 were used for the replacement of surF on Cos994 to 
generate Cos994-ΔsurF. Mutant cosmids were mobilised into S. albus S4 
WT by E. coli-to-Streptomyces conjugation as described in section 2.3.9. 
Transconjugants were replica plated on MS containing apramycin or 
kanamycin to identify apramycin resistant and kanamycin sensitive isolates, 
a phenotype consistent with double cross over event and deletion of region 
of interest. S4 ΔsurE was verified by PCR using the primers DT163a and 
164a and S4 ΔsurF was verified using the primers DT171 and DT172.  
2.4 Generation of chemical extracts and analysis 
2.4.1 Chemical extract preparation from minimal media agar 
plates and LC-HRMSMS analysis  
Minimal media (MM) agar was prepared following an established recipe 
(Kieser et al., 2000), except 25 mM mannitol was used instead of glucose.  
Sporulated lawns of the S. albus S4 strains were grown on MM agar at 30 
°C for 7 days. Following the incubation period, the sporulated lawn 
containing agar was cut up into small pieces and extracted with ethyl acetate 
(Sigma). Five petri dishes worth of agar was extracted with 50 mL of ethyl 
acetate (volumes were scaled up accordingly as number of plates 
increased). Extraction was done at room temperature with periodic shaking 
for approximately 3 h. The extract was then dried in vacuo and resuspended 
in 500 µL of methanol. The methanolic extract was centrifuged for 10 mins at 
16,000 x g to remove any insoluble material. Two microliters of the extract 
was injected into a Bruker MaXis Impact time of flight mass spectrometer 
equipped with a Dionex UltiMate 3000 high-performance liquid 
chromatography apparatus with conditions as described previously for 
analysis by LC-HRMSMS (Liu et al., 2015). 
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2.4.2 Chemical extract preparation and LC-HRMS analysis of 
surugamides                                               
LB seed cultures (10 mL) of the S. albus S4 strains were cultivated while 
shaking at 220 rpm at 30 °C for 3 days, at which point the entire culture was 
added to ISP2 broth (50 mL in a 250 mL flask; 1000 mL dH2O: 4 g yeast 
extract, 10 g malt extract, 4 g dextrose; pH 7.2) and incubated at 30 °C with 
shaking at 180 rpm for 4 days. Following the incubation period, bacterial 
cells were removed by centrifugation and metabolites were extracted from 
the supernatant twice with two volumes of ethyl acetate.  Chemical extracts 
were then pooled and concentrated in vacuo. The remaining residue was 
resuspended in 0.7 mL of 100% methanol (Thermo Fisher) and centrifuged 
at 16,000 x g for 15 mins to remove any insoluble material. LC- HRMS was 
carried out in the mass spectrometry facility in the Department of Chemistry 
at the University of Warwick by Dr Lijiang Song. Two microliters of the 
methanolic extract were injected into a Bruker MaXis II coupled with a 
Dionex 3000 RS UHPLC equipped with an Agilent C18 column (2.1 x 100 
mm).  The solvents used for elution of the column were as follows: solvent A, 
0.1% formic acid in water; solvent B, 0.1% formic acid in acetonitrile and the 
following gradient was used: 0-5 mins, 5% B; 5-20 mins, 5% B to 100% B; 
20-25 mins, 100% B; 25-27 mins, 100% B to 5% B. The flow rate was 0.2 
mL/min. Calibration was achieved with 1 mM sodium formate at the 
beginning of each run. Bruker Data Analysis Software (version 4.1) was 
used to analyse the data.  
 
2.4.3 S. albus S4 and S. albus ∆5 chemical extract preparation 
and HPLC analysis  
S. albus S4 and S. albus ∆5 were cultured in 50 mL of liquid GYM (1000 mL 
dH2O: 4 g glucose, 4 g yeast extract, 10 g malt extract, pH 7.2) and MS 
medium whilst shaking at 220 rpm in a 250 mL flask at 30 ºC for 7 days. 
Bacterial cells were then removed by centrifugation and 45 mL of 
supernatant was extracted with 90 mL of ethyl acetate. The extract was then 
evaporated to dryness in vacuo and resuspended in 500 μL of 100% 
methanol. The chemical extract was then centrifuged for 10 minutes at 
16,000 x g to remove any insoluble material prior to analysis. Ten microliters 
of the methanolic extract was injected into a Dionex HPLC comprising a 
P680 pump, an ASI100 autosampler and a PDA100 detector with diode 
array capability running the Chromeleon software. Compounds were 
separated on a Phenomenex Luna C18 column (150 x 4.6 mm, 100 Å, pore 
- 33 - 
size 5 µm) with a C18 guard cartridge (Phenomenex). The solvents used for 
elution of the column were as follows: solvent A, 5% acetonitrile, 0.1% formic 
acid in water; solvent B, 95% acetonitrile, 0.05% formic acid. The following 
gradient was used: following a 3 min wash with 100% A, samples were 
eluted with a gradient of 0 to 100% B over 40 mins followed by holding at 
100% B for 3 mins before returning to 0% B to re-equilibrate for 9 mins. The 
flow rate was 1 mL/min.  
 
2.4.4 Chemical extract preparation and LC-HRMS analysis of 
cinnamycin production 
S. albus ∆5 and S. albus ∆5-cin2 strains were cultured in 50 mL TSB 
(Sigma) cultures at 30 ºC for 7 days. Bacterial cells were pelleted and the 
supernatant discarded. The cell pellets were extracted with 45 mL of 
methanol and incubated shaking at room temperature for 5 h. The extracts 
were evaporated to dryness in vacuo and resuspended in 500 μL of 
methanol. Equal volumes of methanolic extracts for three independent 
replicates for each Streptomyces strain were pooled together and the extract 
was then centrifuged for 10 mins at 16,000 x g to remove any insoluble 
material prior to analysis by LC-HRMS. Two microliters of the chemical 
extract was injected into a Bruker MaXis Impact TOF mass spectrometer 
equipped with a Dionex Ultimate 3000 HPLC and a Waters Acquity UPLC 
Peptide CSH C18 column (1.7 μm, 2.1 × 100 mm). The solvents used for 
elution were solvent A, 0.1% formic acid in water; solvent B, 0.1% formic 
acid in acetonitrile. The following gradient was used: 0−1.5 min, 1% B; 
1.5−3.5 min, 75−95% B; 3.5−4.5 min, 95% B; 4.5− 5 min, 95−1% B; 5−5.5 
min, 1% B. The flow rate was 0.7 mL/min. 
2.5 Protein expression 
2.5.1 Purification trials of SurE 
Using standard molecular biology techniques, the coding regions of interest 
were cloned into pET28a, pET30a or pDB-His-MBP to have an N-terminal 6x 
His tag, a C-terminal 6x His tag or an N-terminal 6x His- MBP tag, 
respectively. The expression vectors were then introduced into BL21(DE3) 
cells and various growth conditions and lysis methods were tested (briefly 
discussed in chapter 5).  Cells were harvested following the expression trial 
period and the cell pellets weighed. Lysis buffer (100 mM Tris, 500 mM 
NaCl, 10 mM imidazole, pH 7.9) was added at 10x the volume of the weight 
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of the cell pellet and the resuspended cell pellets were lysed either by 
sonication or using the cell disruptor (flow-through option at 20 kpsi or one-
shot option at 27 kpsi). The cell debris was removed by centrifugation at 
16,000 x g for 30 minutes at 4 °C. The soluble fraction was obtained and 
mixed with 4 mL of prepped Ni-NTA affinity resin (Super Ni-NTA Affinity 
resin, Generon) and allowed to mix for approximately 20 mins before 
allowing the mixture to pass through an empty gravity-flow chromatography 
column (Econo-Pac® Chromatography Columns, Bio-Rad). The flow through 
was allowed to pass through the column twice to maximise the chances of 
the protein binding to the resin. The resin was then washed with 6 mL of 20 
mM imidazole containing lysis buffer followed by 5 mL of 60 mM imidazole 
containing lysis buffer and finally by 15 mL of 500 mM imidazole containing 
lysis buffer. The 500 mM imidazole buffer elution was then passed through a 
spin concentrator (Vivaspin® 20; Sartorius Stedim) to concentrate the 
volume to approximately 2.5 mL. The sample was then passed through an 
equilibrated desalting column (Sephadex G-25 in PD-10 desalting columns, 
GE Healthcare) before collecting ten 1 mL fractions. Bradford reagent was 
used to check for the presence of protein. Prior to analysing the samples on 
the gel, 5 µL of 4 x Laemmlli buffer (Bio-rad) was added to 10 µL of the 
samples and samples were denatured at 95 °C for 5 mins. The denatured 
samples were analysed on an SDS-PAGE gel (RunBlue precast gels, 
expedeon) alongside a blue pre-stained protein standard (#P7706S, New 
England Biolabs). The gel was run at 200 V for 45 – 60 mins and then 
stained using InstantBlue (Expedeon). A cell free protein expression kit 
(PURExpress In Vitro Protein Synthesis Kit, NEB E6800S) was also tried to 
synthesise SurE. 
 
2.5.2  Purification of SurE 
BL21(DE3)(pET28:surE) cells were inoculated in autoinduction-LB broth 
base media including trace elements (Formedium) and allowed to grow for 3 
days at 16 °C. Following the incubation period, cells were harvested and 
resuspended in 10 x volume of the weight in lysis buffer (50 mM HEPES, 
200 mM NaCl, pH 7.4). The cells were lysed by sonication (40% power, 2 
cycles of 1 m 30 s with pulses every other second). The soluble fraction was 
collected and mixed with 5 mL of prepped Ni-NTA resin. The sample was 
allowed to flow through the column slowly before washing the resin with the 
wash buffer (50 mM HEPES, 200 mM NaCl, 50 mM imidazole, 1 mM EDTA, 
pH 7.4). The column was washed until there was no more protein detected 
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in the flow through (analysed using Bradford’s reagent). The protein was 
then eluted from the column using the elution buffer (50 mM HEPES, 200 
mM NaCl, 300 mM imidazole, 1 mM EDTA, pH 7.5) as 3 ml fractions and the 
presence of protein was checked using Bradford’s reagent. The resultant 
fractions were analysed on an SDS-PAGE gel. The purification of SurE was 
done together with Asif Fazal. 
2.6 SNAC assays  
Reactions (100 µL) contained 50 mM HEPES (pH 7.5), a peptidyl SNAC-
thioester mimic of surugamide A (0.1 mM; SA-SNAC dissolved in methanol) 
and SurE (18 µg) and were incubated at 30 °C for 5 h along with the control 
reactions. The reactions were quenched by adding 100 µL of 0.05% 
trifluoroacetic acid (TFA). The reactions mixtures were then extracted with 
Phenomenex strata-XL C18 (100 µm, 30 mg, 1 mL) solid-phase extraction 
column (SPE) and a vacuum manifold. The column was first washed with 1 
mL of 100% methanol followed by 1 mL of deionized water. The reaction 
mixture was then loaded onto the column prior to being washed with 1 mL of 
deionized water. Metabolites were eluted from the column with 120 µL of 
100% methanol. The methanolic extract was centrifuged for 10 mins at 
16,000 x g to remove any insoluble material before analysis by LC-HR-ESI 
MSMS on a Bruker MaXis Impact time of flight mass spectrometer equipped 
with a Dionex UltiMate 3000 high-performance liquid chromatography 
apparatus with conditions as described previously (Liu et al., 2015). 
2.7 Synthesis of Surugamide A 
Surugamide A was commercially synthesised through Synpeptide Co., Ltd 
(now Chinapeptides Co., Ltd). Once synthesised, further QC analyses were 
carried out at University of Leeds via LC-HR-ESI MSMS on a Bruker MaXis 
Impact time of flight mass spectrometer equipped with a Dionex UltiMate 
3000 high-performance liquid chromatography apparatus with conditions as 
described previously (Liu et al., 2015).  
2.8 Evaluation of antimicrobial activity 
2.9.1 In vitro antibiotic susceptibility tests 
Minimum inhibitory concentrations (MICs) of antibiotic compounds were 
determined by broth microdilution according to the Clinical and Laboratory 
Standards Institute (CLSI) guidelines (Cockerill et al., 2012). Antifungal 
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activity was assessed in the same way, except LB was used instead of 
Mueller-Hinton broth II (MHBII), and MICs were read after 48 h of incubation 
at 30 °C. Positive growth controls and solvent controls were included in each 
experiment.  
 
2.9.2 Checkerboard MICs 
Compounds used in checkerboard assays in this study in conjunction with 
surugamide A were erythromycin (Sigma), cetyltrimethylammonium bromide 
(CTAB; BDH Laboratory Supplies), nisin (NBS Biologicals) and gramicidin D 
(Sigma). Stock solutions and serial dilutions of the drugs of interest were 
prepared to at least their respective MICs.  The first antibiotic of the 
combination was serially diluted along the x-axis, while the second drug was 
serially diluted along the y-axis of 96 well plates. The indicator organism of 
choice (S. aureus SH100) was diluted in MHBII to OD625nm 0.001 to achieve 
a cell number of ~ 5 x 105 cfu/mL. The diluted culture was then added to the 
wells to contain a total volume of 100 µL and was incubated shaking at 37 
°C for 16 h (personal correspondence with Dr Arya Gupta and Dr Chris 
Randall).  Synergism was calculated using the FIC index. The ΣFIC were 
calculated as follows: ΣFIC = FIC A + FIC B, where FIC A is the MIC of 
compound A in the combination/MIC of compound A alone, and FIC B is the 
MIC of compound B in the combination/MIC of compound B alone. The 
interaction was considered to be synergistic if the ΣFIC is ≤0.5, indifferent 
when the ΣFIC is >0.5 to <4 and antagonistic if the ΣFIC is ≥4 (Odds, 2003).  
 
2.9.3 Bioassays with chemical extracts 
From an overnight culture, the indicator organism of interest was diluted to 
OD625nm 0.08125 in LB and was spread on an LB plate with no selection 
using a rotary platform to allow uniform distribution. Then, small sterilised 
circular paper discs (6 mm diameter) holding 60 μL of the chemical extract to 
be tested were placed on the plate and incubated at the appropriate 
temperature (37 °C for 16 h for S. aureus SH1000 and room temperature for 
48 h for C. albicans) (personal correspondence with Dr Asma Akter).  
 
2.9.4 Whole cell bioassays 
Whole cell bioassays with Streptomyces strains on solid agar were done by 
inoculating the centre of an agar plate with 10 μL of spores, which were 
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allowed to grow for 7 days at 30 °C. The plates were then overlaid with 7 mL 
of soft nutrient agar (SNA) inoculated with 200 μL of an overnight culture of 
S. aureus SH1000 or C. albicans. 
2.10 Generation of S. albus S4 Δ5 
S. albus S4 Δ5 was generated in a multiparty effort with Dr Ryan Seipke and 
Ellie Harris. S. albus S4 Δ5 has mutations in the biosynthetic gene clusters 
(BGC) encoding the production of antimycin, candicidin, surugamide, 
albaflavenone and fredericamycin. Dr Seipke made the mutations in the 
antimycin, candicidin and fredericamycin BGCs. I made the mutations in the 
surugamide and albaflavenone BGCs. Ellie designed and made all the 
constructs for the CRISPR/Cas9 based deletions used in the generation of 
this strain.  
 
Deletion of the antimycin BGC was carried out using Cos213 and the 
apramycin disruption cassette to delete the gene antF following the ReDirect 
PCR targeted mutagenesis as described previously (Gust et al., 2002) to 
generate S. albus S4 ∆antF. Next, antABCDEFGHIJKLMNO on Cos213 
were replaced with the apramycin resistance cassette as above and then 
removed by the FLP recombinase, followed by replacement of the bla gene 
with the hygromycin resistance cassette from pIJ10701 as described 
previously (Gust et al., 2002) to generate Cos213 ∆antFLP B2H (Seipke, 
Barke, et al., 2011).  This mutated cosmid was then mobilised into S. albus 
S4 ∆antF. A single transconjugant was chosen and passaged twice in the 
absence of selection before assessing apramycin and hygromycin 
sensitivity. An apramycin and hygromycin sensitive isolate was identified and 
was named S. albus S4 ∆1 and was confirmed by PCR using primers 
RFS236 and RFS237 (Seipke, Barke, et al., 2011). The candicidin BGC was 
disrupted using the previously constructed fscC (STRS4_02234) deletion 
plasmid, pKC1132-UpDn (Seipke, Barke, et al., 2011). The pKC1132-UpDn 
plasmid was introduced to S. albus S4 ∆1 and a single apramycin resistant 
transconjugant was selected and passaged as above until an apramycin-
sensitive isolate was identified, and was named S. albus S4 ∆2.  
 
The pCRISPomyces-2 system was used to disrupt the surugamide, 
fredericamycin and albaflavenone BGCs as described previously (Cobb et 
al., 2015). Briefly, single-guide RNA protospacers were generated for the 
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three BGS by annealing oligonucleotides EHS9 and EHS10 (surugamide), 
EHS3 and EHS4 (albaflavenone) and EHS7 and EHS8 (fredericamycin); the 
annealed DNA fragments were introduced into the BbsI site of the 
pCRISPomyces-2 plasmid by Golden Gate Assembly. Secondly, homology 
directed repair templates were generated by PCR for each of the three 
BGCs and were cloned into the XbaI site of the pCRISPomyces-2 plasmid 
using the NEBbuilder HiFi DNA assembly kit (New England Biolabs). The 
resulting CRISPR/Cas9 editing plasmids, pCRISPomyces-2-sur, 
pCRISPomyces-2-alb, pCRISPomyces-2-fdm were sequentially mobilised 
into Streptomyces. The temperature sensitive pCRISPomyces-2 plasmids 
were then cured from the transconjugants by passage in LB at 37 °C (twice) 
prior to the cultivation of a sporulated lawn on MS agar at 37 °C. Serial 
dilutions of the resultant spores were replica plated to examine apramycin 
sensitivity. Apramycin sensitive colonies were identified and were analysed 
for the respective deletion. The sequential mutations of the surugamide, 
albaflavenone and fredericamycin BGCs in S. albus S4 ∆2 resulted in the 
generation of the strains:  S. albus S4 ∆3, S. albus S4 ∆4 and the final strain, 
S. albus S4 ∆5.  
 
2.11 Bioinformatic prediction of putative proteins and amino 
acid sequence alignment 
The sequence analysis tools, BLASTP (Altschul et al., 1990; Altschul et al., 
1997) and InterPro (Mitchell et al., 2018), were used to predict the proteins 
encoded by the genes in the surugamide biosynthetic gene cluster by 
submitting the amino acid sequences of the respective genes to these 
platforms. Amino acid alignments were done using the Clustal Omega Tool 
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Chapter 3 Generation of a chromatogram-simplified 
Streptomyces albus S4 heterologous host 
Abstract 
Secondary metabolites are an important source of medically relevant 
compounds. Genome sequencing and genome mining of actinomycetes has 
revealed the presence of many silent biosynthetic gene clusters in their 
genomes, which are not expressed under standard laboratory conditions. 
These silent biosynthetic gene clusters have the potential to produce 
secondary metabolites with important bioactivities. Heterologous expression 
of biosynthetic gene clusters in an optimised host is a powerful strategy to 
activate silent gene clusters, to engineer variants and to optimise product 
yields. The availability of suitable hosts is therefore important in the 
continued discovery and production of new and useful secondary 
metabolites. In this study, a chromatogram-simplified Streptomyces albus S4 
heterologous host was generated. Five gene clusters were targeted and 
disrupted in Streptomyces albus S4 to generate Streptomyces albus S4 D5. 
These gene clusters were targeted as they encode the production of known 
antifungal or antibacterial compounds. The resultant strain does not exhibit 
antifungal or antibacterial activity. Comparison of chromatograms of 
Streptomyces albus S4 D5 and the wild type Streptomyces albus S4 
revealed that Streptomyces albus S4 D5 possess a much simpler 
chromatogram profile, which will ease the detection of compounds that are 
heterologously produced. Additionally, the cinnamycin encoding biosynthetic 
gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005 
was successfully expressed in Streptomyces albus S4 D5 demonstrating its 
utility. Streptomyces albus S4 D5 will be a useful tool in the continued 
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3.1 Introduction 
Genome sequencing and genome mining of actinomycetes have revealed 
the presence of many silent or cryptic biosynthetic gene clusters (BGCs) in 
their genomes. With that, one of the current challenges in natural product 
discovery is the development of strategies to activate and study the BGCs of 
interest (Ziemert et al., 2016; Bekiesch et al., 2016). The strategies to 
activate the silent BGCs can be divided into two major groups: pleiotropic 
approaches and cluster-specific approaches (both of which will be explored 
further in chapter 4) (Zhu et al., 2014; Ziemert et al., 2016). A different way 
to classify the strategies would be: i) activation of the BGCs in the natural 
host versus ii) the expression of the BGC heterologously in a surrogate 
strain (Gomez-Escribano and Bibb, 2011). Heterologous expression is the 
expression of BGCs from one organism in a surrogate host with a known 
secondary metabolome (Baltz, 2010; Gomez-Escribano and Bibb, 2011; 
Rutledge and Challis, 2015). Heterologous hosts are usually faster growers 
and genetically tractable, which enable genetic manipulation of BGCs even 
from genetically recalcitrant strains. Heterologous expression can be used to 
activate a silent BGC, confirm production of a compound by the putative 
gene cluster, to determine the borders of the BGC and to investigate the 
biosynthesis of secondary metabolites. It can also be used to  yield the 
compounds, which can then be used for further studies. It is a powerful way 
of identifying novel compounds and to investigate their properties (Ongley et 
al., 2013; Rutledge and Challis, 2015; Bekiesch et al., 2016). Additionally, 
heterologous expression combined with rational engineering and the 
refactoring of BGCs in a genetically amenable host strain paves the way for 
combinatorial biosynthesis and molecular engineering to generate natural 
product variants (Ongley et al., 2013).  
3.2 Heterologous expression is a powerful strategy  
Many secondary metabolites have evaded discovery due to their 
biosynthetic pathways not being prevalent in the commonly isolated 
actinomycetes or because they are expressed poorly or not at all under 
standard fermentation conditions (Baltz, 2010). Modifications such as growth 
media variation, precursor feeding and manipulation of cluster-specific 
regulators can sometimes be used to induce or increase the production of 
the compound in the native host. However, despite such strategies, many 
BGCs still only produce the compounds at low yields in the native host 
(Zhang et al., 2011; Zhu et al., 2014; Baral et al., 2018). Additionally, the 
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slow growth and sparse sporulation of many strains coupled with the 
difficulties in their genetic manipulation is often challenging (Baltz, 2010; 
Bekiesch et al., 2016). Moreover, metagenomic sequences have revealed 
that out of the approximately 4 million rRNA sequences deposited, less than 
1% of these belong to cultured microbes (Konstantinidis and Rosselló-Móra, 
2015). Metagenomic sequencing has revealed the presence of many 
secondary metabolite BGCs in these difficult-to-culture microbes that are 
capable of producing interesting natural products (Katz et al., 2016). An 
important approach in overcoming these bottlenecks is to clone the BGC of 
interest to express them in a heterologous host optimised for production that 
is genetically amenable (Baltz, 2010; Gomez-Escribano and Bibb, 2011; 
Zhang et al., 2011; Ongley et al., 2013; Bekiesch et al., 2016; Katz et al., 
2016). 
 
To heterologously express a BGC, access to the sequence information 
and/or the genetic material is required along with tools for its cloning and a 
well characterised host. Genes encoding secondary metabolites are often 
clustered together in the genome, which makes cloning these BGCs 
relatively easier (Bentley et al., 2002; Zhang et al., 2011). Technologies 
have emerged to capture the pathway of interest to be heterologously 
expressed (Zhang et al., 2011). There are well established strategies for 
capturing the BGC of interest for heterologous expression. Target BGCs 
have classically been captured through the generation and screening of 
cosmid or bacterial artificial chromosome libraries. The development of 
direct cloning strategies that bypass library construction such as 
transformation-associated recombination, φBT1 integrase-mediated direct 
cloning and RecET mediated recombineering strategies have played a major 
role in allowing the BGCs to be more accessible for heterologous expression 
(Fu et al., 2012; Yamanaka et al., 2014; Du et al., 2015). The advances in 
gaining access to the BGCs have made heterologous expression a powerful 
tool in the activation and expression of BGCs.  
 
3.3 Heterologous hosts 
Successful expression of the BGC and production of the desired product is 
dependent on many factors and therefore, the choice of host is not trivial. 
The production of the compound is dependent upon the enzymatic and 
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metabolic capability of the host to support the biosynthesis of the secondary 
metabolites (Zhang et al., 2011). Factors such as growth rate, self-
resistance if the compound exhibits antibacterial activity, metabolic flux and 
the availability of precursors play key roles (Zhang et al., 2011; Ongley et al., 
2013; Baral et al., 2018). Additionally, the heterologous hosts themselves 
should be well characterised and genetically tractable (Bekiesch et al., 
2016). Escherichia coli, Saccharomyces cerevisiae, Bacillus subtilis and 
Pseudomonas have all been shown to be used as heterologous hosts for the 
expression of secondary metabolite BGCs from streptomycetes (Zhang et 
al., 2011; Liu et al., 2016; Baral et al., 2018; Choi et al., 2018). However, it 
appears that evolutionarily closely linked organisms are most often better 
suited as hosts for the heterologous expression of BGCs  (Ongley et al., 
2013; Baral et al., 2018).  It is important to consider the precursors required 
for the production of the target compound and therefore, it is not surprising 
that streptomycetes are among the most frequently used heterologous host 
strains, especially for BGCs originating from actinomycetes (Baltz, 2010; 
Ongley et al., 2013; Bekiesch et al., 2016). Phylogenetically related species 
will also possess a similar codon usage, which provides a greater 
translational efficiency compared to distantly related species (Ongley et al., 
2013).  There are a number of established actinomycete heterologous hosts 
that are genetically tractable such as Saccharopolyspora erythraea, 
Salinispora tropica, Streptomyces avermitilis, Streptomyces coelicolor, 
Streptomyces  lividans and Streptomyces albus J1074 that have been used 
for this purpose (Baltz, 2010; Zhang et al., 2011; Huang et al., 2016; Jia 
Zhang et al., 2018). A few of the streptomycete heterologous hosts are 
discussed in this section.  
 
S. avermitilis SUKA5, SUKA17 and SUKA22 are three examples of genome 
minimised S. avermitilis derived heterologous hosts. S. avermitilis is the 
industrial producer of avermectins and therefore, has a good supply of 
primary metabolic precursors, which is an important factor for a heterologous 
host (Luo et al., 2015). Several S. avermitilis strains have been developed 
as heterologous hosts with deletions of large DNA segments resulting in 
reduced genome sizes. These strains are mutants in the production of 
endogenous secondary metabolites found in the parent strain such as 
avermectins, filippin, oligomycin, geosmin, neopentalenolactone and a 
carotenoid, presenting a clean metabolic profile (Komatsu et al., 2010; 
Komatsu et al., 2013).  S. avermitilis SUKA5 is deficient in the production of 
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avermectins, oligomycins and filippins while S. avermitilis SUKA17 is also 
deficient in the production of the terpenoid metabolites geosmin, 
neopentalenolactone and a carotenoid (Komatsu et al., 2010; Komatsu et 
al., 2013). With these deletions,  approximately 78% of the putative 
transposase encoding genes were also deleted, which was suggested to 
further contribute to the stability of the engineered mutants (Komatsu et al., 
2010; Komatsu et al., 2013; Ikeda et al., 2014; Luo et al., 2015). These 
engineered strains have been shown to successfully heterologously express 
a wide array of secondary metabolite BGCs with the yield of the compounds 
found to be greater in the engineered host when compared to the parent 
strain. For example, the heterologous production of chloramphenicol in S. 
avermitilis SUKA22 was ten-fold greater than its production in its native host 
Streptomyces venezuelae (Ikeda et al., 2014). 
 
S. coelicolor M512, M1146, M1152 and M1154 are examples of 
heterologous host strains derived from the model streptomycete S. coelicolor 
A3(2) (Gomez-Escribano and Bibb, 2011; Bekiesch et al., 2016). S. 
coelicolor is known for its production of the bioactive secondary metabolites 
actinorhodin (Act), undecyleprodigiosin (Red), calcium-dependent antibiotic 
(CDA) and coelimycin (CPK). S. coelicolor M512 is a mutant in 
methylenomycin production via the loss of plasmids SCP1 and SCP2 as well 
as being deficient in the production of Act and Red via the deletion of the 
pathway specific regulatory genes redD and actII-ORF4 (Floriano and Bibb, 
1996). The quadruple deletion strain S. coelicolor M1146 is derived from S. 
coelicolor M512 with deletions in the BGCs encoding Act, Red, CDA and 
CPK possessing an even cleaner metabolic profile (Gomez-Escribano and 
Bibb, 2011). It has previously been shown that mutations in some genes 
encoding some of the ribosomal proteins or RNA polymerase can have a 
positive effect on antibiotic production (the basis for ribosome engineering in 
switching on silent BGCs) (Shima et al., 1996; Hu et al., 2002; Hosaka et al., 
2009). S. coelicolor M1152 and M1154 are derived from S. coelicolor M1146 
with an additional mutation in the RNA polymerase b-subunit encoding gene 
rpoB (M1152) or mutations in both the rpoB gene and the ribosomal gene 
rpsL encoding the ribosomal S12 protein (M1154) with the yield of the 
heterologously expressed compounds usually found to be greater in M1146 
even though the growth and sporulation of the strains are slightly reduced 
(Jones et al., 2013). 
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S. lividans is very closely related to S. coelicolor, differing primarily only in 
horizontally acquired genes (Rückert et al., 2015). However, they 
dramatically differ in the expression of the commonly shared secondary 
metabolite BGCs. While Act, Red and CDA are all produced by S. coelicolor 
normally, the BGCs encoding these products are silent in S. lividans (Baltz, 
2010). Upon deletion of the polyphosphate kinase gene (ppk), whose 
product (Ppk) is responsible for the formation of polyphosphate (a stock 
polymer of inorganic phosphate), the production of Act, Red and CDA was 
induced in S. lividans (Chouayekh and Virolle, 2002). Thus, the availability of 
inorganic phosphate plays a role in the biosynthesis of Act, Red and CDA in 
S. lividans. S. lividans TK24 is a plasmid free strain derived from S. lividans 
66. It is a popular heterologous host especially as it can accept methylated 
DNA (Rückert et al., 2015). Additionally, its low protease activity has allowed 
it to be used as a heterologous expression/secretion system for proteins 
ranging from human cytokines to industrial enzymes such as cellulases 
(Rückert et al., 2015).  
 
The readily transformable S. albus G expresses the restriction endonuclease 
SalI. S. albus J1074 is derived from S. albus and is defective in SalI. S. 
albus J1074 is an established heterologous host (Cox and Baltz, 1984; 
Baltz, 2010). For example, the heterologous expression of the BGC for 
isomigrastatin from Streptomyces platensis NRRL18993 in S. avermitilis, S. 
coelicolor, S. lividans and S. albus revealed that while the production in none 
of these heterologous hosts matched the production in the parental strain, 
production of isomigrostatin in S. albus J1074 was the closest with 46 mg/L 
compared to 58 mg/L in the parent strain (Feng et al., 2009). Additionally, S. 
albus J1074 (and S. lividans) was also able to heterologously express a 
BGC from a non-streptomycete marine actinomycete. The thiocoraline BGC 
from a marine Micromonospora strain was successfully expressed in both S. 
albus J1074 and S. lividans when the positive regulatory gene tioA was 
transcribed from the ermEp* promoter (Lombó et al., 2006). As with S. 
avermitilis, reducing the genome size can increase the yield of secondary 
metabolites produced through heterologous production. The deletion of more 
than 1.4 Mb resulted in a genome size of approximately 7.62 Mb in S. 
avermitilis, which increased the stability of the strain as well as the yield of 
the secondary metabolites heterologously produced (Komatsu et al., 2010; 
Komatsu et al., 2013). S. albus J1074 has a naturally minimised genome 
(6.83 Mb) making it an attractive heterologous host. Additionally, S. albus 
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J1074 is a relatively fast grower and is genetic tractable, which are all 
important factors when choosing a heterologous host (Baltz, 2010; 
Zaburannyi et al., 2014).  
3.4 S. albus S4 as a heterologous host 
With the continued discovery of silent, new or interesting BGCs, it will be key 
to have a suite of Streptomyces hosts available to enable rapid identification 
and high-level expression of specific secondary metabolites (Baltz, 2010; 
Nah et al., 2017). S. albus J1074 has been successful in the heterologous 
production of a diverse array of secondary metabolites such as 
fredericamycin, isomigrastatin, napyradiomycin, cyclooctatin, thiocoraline 
and moenomycin  (Wendt-Pienkowski et al., 2005; Lombó et al., 2006; 
Winter et al., 2007; Feng et al., 2009; Kim et al., 2009; Makitrynskyy et al., 
2010). The phylogenetically closely related strain, S. albus S4, was originally 
isolated from the leaf-cutting Acromyrmex octospinosus ant colonies by 
bioprospecting in underexplored niches. (Barke et al., 2010; Seipke, Barke, 
et al., 2011; Seipke, 2015; Joynt and Seipke, 2018). S. albus J1074 and S. 
albus S4 share approximately 80% of the secondary metabolome, however, 
the genome of S. albus S4 is slightly larger (7.61 Mb) and harbours an 
additional six strain-specific BGCs with their products comprising 21% of its 
secondary metabolome (Seipke, Barke, et al., 2011; Seipke, Crossman, et 
al., 2011; Seipke, 2015). Two of the strain-specific BGCs in S. albus S4 
encodes the production of kendomycin (a type I/III polyketide) and  
fredericamycin (a type II polyketide) (Seipke, 2015). The fast growth and 
genetic tractability of S. albus S4 coupled with its ability to produce a diverse 
array of secondary metabolites motivated the initiative to engineer this strain 
to be a heterologous host. 
3.5 Aims and objectives 
S. albus S4 produce two antifungals: antimycin and candicidin, but it does 
not produce an antibacterial compound under standard laboratory conditions 
(Seipke, Barke, et al., 2011). Submission of its genome sequence to the 
anitSMASH server (version 2.0) revealed that its genome harbours at least 
28 BGCs (Figure 3.1) (Blin et al., 2013; Seipke, 2015). Even though the 
genome of S. albus S4 is predicted to encode secondary metabolite BGCs 
with the potential to produce metabolites with antibacterial activities, S. albus 
S4 does not exhibit antibacterial activity under standard laboratory 
conditions (explored further in Chapter 4) (Seipke, 2015). S. albus S4 is 
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predicted to have the potential to produce some known compounds with 
antibacterial activities such as albaflavenone, fredericamycin and a 
gramicidin-like compound, which was later identified to be surugamides 
(surugamides are explored further in Chapters 4 and 5) (Pandey et al., 1981; 
Gurtler et al., 1994; Takada et al., 2013; Seipke, 2015; Ninomiya et al., 
2016). The albaflavenone and surugamide encoding BGCs are conserved in 
the core metabolome across S. albus species while the fredericamycin BGC 
is unique to S. albus S4 (Seipke, 2015).  
 
Antimycin and candicidin are prominent in the chemical extracts prepared 
from S. albus S4 (Seipke, Barke, et al., 2011). While no antibacterial activity 
is seen on the routinely used MS agar, culturing on alternative media 
conditions may elicit the production of these known antibacterial compounds 
(as is seen with surugamides, Chapter 4).  Therefore, inactivation of these 
known BGCs is important in the generation of a heterologous host. To 
generate a chromatogram-simplified S. albus S4 heterologous host that is 
unable to produce any antifungal or antibacterial compounds under routinely 
used laboratory conditions, this project aims to:  
 
• Generate an S. albus S4 strain compromised in production of 
antimycin, candicidin, albaflavenone, surugamide and fredericamycin 
(done in a multiparty effort with Dr Ryan Seipke and Ellie Harris) 
• Compare the bioactivities of chemical extracts obtained from S. albus 
S4 WT and S. albus S4 D5 and compare the metabolic profile of the 
chemical extracts using analytical techniques such as HPLC 




















3.6.1 Construction of S. albus S4 D5 
S. albus S4 D5 was constructed by sequentially targeting the BGCs 
encoding the production of antimycin, candicidin, surugamide, albaflavenone 
and fredericamycin.  The construction of S. albus S4 D5 is described in 
greater detail in Chapter 2 (Section 2.10). Dr Ryan Seipke previously made 
a strain deficient in the production of antimycin and candicidin (Seipke, 
Barke, et al., 2011), which was renamed S. albus S4 D2 in this work. An 
undergraduate student, Ellie Harris, designed and made the constructs for 
the CRISPR/Cas9 based deletions of surugamide (D3), albaflavenone (D4) 
and fredericamycin BGCs. I mutated the surugamide and albaflavenone 
BGCs and Ryan Seipke mutated the fredericamycin BGC. The overall 
integrity of the final strain, S. albus S4 D5 was verified by genome 

























































































































































Figure 3.1 antiSMASH predicted biosynthetic gene clusters encoded 
in the genome of Streptomyces albus S4. The BGCs targeted to 
mutate to generate S. albus S4 D5 are highlighted in red, and they 
are: antimycin, candicidin, albaflavenone, fredericamycin and 
surugamide encoding BGCs.  
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3.6.2 S. albus S4 D5 does not exhibit antifungal activity or 
antibacterial activity  
Ethyl acetate extracts were prepared from S. albus S4 WT and S. albus S4 
D5 grown in two different liquid media: MS and GYM media (in duplicate). 
The chemical extracts prepared were checked for antibacterial activity using 
Micrococcus luteus and for antifungal activity using Candida albicans. As 
expected, the chemical extracts prepared from the media only controls of 
MS and GYM media did not exhibit any bioactivity (Figure 3.2). The chemical 
extracts prepared from S. albus S4 WT obtained from MS or GYM media did 
not show antibacterial activity against M. luteus (Figure 3.2). Only the S. 
albus S4 WT chemical extracts from MS media showed antifungal activity 
against C. albicans. The chemical extracts prepared from S. albus S4 D5 
cultivated in MS or GYM media did not exhibit any antibacterial or antifungal 






































Figure 3.2 Antibacterial and antifungal bioassays of the chemical 
extracts prepared from S. albus S4 WT and S. albus S4 D5. The 
strains were cultivated in duplicate in liquid MS and GYM media. 
Antibacterial activity was assessed against Micrococcus luteus and 
antifungal activity was assessed against Candida albicans. The key 
for the samples are: 1- methanol control; 2- MS media only chemical 
extract; 3 & 4- MS media S. albus S4 Δ5 chemical extracts; 5 & 6: - 
MS media S. albus S4 WT chemical extracts; 7- methanol control, 8- 
GYM media only chemical extract; 9 & 10- GYM S. albus S4 Δ5 
chemical extracts; 11 & 12- GYM S. albus S4 WT chemical extracts. 
Only S. albus S4 WT grown up in MS media exhibited antifungal 
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3.6.3 S. albus S4 D5 has a simplified metabolic profile compared 
to S. albus S4 WT  
The chemical extracts prepared from S. albus S4 WT and S. albus S4 D5 
cultivated in MS and GYM media were analysed by HPLC to compare the 
metabolic profiles. The chromatograms of the elutions were monitored at 
256 nm. Many of the metabolites produced by S. albus S4 WT in the 
routinely used MS media are absent in S. albus S4 D5 revealing a 
significantly less complex chromatogram background (Figure 3.3). Chemical 
extracts obtained from S. albus S4 WT and S. albus S4 D5 grown in GYM 
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Figure 3.3 Comparison of the HPLC chromatogram profiles of the 
ethyl acetate extracts from S. albus S4 WT and S. albus S4 D5 
cultivated in liquid MS and GYM media. The chromatogram 
profile of S. albus S4 D5 cultivated in MS media is cleaner and 
simpler than that of S. albus S4 WT cultivated in MS media. The 
latter peaks present in the wild type strain cultivated in MS media 
are absent in the engineered strain. No major differences were 
observed in the chemical extracts prepared from S. albus S4 WT 
and S. albus S4 D5 cultivated in GYM media. 
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3.6.4 Heterologous expression of the cinnamycin BGC in S. albus 
S4 D5 
To demonstrate that S. albus S4 D5 can heterologously produce secondary 
metabolites, the lantibiotic cinnamycin encoding BGC from Streptomyces 
cinnamoneus cinnamoneus DSM 40005 was heterologously expressed. The 
previously described cinnamycin BGC encoding plasmid pIJ10109 was used 
to generate the recombinant strain S. albus S4 D5-cin2 (made by Ryan 
Seipke) (Widdick et al., 2003). Ethyl acetate extracts obtained from the cell 
pellets of S. albus S4 D5 and S. albus S4 D5-cin2 cultivated in liquid TSB 
were analysed by LC-HRMS. A compound consistent with the chemical 
formula and mass was only observed in the chemical extract from S. albus 
S4 D5-cin2 and as expected; no production was seen in the ‘empty’ host 
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Figure 3.4 Heterologous production of cinnamycin in S. albus S4 
D5. The EICs corresponding to the [M+2H]2+ ions are shown for 
cinnamycin (C89H125N25O25S3). (The y-axis is set to a maximum of 
1.8 x 104). Cinnamycin production was observed in the recombinant 
strain S. albus S4 D5-cin2 while no production of cinnamycin was 
observed in the ‘empty’ heterologous host S. albus S4 D5 
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3.7 Discussion 
Heterologous expression is a powerful strategy, which plays a key role in the 
activation of silent BGCs and production of secondary metabolites. 
Activation of BGCs and improving the yields of secondary metabolites within 
the native host is often extremely time consuming and laborious (Ongley et 
al., 2013). Heterologous hosts that are optimised for the production of 
secondary metabolites can allow faster screening and identification of the 
compounds with increased yields. It is an especially valuable tool in the 
expression of BGCs from unculturable or poorly cultivable microbes (Baltz, 
2010; Zhang et al., 2011; Ongley et al., 2013). In this study, a 
chromatogram-simplified S. albus S4 D5 heterologous host was generated 
as a tool to aid in the continued discovery of secondary metabolites.  
 
There are many factors to consider in the construction of an optimal host. 
Deletions in the genome to generate a genome minimised strain and 
inactivation of native BGCs make way for a cleaner metabolic profile. This is 
in turn allow the identification and purification of the heterologously produced 
compound easier and represent a valuable tool in identifying unknown 
compounds. Furthermore, these deletions increase precursor availability as 
there will be less competition with the reduced production of endogenous 
metabolites (Ongley et al., 2013; Bekiesch et al., 2016). Antimycin, 
candicidin, surugamide, albaflavenone and fredericamycin encoding BGCs 
in the S. albus S4 genome were targeted rationally to make way for a better 
heterologous host (Figure 3.1). Antimycin and candicidin are prominent in 
the metabolic profile of S. albus S4 grown under standard laboratory 
conditions (Seipke, Barke, et al., 2011). Therefore, these BGCs were 
targeted to abolish the production of these compounds. Additionally, both 
antimycin and candicidin are antifungal compounds (Seipke, Barke, et al., 
2011). A heterologous host itself should preferably not exhibit any bioactivity 
as it can interfere with the screening of exogenous BGCs that may encode 
the production of bioactive secondary metabolites. The disruption of these 
BGCs was therefore desired to abolish the existing antifungal activity.  
 
Although, S. albus S4 does not exhibit antibacterial activities under standard 
laboratory conditions, albaflavenone, surugamide and fredericamycin are 
known compounds with reported bioactivities. Therefore, to reduce the 
chances of rediscovery when bioactivity is observed as well as to make way 
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for a better heterologous host that can be used to screen under different 
conditions, these BGCs were also mutated. Chemical extracts prepared from 
S. albus S4 D5 did not exhibit any antifungal or antibacterial activity (Figure 
3.2). Additionally, a cleaner metabolic profile is observed with the deletion of 
the five BGCs when grown in the routinely used MS media, which will make 
identification and purification of heterologously produced compounds easier. 
(Figure 3.3). Furthermore, even with the mutations in the five BGCs, S. albus 
S4 D5 sporulated and grew equally as well as the S. albus S4 WT strain 
(Ryan Seipke, unpublished data). While this work was in progress, 
Myronovskyi et al., published a new heterologous host named S. albus 
Del14 (Myronovskyi et al., 2018). Fifteen BGCs in S. albus J1074 were 
mutated to generate S. albus Del14 and no secondary metabolites were 
detected in the chromatogram from the chemical extract prepared from S. 
albus Del14 (Myronovskyi et al., 2018). S. albus Del14 adds to the suite of 
heterologous hosts available and will be a valuable tool in the activation 
and/or expression of BGCs.  
 
To demonstrate the potential of S. albus S4 D5 as a heterologous host, the 
17 kb lantibiotic cinnamycin BGC from Streptomyces cinnamoneus 
cinnamoneus DSM 40005 was successfully heterologously expressed 
(Figure 3.4). Current work in the laboratory also aims to heterologously 
produce different types of secondary metabolites such as polyketides and 
non-ribosomal peptides along with the use of replicative and integrative 
vectors to further demonstrate the stability and utility of S. albus S4 D5 as a 
heterologous host. Additionally, comparing the production of the 
heterologously produced compounds in S. albus S4 D5 with other 
heterologous hosts can shed further light into the utility of S. albus S4 D5 as 
an optimal host. Reducing the genome size has been shown to have a 
positive impact on the heterologous expression of secondary metabolite 
BGCs as with S. avermitilis (Komatsu et al., 2010; Komatsu et al., 2013). 
Therefore, future work also aims to target known BGCs to further reduce the 
genome size along with creating an even more simplified chromatogram 
profile. As many of the BGCs in the genome in S. albus S4 are silent, these 
mutations can also pave the way to activate these BGCs with the increased 
precursor availability. Additionally, any cluster-specific approaches that may 
lead to the activation of these silent BGCs may be identified easier with the 
newly simplified chromatogram profile.  
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3.8 Conclusions 
Though an ideal ‘super host’ strain is not yet available for the heterologous 
production of any and every BGC of interest, continued development of 
heterologous hosts will be of great value in the discovery and production of 
secondary metabolites. In this study, a new heterologous host, S. albus S4 
D5 was generated. Five BGCs, antimycin, candicidin, albaflavenone, 
surugamide and fredericamycin BGCs were rationally chosen and mutated 
to generate S. albus S4 D5. The final strain has a cleaner metabolic profile 
than the wild type strain, which will aid in the identification and purification of 
any heterologously produced compounds. Chemical extracts prepared from 
S. albus S4 D5 did not exhibit any antifungal activity with the loss of 
candicidin and antimycin and no antibacterial was observed either. 
Furthermore, the utility of S. albus S4 D5 was demonstrated through the 
heterologous production of cinnamycin. With the wealth of information 
available from genome mining efforts about silent BGCs from individual and 
metagenome sequences, heterologous hosts provide conditions that enable 
the screening of cloned BGCs under optimal conditions (Ongley et al., 
2013). S. albus S4 D5 was generated as a tool to aid in the continuing 
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Chapter 4 Identification of surugamides in Streptomyces 
albus S4 and the bioactivity profile of surugamides 
Abstract 
Genome mining has revealed the presence of many silent biosynthetic gene 
clusters in the genomes of streptomycetes with the potential to produce new 
and useful bioactive compounds. Approaches to awaken these silent gene 
clusters can be classified as pleiotropic approaches and cluster-specific 
approaches. The microbe of interest in this study, Streptomyces albus S4, 
does not produce any antibacterial compounds under standard laboratory 
conditions. However, genome mining has revealed the presence of 
biosynthetic gene clusters in its genome with the potential to produce 
antibacterial compounds. In this study, minimal medium agar facilitated the 
production of an antibacterial compound(s) in S. albus S4. Submission of the 
MSMS data prepared from the chemical extracts from S. albus S4 grown on 
minimal media to the GNPS platform identified surugamides within the 
chemical extract. Surugamide A was previously reported to have 
antibacterial activity against Staphylococcus aureus, however its mode of 
action is unknown. In this study, surugamide A was identified in the chemical 
extracts prepared from S. albus S4 and gene inactivation studies were used 
to link the compound to its gene cluster. Surugamide A was commercially 
synthesised to further investigate its bioactivity profile. Surprisingly, an MIC 
that is approximately 28 times greater than the reported MIC of surugamide 
A was observed. As the surugamide biosynthetic gene cluster also encodes 
the production of a linear peptide, surugamide F, the possibility of 
surugamide A working synergistically with linear peptide antibiotics was also 
investigated. In this study, surugamide A demonstrated synergism with 
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4.1 Introduction 
Genome mining of numerous Streptomyces spp. has revealed the presence 
of many silent biosynthetic gene clusters (BGCs) in their genomes. The 
published genomes of many actinomycetes have revealed that about 90% of 
the chemical potential of these microbes still remain to be discovered 
(Bentley et al., 2002; Wilkinson and Micklefield, 2007). These silent BGCs 
embody a large reservoir of therapeutic leads (Rutledge and Challis, 2015; 
Ziemert et al., 2016). Development of strategies to activate these BGCs is 
crucial in reaching the maximum potential of the genomics-driven endeavour 
in the discovery of novel antimicrobial compounds (Figure 4.1) (Rutledge 
and Challis, 2015). The methods developed thus far can be broadly divided 
into two major categories: pleiotropic approaches and cluster-specific 
approaches (Figure 4.1). Pleiotropic approaches hardly require any 
knowledge about specific gene clusters; rather, such approaches work by 
exerting their influence on more than one gene, triggering global changes 
and activating BGCs. On the other hand, cluster-specific approaches involve 
prioritisation of specific silent BGCs and allow more control. Such methods 
are particularly useful when information regarding the structural novelty of 
the predicted compound of a specific BGC can be garnered from 
bioinformatic analyses (Zhu et al., 2014; Ziemert et al., 2016). Though not 





























Figure 4.1 Genomics-driven activation of silent gene clusters 
summary 
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4.2 Pleiotropic approaches 
4.2.1 Ribosome engineering 
Due to an altered 30S ribosomal S12 protein responsible for streptomycin 
resistance, a Streptomyces lividans strain was able produce the blue 
pigmented antibiotic actinorhodin (Act) in ample amounts, which is an 
otherwise silent BGC in S. lividans (Ochi et al., 2004). Thus, it was proposed 
that modulation of ribosomal proteins or rRNA can lead to the activation of 
silent BGCs and the concept of ‘ribosome engineering’ was put forward 
(Ochi et al., 2004). Guanosine tetraphosphate (ppGpp), synthesised by the 
ribosomal enzyme ppGpp synthetase (relA gene product), is a bacterial 
alarmone involved in the stringent response (Artsimovitch et al., 2004). 
During the stringent response, uncharged tRNA, whose levels increase due 
to amino acid shortage, enter the A-site of the ribosome. When this 
happens, ppGpp synthetase utilises ATP and GTP to synthesise ppGpp. 
The alarmone ppGpp then binds directly onto the RNA polymerase and 
modulates transcription by up/downregulating various promoters (Ochi, 
1987; Artsimovitch et al., 2004; Ross et al., 2013). In streptomycetes, 
morphological differentiation and antibiotic production are interlinked with the 
ribosomal machinery playing an essential role in the modulation of gene 
expression during nutrient limitation via ppGpp (Chakraburtty et al., 1996; 
Hoyt and Jones, 1999). 
 
Therefore, it was postulated that mutations that can make the RNA 
polymerase to mimic the ppGpp bound conformation may result in the 
activation of silent BGCs (Ochi et al., 2004). As a result, ribosome 
engineering utilises sub-lethal concentrations of antibiotics that target the 
ribosome or RNA polymerase such as rifampicin, streptomycin and 
gentamycin with the hypothesis that altering the bacterial transcriptional and 
translational pathways can lead to enhanced levels of gene expression (Ochi 
et al., 2004; Ochi, 2007; Ochi and Hosaka, 2013). Induction of antibiotic 
producing silent gene clusters was observed in various actinomycetes by 
screening and selecting for spontaneous mutants of the genes encoding the 
RNA polymerase β-subunit (rpoB), S12 (rpsL) using gentamycin and 
streptomycin and the RNA polymerase targeting rifampicin, which led to the 
production and identification of a novel class of antibiotics called 
piperidamycins from Streptomyces mauvelicolor (Hosaka et al., 2009).  
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4.2.2 Variation in cultivation parameters 
Variation in growth conditions is a relatively simple approach in exploiting the 
secondary metabolism potential of microbes. Changes in the media 
composition, aeration rate and culturing vessel are all changes that can 
contribute to the induction of silent BGCs and improvement in production 
titre (Bode et al., 2002). The term ‘OSMAC’ (one strain many compounds) 
was coined by Zeeck and coworkers to describe the ability of strains to 
produce different secondary metabolites when grown under different 
fermentation conditions (Bode et al., 2002). Using the OSMAC approach and 
eight different culture conditions, Streptomyces sp. strain C34 was able to 
produce the newly identified polyketides (PKs) chaxalactins A-C as well as 
the previously known compounds desferroxamine E, hygromycin A and 5’’-
dihydrohygromycin A (Rateb et al., 2011).  
 
Using external signals called ‘elicitors’ is another recognised strategy in 
activating silent BGCs. The use of both chemical and biological elicitor 
molecules have proven to be successful in the activation of silent BGCs (Zhu 
et al., 2014). Chemical elicitation involves the use of compounds that are not 
of biological origin in the activation process that can lead to changes in the 
metabolite profile. Some examples of chemical elicitors include rare-earth 
elements, heavy metal ions and inorganic compounds (Abdelmohsen et al., 
2015). Supplementation of culture media with scandium activated the 
production of Act in S. lividans (Kawai et al., 2007). A threshold 
concentration of ActII-ORF4, the cluster-specific primary transcriptional 
regulatory protein in Act production, is required for the efficient transcription 
of its associated genes for Act production. The addition of scandium 
enhanced the transcription of actII-ORF4 to activate Act production in S. 
lividans (Kawai et al., 2007). Addition of other rare-earth elements such as 
lanthanum, yttrium, cerium and europium were also able to upregulate the 
production of Act in S. coelicolor (Kawai et al., 2007). Rare-earth elements 
are found around the globe, it is presumable that microbes have developed 
ways to respond to the low level concentrations of these elements to adapt 
to the conditions they are exposed to (Ochi and Hosaka, 2013).   
 
A large-scale screen of streptomycetes with a compound collection 
encompassing 30,569 small molecules identified 19 compounds that could 
remodel the secondary metabolite profile of streptomycetes. Out of the 19 
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compounds, 4 compounds referred to as the antibiotic remodelling 
compounds (ARCs), ARC2, ARC3, ARC4 and ARC5 were able to induce the 
production of Act in S. coelicolor, of which ARC2 was the most active 
(Craney et al., 2012). LCMS (liquid chromatography mass spectrometry) 
analyses also revealed that the S. coelicolor treated with the triclosan like 
ARC2 showed elevated production levels of the pyranone germicidins A-C 
and a reduction in the production of prodiginines and the daptomycin-like 
calcium dependent antibiotic (CDA) (Craney et al., 2012). Addition of ARC2 
to cultures of other actinomycetes such as Kutzneria sp. 744, Streptomyces 
pristinaespiralis ATCC 25486 and Streptomyces peucetius 27952 altered 
their secondary metabolite profiles also suggesting that ARC2 could be used 
as an elicitor across various actinomycetes (Craney et al., 2012). ARC2 
shares structural similarity with the fatty acid synthesis inhibitor triclosan, 
which inhibits the enoyl-acyl carrier protein FabI. FabI is responsible for 
catalysing the final and rate limiting step of fatty acid synthesis. Secondary 
metabolism such as PK biosynthesis and fatty acid biosynthesis share the 
common precursors of acetyl- CoA and malonyl-CoA and so, ARC2 may be 
acting by allowing these precursors to flow to secondary metabolism instead 
by partially inhibiting fatty acid biosynthesis (Craney et al., 2012).  
 
The addition of organic compounds such as dimethyl sulfoxide (DMSO) and 
ethanol can induce antibiotic production in some streptomycetes. The 
production of tetracenomycin C and chloramphenicol increased about 3-fold 
in Streptomyces glaucescens and Streptomyces venezuelae, respectively 
and the production of thiostrepton increased around 2-fold in Streptomyces 
azureus in the presence of 3% DMSO (Chen et al., 2000). Addition of 
ethanol (6%) dramatically increased the production of jadomycin B in S. 
venezuelae (Doull et al., 1994). Organic compounds such as DMSO and 
ethanol cause mistranslation, which probably results in the induction of a 
stress response and the promotion of secondary metabolism (Pettit, 2011). 
Inhibitors of the zinc containing enzymes and histone deacetylases (HDACs) 
such as sodium butyrate can activate antibiotic production via epigenetic 
perturbation (Moore et al., 2012). In eukaryotes, HDACs influence chromatin 
structure and gene expression by antagonizing histone acetylation (Pazin 
and Kadonaga, 1997). S. coelicolor harbours three HDAC-like genes. 
Sodium butyrate showed both stimulatory and inhibitory effects on the 
production of Act in S. coelicolor depending on the agar medium used. While 
addition of sodium butyrate to minimal medium agar activated Act production 
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in S. coelicolor,  repression of production was observed on the otherwise 
permissive R5 medium (Moore et al., 2012).  A similar pattern of production 
was also observed with N-acetyl glucosamine (GlcNAc) under poor nutrient 
and nutrient rich conditions (Rigali et al., 2008).  
 
Components of the cell wall, microbial hormones or molecules involved in 
signalling carbohydrates or cell derived biopolymers have also been 
successfully used as elicitors to activate the production of secondary 
metabolites. GlcNAc, the peptidoglycan cell wall constituent and chitin 
monomer elicited Act and undecylprodigiosin (Red) production in S. 
coelicolor under poor nutrient (famine) conditions via the de-repression of 
DasR- a GntR-family regulator. High concentrations of GlcNAc (5-10 mM) 
activated development and production of antibiotics under famine conditions 
and blocked antibiotic production under nutrient rich (feast) conditions (Rigali 
et al., 2008). The DNA binding sites of DasR (dre) are located upstream of 
the genes encoding activators of Act and Red. Electrophoretic mobility shift 
assays and reverse transcription-PCR revealed that the binding of DasR to 
the dre regions resulted in the down-regulation of antibiotic production 
(Rigali et al., 2006; Rigali et al., 2008). The PEP-dependent 
phosphotransferase system PTS is responsible for the import of GlcNAc, 
which is then deacetylated to form glucosamine-6-phosphate (GlcN-6P). 
GlcN-6P is a ligand for DasR and its allosteric binding to DasR reduces the 
affinity of DasR for its binding sites resulting in the de-repression and 
production of the antibiotics (Rigali et al., 2006; Rigali et al., 2008; Nothaft et 
al., 2010). Treatment of Streptomyces clavuligerus, S. griseus, 
Streptomyces hygroscopicus, S. venezuelae and Streptomyces collinus with 
GlcNAc also activated antibiotic production under famine conditions (Rigali 
et al., 2008) Rigali et al., found the stimulating effect of GlcNac to be 
common among various streptomycetes, but not universal (at least not under 
the conditions studied) and so, elicitation using GlcNAc in streptomycetes is 
another promising strategy in triggering secondary metabolism (Rigali et al., 
2008).  
 
Microbial hormones such as γ-butyrolactones play a major role in regulating 
morphological differentiation and secondary metabolism in streptomycetes 
(Hsiao et al., 2009). As with the A-factor in S. griseus, many γ-
butyrolactones are involved in the regulation and production of secondary 
metabolites in other streptomycetes such as Streptomyces virginiae and 
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Streptomyces aurefaciens, and the production of virginiamycin and auricin, 
respectively  (Kawachi et al., 2000; Novakova et al., 2011; Zhu et al., 2014). 
Addition of exogenous γ-butyrolactones can also be used as environmental 
cues to trigger secondary metabolite production. An example is the 
production of pimaricin by Streptomyces natalensis that is triggered by the 
addition of S. griseus A-factor. In S. natalensis, the hydrophilic autoinducer 
molecule PI factor is normally responsible for the production of pimaricin. S. 
natalensis mutant strain lacking the PI factor is unable to produce pimaricin 
and production is restored upon addition of the PI factor (Recio et al., 2004). 
Surprisingly, the production of pimaricin was also restored by the addition of 
A-factor from S. griseus, thus demonstrating the fact that the exogenous 
addition of these small molecules can also aid in the activation of secondary 
metabolism (Recio et al., 2004).   
 
Addition of microbial lysates can also elicit antibiotic production in 
actinomycetes. While pure cultures of S. coelicolor only produced low 
concentrations of Red, the treatment of cultures with live and heat killed 
Bacillus subtilis increased the yield of Red (Luti and Mavituna, 2011; Jaber 
et al., 2014). On solid medium, the production of Red was observed at the 
interface between S. coelicolor and B. subtilis and no production of Red was 
seen with S. coelicolor grown alone (Luti and Mavituna, 2011). Another 
study, which utilised heat killed B. subtilis and S. aureus cells, also found 
upregulated production of Red with a higher yield observed with heat killed 
S. aureus (Luti and Mavituna, 2011). As S. coelicolor and B. subtilis are both 
found in the soil, S. coelicolor probably has recognition mechanisms in place 
leading to interspecies interactions (Luti and Mavituna, 2011). The higher 
production of the antibiotic with the heat killed S. aureus may be because S. 
aureus is more foreign to S. coelicolor and therefore, simulates a more 
competitive environment (Abdelmohsen et al., 2015).   
 
4.2.3 Co-cultivation 
Another approach in activating silent BGCs is via the co-cultivation of 
microorganisms. The vast structural diversity observed among the natural 
products is thought to have evolved through the interactions with other 
microbes and higher organisms and as a result, being produced only at 
certain times (Zhu et al., 2014). In nature, many secondary metabolites will 
only be produced upon detection and receipt of specific signals from their 
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surroundings or surrounding microbes. Streptomycetes are predominantly 
soil-dwelling microbes that exist with other microbes. Their interactions with 
other microbes in the soil therefore has the potential to activate gene 
clusters to initiate secondary metabolite production (Zhu et al., 2014).  
 
The intricate mechanisms involved in such interactions are not well 
understood but the activation or repression of metabolite production may be 
via physical cell-to-cell interactions, via small molecules such as quorum 
sensing molecules or siderophores, horizontal gene transfer or through the 
catalytic activation of precursor metabolites (Abdelmohsen et al., 2015). For 
example, the co-cultivation of S. lividans with Tsukamurella pulmonis, a 
mycolic-acid containing actinomycete induced the production of Act and Red 
in S. lividans via cell-to cell interactions (Onaka et al., 2011). Members of the 
Corynebacterium genus along with other closely related strains of T. 
pulmonis were also able to activate the production of the pigment in S. 
lividans (Onaka et al., 2011). In these cell-to-cell interactions, mycolic-acid 
was identified to be essential. The mycolic-acid mutant of Corynebacterium 
glutamicum was unable to stimulate the production of Red in S. lividans. 
Additionally, the treatment of the co-culture with a mycolic-acid inhibitor also 
inhibited the production of the red pigment (Onaka et al., 2011).  
 
Co-cultivation of streptomycetes with predator microbes can also induce 
antibiotic production. Cultivation of S. coelicolor with one its predatory 
microbes, Myxococcus xanthus, induced the production of Act (Pérez et al., 
2011). The Act producing S. coelicolor colonies also repelled the growth of 
M. xanthus around the colonies. Actinorhodin is an antibiotic that shows 
antibacterial activity against Gram-positive bacteria (Mak and Nodwell, 
2017). The inhibition in growth of the Gram-negative M. xanthus strain 
around the Act producing S. coelicolor strain suggests that S. coelicolor 
might be able to use Act as a repellent signal against M. xanthus (Pérez et 
al., 2011).  
4.3 Cluster-specific approaches 
The incredible amount of genome sequence data available has led to the 
development of sophisticated bioinformatic tools for the characterisation of 
BGCs. For instance, the computational tool antiSMASH (antibiotics & 
Secondary Metabolite Analysis Shell) can identify and predict known classes 
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of secondary metabolite BGCs in the genome sequence. AntiSMASH is also 
able to provide comprehensive functional annotations of biosynthetic 
systems such as non-ribosomal peptide synthetase (NRPS) and polyketide 
synthetase (PKS) systems identified and can predict the possible chemical 
structures of the compounds predicted to be produced by these 
megaenzymes (Medema et al., 2011). Advances in bioinformatics have 
aided researchers in prioritising silent BGCs, which are predicted to encode 
the production of potentially novel secondary metabolites, thereby lowering 
the chances of rediscovery (Rutledge and Challis, 2015). Cluster-specific 
approaches are of great use when a novel structure is predicted via 
bioinformatics as well as when pleiotropic approaches fail to bear fruit (Zhu 
et al., 2014; Rutledge and Challis, 2015).  
 
4.3.1 Manipulation of gene cluster specific regulatory genes 
Insights into the composite regulation of secondary metabolites in 
actinomycetes has been invaluable in natural product discovery. Gene 
cluster specific transcriptional activators or repressors often control the 
expression of BGCs and the genes encoding these regulators are commonly 
found within the gene cluster itself. Overexpression of gene cluster specific 
activator genes or deleting the genes encoding repressors in the BGC is a 
common and promising strategy in awakening silent BGCs (Baral et al., 
2018). Though not exhaustive, some examples where overexpression of 
activator genes or deletion of repressor genes has led to the activation of 
silent BGCs are described below.  
 
One of the earliest examples of its use was carried out in Streptomyces 
ambofaciens with the stambomycin BGC. The genome of S. ambofaciens 
harbours a large PKS BGC and transcriptional analysis revealed that this 
BGC was not expressed under standard laboratory growth conditions. In 
silico analyses predicted that the regulatory gene samR0484 located within 
the BGC encodes a putative activator belonging to the LAL (Large ATP 
binding regulators of the LuxR family) family. Subsequently, the constitutive 
expression of this activator triggered the production of  stambomycins 
(Laureti et al., 2011). Many such LAL activators have since been identified in 
the genomes of various actinomycetes (Laureti et al., 2011). Recently, the 
overexpression of a pathway specific LAL-family activator in Streptomyces 
pactum  activated the production of totopotensamides (Chen et al., 2017). 
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The chattamycin BGC in Streptomyces chattanoogensis L10 was 
successfully activated via the overexpression of a putative pathway specific 
activator encoded by chaI, which led to the discovery of two angucycline 
antibiotics- chattamycins A and B (Zhou et al., 2015). Thus, the constitutive 
expression of pathway specific activators is a powerful tool in the activation 
of silent gene clusters.  
 
Inactivation of repressors is another common strategy used to activate silent 
BGCs. In S. ambofaciens, the kinamycin antibiotics were discovered 
following the deletion of the gene alpW, which encodes a repressor of the 
otherwise silent type II PKS system (Bunet et al., 2011). Another example is 
the induced production of gaburedins, a new family of γ-aminobutyrate 
ureas, in S. venezuelae via the deletion of a transcriptional repressor GbnR 
(Sidda et al., 2014). Another strategy that has the potential to activate silent 
BGCs is reporter-guided mutant selection. This strategy uses genome scale 
random mutagenesis to awaken cryptic clusters with a promoter-reporter 
selection system for successfully identifying the activated mutants based on 
specific phenotypes. Reporter-guided mutant selection was used to activate 
a silent gene cluster in Streptomyces sp. PGA64, which in turn produced two 
new anthraquinone aminoglycosides (Guo et al., 2015).  
 
4.3.2 Refactoring 
The affordable costs of DNA synthesis in recent years and the emergence of 
new metabolic engineering strategies has made refactoring BGCs possible. 
Refactoring of a BGC involves the replacement of the native host promoter 
of the gene cluster of interest with constitutive or inducible promoters (Baral 
et al., 2018). For example, a CRISPR-Cas9 knock in strategy, which can 
introduce heterologous promoters, was used to activate various BGCs in 
Streptomyces species. This strategy was used to activate the production of 
indigoidine in Streptomyces albus with the introduction of the strong 
promoter kasO*p upstream of the biosynthetic gene. The CRISPR-Cas9 
knock-in strategy was also successful in activating previously 
uncharacterised silent BGCs in Streptomyces roseosporus, S. venezuelae 
and Streptomyces viridochromogenes (Zhang et al., 2017). In another study, 
the insertion and expression of the promoter ermE*p in a silent gene cluster 
in S. albus J1074 activated the production of two new alteramide derivatives 
(6-epi-alteramides A and B) (Olano et al., 2014). Refactoring is often used in 
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heterologous expression where the heterologous host of a minimalised 
secondary metabolite profile is optimised for production (explored further in 
chapter 3). Upon successfully cloning and expressing the BGC in an 
optimised heterologous host, it can help confirm the production of the 
compounds by the putative cluster, investigate the biosynthesis of natural 
products and yield the compounds which can then be used for further 
studies (Gomez-Escribano and Bibb, 2011).  
 
4.3.3 Gene knock out studies or heterologous expression 
combined with comparative metabolite analyses 
For biosynthetic systems where bioinformatic tools are not yet able to predict 
substrate specificity with confidence, two fruitful strategies that can be 
utilised are gene knock out/comparative metabolic profiling and heterologous 
gene expression/comparative metabolic profiling (Corre and Challis, 2007). 
In gene knock out/comparative metabolic profiling studies, genes from the 
BGC of interest identified via genome mining that are hypothesized to be 
required for the metabolite production are first inactivated and the metabolic 
profile of the culture supernatants of mutant is compared with that of the wild 
type using analytical techniques such as LCMS. The metabolites that are 
present in the wild type but not present in the non-producing mutant are 
likely the products of the gene cluster of interest. These metabolites can 
then be isolated and characterised structurally (Corre and Challis, 2007; 
Challis, 2008b). In heterologous expression/comparative metabolic profiling 
studies, the entire gene cluster is cloned and is expressed in a heterologous 
host optimised for the production. The metabolic profile of the heterologous 
host expressing the gene cluster is compared to the same host lacking the 
gene cluster via analytical techniques. And as with the first approach, the 
metabolites that are present in the gene cluster containing host but not found 
in the ‘empty’ host are likely the products of the gene cluster (Corre and 
Challis, 2007; Challis, 2008b). 
 
4.4 Limitations of pleotropic approaches and cluster-specific 
approaches  
Both pleiotropic and pathway specific approaches have demonstrated the 
potential of microbes in producing structurally diverse metabolites with 
interesting bioactivities. Though specific approaches have their benefits, 
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there are also various limitations to both (Rutledge and Challis, 2015). In 
comparison to cluster-specific approaches, pleiotropic approaches enable a 
higher throughput even when very little is known about the regulation of the 
silent BGC. Pleiotropic approaches can also be applied to a wide variety of 
strains. However, with such approaches, the results are extremely hard to 
predict as they are intrinsically empirical. The induction of many BGCs at the 
same time brings about global changes in the cell and can make 
identification and isolation of new metabolites extremely difficult (Rutledge 
and Challis, 2015). On the other hand, gene cluster specific approaches 
provide more predictability and control. However, these approaches are 
generally lower throughput compared to pleiotropic approaches as it requires 
specific strategies for the awakening of each silent BGC and as a result, can 
be extremely time consuming. Insight is often required about the biosynthetic 
and regulatory genes of the BGC involved in the production of the metabolite 
of interest too (Rutledge and Challis, 2015). The regulatory systems are 
complex, with multiple players involved. Cluster-situated and global 
regulators can add multiple layers of regulation and can complicate cluster-
specific approaches (Liu et al., 2013). Additionally, such approaches can be 
extremely challenging if the source organism is not genetically amenable 
(Rutledge and Challis, 2015).   
4.5 Silent biosynthetic gene clusters in Streptomyces albus 
S4 
Streptomyces albus S4 was originally isolated from the leaf-cutting 
Acromyrmex octospinosus ant colonies (Barke et al., 2010; Seipke, Barke, et 
al., 2011). The A. octospinosus ant species form a mutualistic relationship 
with the fungus Leucoagaricus gongylophorus exchanging food, protection 
and transport services with the fungal cultivar (Schultz and Brady, 2008). 
The fungal garden is prone to attack from different microbes such as the 
necrotrophic fungus genus Escovopsis. The ants help defend the fungal 
garden though grooming, weeding, antifungal secretions and through the 
application of weed-killers (Schultz and Brady, 2008). The ants also form a 
symbiotic relationship with actinomycetes such as those belonging to the 
genera Pseudonocardia, Amycolatopsis and Streptomyces (Currie et al., 
1999; Sen et al., 2009; Haeder et al., 2009). It is thought that the 
actinomycete bacteria associated with the ants help protect the fungal 
garden through the production of antimicrobial compounds (Currie et al., 
1999; Haeder et al., 2009). 
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When cultivated using mannitol-soya agar, S. albus S4 produces antimycin 
and candicidin antifungals, but it does not produce an antibacterial 
compound (Figure 4.2) (Barke et al., 2010; Seipke, Barke, et al., 2011; 
Seipke, Crossman, et al., 2011). Submission of its genome sequence to the 
antiSMASH server (version 2.0) revealed that its genome encodes at least 
28 BGCs (Figure 4.3) (Blin et al., 2013; Seipke, 2015). Of the 28 predicted 
BGCs, some are predicted to produce secondary metabolites that may have 
antibacterial properties (Seipke, 2015). For example, BGC 19 is predicted to 
encode a terpene biosynthetic system with the putative product predicted to 
be albaflavenone (Seipke, Barke, et al., 2011; Seipke, 2015). Albaflavenone 
is a volatile tricyclic sesquiterpene with antibacterial activity (Gurtler et al., 
1994; Moody et al., 2012). BGC 22 is an NRPS system whose putative 
product is predicted to be a lipoglycopeptide- an established antibacterial 
class against Gram-positive bacteria (Kahne et al., 2005; Seipke, Barke, et 
al., 2011; Seipke, 2015). Another example is BGC 28, which is an NRPS 
biosynthetic system that is predicted to produce a gramicidin-like compound 
(Seipke, Barke, et al., 2011). The albaflavenone and gramicidin-like 
compound encoding gene clusters (BGCs 19 and 28, respectively) are 
conserved in the core secondary metabolome across S. albus strains, while 
the lipoglycopeptide BGC is unique to S. albus S4 (Seipke, 2015). 
Therefore, genome mining revealed that the genome of S. albus S4 
harbours silent gene clusters, which hold the potential to encode the 
































Figure 4.2 S. albus S4 does not exhibit antibacterial activity on 
mannitol-soya flour agar. A whole cell bioassay of S. albus S4 
challenged with S. aureus SH1000.  
Figure 4.3 antiSMASH predicted biosynthetic gene clusters 
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4.6 Aims and objectives 
As the genome of S. albus S4 encodes silent BGCs with the potential to 
make secondary metabolites with antibacterial properties, this study aimed 
to: 
• Activate the production of an antibacterial compound(s) using 
pleiotropic strategies 
• Identify and chemically characterise the activated antibacterial 
compound(s) 
• Characterise the bioactivity of the activated antibacterial compound(s) 
4.7 Results 
4.7.1 Minimal medium facilitates the production of an antibacterial 
compound in S. albus S4 
S. albus S4 does not exhibit antibacterial activity on the routinely used MS 
agar (Figure 4.2).  However, mannitol minimal medium (MM, containing 25 
mM mannitol) facilitated the production of an antibacterial compound(s).  S. 
albus S4 and S. albus DantDcan (mutant in antimycin and candicidin 
production and therefore, a cleaner metabolic profile for LC-HRMS analysis) 
strains both exhibited antibacterial activity against S. aureus SH1000 (Figure 
4.4). Since the zone of inhibition observed on MM agar although 
reproducible, was relatively small, elicitor molecules were used to try and 
enhance the antibacterial activity seen. Following the findings of Rigali et al., 
the cell-wall component GlcNAc was tested as a chemical elicitor at a final 
concentration of 10mM under famine (MM) conditions. However, the addition 
of GlcNAc had no additive effect on the antibacterial activity (Appendix, 
Figure A2.1). The sizes of the zones of inhibition observed on MM agar 
remained similar to the sizes observed with the addition of 10 mM GlcNAc. 
The addition of sodium butyrate to MS agar had no phenotypic effect and no 
antibacterial activity was observed with S. albus S4 (Figure A2.1). 
Surprisingly, on MM, the addition of sodium butyrate switched off the 
antibacterial activity (Figure A2.1).  
  











4.7.2 Surugamides identified in the S. albus S4 chemical extracts 
prepared from MM 
Ethyl acetate extracts prepared from S. albus S4 grown on MM agar 
retained antibacterial activity (Figure A2.2) and were analysed by LC-
HRMSMS. The MSMS data obtained was submitted to the GNPS (Global 
Natural Products Social molecular networking) infrastructure (Mohimani et 
al., 2016; Wang et al., 2016). One of the tools the GNPS platform offers is 
DEREPLICATOR. DEREPLICATOR compares the fragmentation patterns of 
peptidic natural products within the experimental MSMS input data against a 
database of theoretical MSMS spectra of a chemical library. The 
dereplication algorithms identify peptide spectrum matches and statistically 
significant matches based on similarities are reported (Mohimani et al., 
2016). In this study, the GNPS platform identified antimycin (antifungal), 
homosalate (hormone disruptor), cyclopentyladenosine (A1 adenosine 
receptor agonist), benzalkonium chloride (BAC, a quaternary ammonium 
compound) and the GNPS DEREPLICATOR tool identified surugamide A 
(SA) and D within the chemical extract (Figure A2.3). Of the compounds 
detected by GNPS, two are reported to have antibacterial activity. BAC is a 
cationic surfactant often used in disinfectants owed to its biocidal properties 
(Kim, Hatt, et al., 2018; Kim, Weigand, et al., 2018). Additionally, SA has 
S.	albus	S4	WT S.	albus	S4	DantDcan
Figure 4.4 Minimal medium facilitates the production of an 
antibacterial compound in S.  albus S4 WT. S. albus S4 WT and 
S. albus S4 DantDcan (mutant in antimycin and candicidin 
production) both exhibit antibacterial activity against S. aureus 
SH1000 on MM.  
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been reported to have antibacterial activity (Wang et al., 2014). While BAC is 
a broad-spectrum biocide, SA is a non-ribosomal peptide (NRP) with specific 
bioactivity and an unknown mode of action (Wang et al., 2014; Kim, Hatt, et 
al., 2018). Therefore, SA was chosen to be investigated further.  
 
Surugamides are a group of NRPs that were first identified from the marine 
Streptomyces sp. JAMM992 (Takada et al., 2013). The sur BGC encodes 
the production of five cyclic octapeptides surugamides A-E (SA-SE) and a 
linear decapepetide named surugamide F (SF) (Takada et al., 2013; 
Ninomiya et al., 2016). A schematic diagram of the surugamide (sur) BGC 
from S. albus S4 is presented in Figure 4.5. SA was previously reported to 
have antibacterial activity against S. aureus. The surugamide BGC is further 
explored in chapter 5. Here, the fragmentation pattern of SA from the MSMS 
data from S. albus S4 chemical extract matched the fragmentation pattern of 
SA in the GNPS database (Figure A2.4). Further LC-HRMS analyses 
confirmed the presence of SA in the chemical extract prepared from S. albus 
S4 DantDcan (Figure 4.5). In order to corroborate these data, a 
CRISPR/Cas9 mutational strategy was used to mutagenize the sur BGC, 
which resulted in the generation of the strain DantDcanDsurA (Figure A2.5; 
the generation of S. albus S4 DantDcanDsurA was done together with 
Ellie Harris). Ethyl acetate extracts prepared from S. albus S4 
DantDcanDsurA were analysed by LC-HRMS to check for the 
presence/absence of SA. Deletion of surA abolished the production of SA, 

























4.7.3 S. albus S4 DantDcanDsurA retained antibacterial activity 
To check whether the activity seen on MM agar was attributable to SA, 
whole cell bioassays against S. aureus SH1000 were carried out with S. 
albus S4 DantDcan and S. albus S4 DantDcanDsurA. However, S. albus 





Figure 4.5 S. albus S4 encodes the production of surugamides. a) A 
schematic of the surugamide biosynthetic gene cluster in S. albus 
S4. The BGC comprises of four non-ribosomal peptide synthetases 
(surABCD) of which surAC encodes the production of surugamide A 
(SA) and surBC encodes the production of surugamide F. b) The 
EICs corresponding to the [M+H]+ ions are shown for SA 
(C48H81N9O8). While SA is present in the chemical extracts from S. 




















4.7.4 Commercially synthesised SA 
SA is reported to have antibacterial activity against S. aureus, however, its 
mode of action is unknown (Wang et al., 2014). Therefore, to probe further 
into its bioactivity profile in vitro, SA was commercially synthesised. Detailed 
LC-HRMS was performed to verify that the synthesised compound was in 
fact SA. The synthetic SA and biologically produced SA both possess the 
same retention time and their respective MS2 fragmentation patterns are 








Figure 4.6 Whole cell bioassays of S. albus S4 DantDcan and S. 
albus S4 DantDcanDsurA on MM against S. aureus SH1000. 
The surugamide A mutant S. albus S4 DantDcanDsurA retained 
antibacterial activity on MM. 








4.7.5 Antimicrobial activity of SA 
To probe into the bioactivity profile of SA, minimum inhibitory concentration 
(MIC) assays were performed with SA against Escherichia coli BW25113, 
Candida albicans and S. aureus SH1000. SA did not exhibit any antibacterial 
activity against E. coli and no antifungal activity was observed against C. 
albicans (Figure 4.8). Surprisingly, in this study, SA had an MIC of 256 
µg/mL against S. aureus SH1000, which is approximately 28 times greater 





Figure 4.7 Comparison of commercially synthesised surugamide 
A (SA) with SA from the chemical extracts of S. albus S4. a) 
The EICs corresponding to the [M+H]+ ions are shown for SA 
(C48H81N9O8) from the chemical extract from S. albus S4 and 
commercially synthesised SA. Both possess the same retention 
time. b) The fragmentation pattern of SA from the MSMS data 
from the chemical extract of S. albus S4 compared to that of the 
commercially synthesised SA. The fragmentation patterns were 























4.7.6 SA shows synergism with other linear membrane damaging 
antibiotics 
 
In lieu of the lack of antibacterial activity with SA, we hypothesised that SA 
and SF may work synergistically. The organisation of the biosynthetic genes 
(surABCD) of the sur BGC means that SA and SF are both presumably co-
produced at the same time (Figure 4.5). To explore the possibility of SA and 
SF working together as a compound antibiotic to exert antibacterial activity, 
checkerboard MIC assays were used to investigate whether SA 
demonstrated synergism with the linear peptide antibacterial compound 
gramicidin D. Gramicidin D is a linear polypeptide antibiotic complex 
comprising of a heterogeneous mix of gramicidin A, B and C; of which 
gramicidin A is the most abundant (80%) (Kelkar and Chattopadhyay, 2007). 
Looking at the chemical structures of SF and gramicidin A, both compounds 
appear to share structural similarity (Figure 4.9). Checkerboard MIC assays 
of SA were also performed with the membrane damaging detergent 
cetyltrimethylammonium bromide (CTAB) and the cyclic, non-membrane 
damaging antibiotic erythromycin. The chemical structures of SA, SF, 






Figure 4.8 Bioactivity profile of surugamide A against E. coli 
BW25113, C. albicans and S. aureus SH1000. Bioactivity was 
only seen against S. aureus and the MIC was 256 µg/mL  


























The MICs of the compounds against S. aureus SH1000 were first 
determined before carrying out the checkerboard assays. The MICs were as 
follows: 0.5 µg/mL for gramicidin D, 2 µg/mL for CTAB and 0.25 µg/mL for 
erythromycin. In the checkerboard assays, SA and gramicidin D 
demonstrated synergism (Figure 4.10) with an FIC (fractional inhibitory 
concentration) of 0.281. Neither CTAB nor erythromycin showed any effect, 
with inhibition in growth only seen at the respective MICs of the compounds 





































































































































































Figure 4.9 Chemical structures of surugamide A, surugamide 
F, gramicidin A, CTAB and erythromycin 








4.7.7 The titre of SF is much lower than SA in vivo 
On MM, though the production of SA is readily detectable, hardly any SF is 
detected (Figure 4.11). In the first ever report of SF, liquid ISP2 media was 
used as the growth media for Streptomyces sp.JAMM992 (Ninomiya et al., 
2016). When S. albus S4 is cultivated using ISP2, the yield of SF increases, 
but it is still dramatically lower than that of SA (Figure 4.12, Figure A2.6). 
Comparing the peak area of SA and SF from the ISP2 culture chemical 
extracts, the titre of SF is 98.9% lower than that of SA. Additionally, a 
bioassay of the chemical extract obtained from S. albus S4 grown in liquid 
ISP2 media did not exhibit any antibacterial activity against S. aureus 
SH1000 (Figure 4.12). The relatively low titre of SF produced by S. albus S4 
may explain the lack of bioactivity of crude extracts.  
 
Figure 4.10 Checkerboard assays of surugamide A with gramicidin 
D, CTAB and erythromycin. Synergy was only observed with SA 
and gramicidin D with an FIC of 0.281, which is consistent with 
synergism. SA did not show any interaction in terms of antibacterial 
activity with CTAB or erythromycin, with inhibition in the growth of 















































0 1 2 3 4 5 6 7
Time	(minutes)
SA
SF Figure 4.11 Production of surugamide A (SA) and 
surugamide F (SF) in MM. 
The EICs corresponding to 
the [M+H]+ ions are shown 
for SA (C48H81N9O8) and SF 
(C52H85N11O12). While SA is 
easily detectable in the 
chemical extracts of S. albus 
S4 grown on MM agar, the 
yield of SF is drastically 
lower. The y-axis intensity 



























Figure 4.12  Comparison of the production of surugamide A (SA) 
and surugamide F (SF) in MM to ISP2 liquid cultures. a) The 
EICs corresponding to the [M+H]+ ions are shown for SA 
(C48H81N9O8) and SF (C52H85N11O12). The y-axis scale is set to a 
max of 6 x 106. Due to technical issues at the time, the extracts 
were run on two different columns. The production of SA and SF by 
S. albus S4 is greater in ISP2 than on MM agar. However, the yield 
of SF is still drastically lower. b) Antibacterial assays of the 
chemical extract prepared from S. albus S4 grown in ISP2. 1- 
methanol, 2- chemical extract prepared from S. albus S4. No 
antibacterial activity against S. aureus was observed with the S. 
albus S4 chemical extract. 
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4.8 Discussion 
Pleiotropic approaches hold great potential in the activation of silent BGCs 
(Zhu et al., 2014; Baral et al., 2018). In this study, the use of MM agar 
facilitated the production of an antibacterial compound(s) in S. albus S4 
(Figure 4.4) and led to the identification of a group of compounds called 
surugamides from S. albus S4 (Figure A2.3, Figure A2.4, Figure 4.5). 
Although such approaches are generally high throughput, they bring about 
global changes in the metabolome making identification of the compound(s) 
responsible for the observed bioactivity challenging (Baral et al., 2018). Even 
though SA is reported to have antibacterial activity in the literature, it was not 
responsible (at least not solely) for the antibacterial activity observed on MM 
as the SA mutant still retained antibacterial activity (Figure 4.6). The 
antibacterial activity observed could be attributable to BAC or another 
compound(s). Additionally, pleiotropic approaches also do not make use of 
the information available from genome sequencing and genome mining to its 
full potential as such approaches are not able to target the most interesting 
gene clusters. As a result, the use of this approach also suffer from 
rediscovery issues (Baral et al., 2018). Therefore, the use of data driven 
platforms such as GNPS is highly valuable as they enable dereplication to 
identify previously known compounds (Wang et al., 2016; Mohimani et al., 
2016). Recently, the putative gramicidin-like compound that S. albus S4 
shares with S. albus J1074 was in fact identified to be surugamides in S. 
albus J1074 using the GNPS platform and was confirmed through 
experimental work (Mohimani et al., 2016). In this study, the GNPS platform 
identified surugamides from S. albus S4 MM agar extracts (Figure A2.3) and 
experimental work with the SA mutant S. albus S4 DantDcanDsurA 
matched the compound to the BGC as the production of SA was abolished 
in the mutant strain (Figure 4.5). 
 
Surugamides are a known group of compounds with SA reported to have 
antibacterial activity (Takada et al., 2013; Wang et al., 2014; Ninomiya et al., 
2016). However, their mechanism of action is unknown, which fuelled the 
initiative to further explore the bioactivity profile of SA. SA did not exhibit 
antifungal activity against C. albicans or antibacterial activity against E. coli 
(Figure 4.8). Previously, SA was reported to have antibacterial activity 
against S. aureus with an MIC of 10 µM (= 9 µg/mL) (Wang et al., 2014). 
However, in this study, SA had an MIC of 256 µg/mL, which is approximately 
28 times greater than the reported MIC (Figure 4.8). In the report by Wang et 
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al.,  SA was purified from a Streptomyces isolate from an underground coal 
mine fire site, Streptomyces sp. RM-27-46. The isolated compound was 
identified to be SA via correlation of 1H-NMR and 13C-NMR analyses data 
and HRMS data to what is reported in the literature, which was then used in 
the MIC assay (Wang et al., 2014). In contrast, in this study, commercially 
synthesised SA was used (Figure 4.7) as purification of secondary 
metabolites can often be extremely challenging (Rutledge and Challis, 
2015). However, it was surprising that the commercially synthesised SA 
showed a much higher MIC than the reported MIC of SA. The isolation and 
purification of secondary metabolites is challenging and laborious and as a 
result, the compound can sometimes be contaminated with other molecules 
from the crude extract (Bucar et al., 2013; Xiao et al., 2013). This possibly 
could explain the lower MIC of SA that was previously reported, where a low 
but potent concentration of a contaminant might be present, which is likely 
the source of the bioactivity observed. 
 
The higher MIC of SA led us to hypothesize that SA and SF may function 
synergistically. Many examples of antibiotics that work synergistically have 
been reported (Acar, 2000). For example, streptomycin and penicillin G acts  
synergistically with an increased uptake of streptomycin into enterococci in 
the presence of penicillin, which acts on the cell wall. The combination 
therapy of penicillin G and streptomycin in turn reduced the frequency of 
relapse in entercoccal endocarditis treatment (Reynolds and Rowley, 1953; 
Moellering and Weinberg, 1971). Quinupristin-dalfopristin is a combination of 
two semi-synthetic streptogramin antibiotics, which exhibit synergistic 
antibacterial activity against a wide array of Gram-positive bacteria by 
stabilising the binding of each other to the ribosome (Finch, 1996; Speciale 
et al., 1999).  
 
As purified/synthesised SF was not available, gramicidin D was used to 
initially test this hypothesis in a preliminary test. Gramicidin A, which makes 
up 80% of gramicidin D is a linear peptide antibiotic and shares structural 
similarity with SF (Figure 4.9). Linear gramicidins are ionophores that work 
by forming well-defined cation specific ion channels with a pore size of 4 Å. 
The ion channels formed are permissive to the passage of monovalent 
cations (Kelkar and Chattopadhyay, 2007). In the checkerboard assays 
conducted, SA displayed synergism with gramicidin D. Synergism was 
determined using the FIC index with a value of ≤ 0.5 interpreted as a 
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synergistic interaction (Schwalbe and Steele-Moore, L (Ed.) Goodwin, 2007). 
The ƩFIC of SA and gramicidin D was calculated to be 0.281, which is 
consistent with synergism. SA did not exhibit any synergism with the control 
compounds CTAB or erythromycin (Figure 4.10). CTAB is a cationic 
surfactant, which works by rupturing the cell membrane resulting in cell lysis 
(Simões et al., 2005). SA did not demonstrate any interaction with the 
detergent CTAB in terms of antibacterial activity with growth inhibition only 
seen at the respective MICs of SA (256 µg/mL) and CTAB (2 µg/mL), 
suggesting that the interaction of SA and the peptide antibiotic gramicidin D 
is specific (Figure 4.10). Additionally, as with CTAB, SA did not show any 
changes in the antibacterial activity in the presence of the macrolide 
antibiotic erythromycin with inhibition in growth only seen at their respective 
MICs (Figure 4.10). To speculate, it maybe that SF plays a role in helping 
SA gain access to its target site, or it may be that SA and SF interact to work 
together as a compound antibiotic.  
 
As the genes for the production of SA and SF are arranged in an operon in 
the surugamide BGC, both compounds are most likely produced at the same 
time (Figure 4.5). However, the yield of SF is drastically lower compared to 
that of SA. While on MM SF was barely detectable (Figure 4.11), chemical 
extracts prepared from S. albus S4 grown in ISP2 cultures showed that SF 
was produced at a detectable yield (Figure A2.6). However, the titre of SF 
was ~98.9% lower than that of SA, which may explain why no antibacterial 
activity was observed with the S. albus S4 ISP2 crude extract (Figure 4.12). 
It may be that a sufficient quantity of SF is not available for SA and SF to 
exhibit synergism. Future work with purified/synthesised SF on its own and 
with SA can shed light on whether they do in fact act synergistically. If they 
are in fact synergistic, to my knowledge, two compounds that are produced 
from the same biosynthetic locus has previously not been reported to exhibit 
such an interaction. The synergistic interaction of SA with gramicidin D is an 
interesting phenomenon. Use of other linear membrane damaging antibiotics 
as well as structurally different membrane damaging antibiotics (such as 
nisin and gramicidin S) can also provide further insight  (Guilhelmelli et al., 
2013).  
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4.9 Conclusions 
In this study, the use of MM facilitated the production of an antibacterial 
compound(s) in S. albus S4, which does not otherwise exhibit antibacterial 
activity under standard laboratory conditions. The GNPS platform identified a 
group of compounds called surugamides from the chemical extracts of S. 
albus S4 grown on MM. The production of SA was experimentally verified, 
linking the compound to its BGC. In this study, the MIC of SA against S. 
aureus was 28 times greater than the reported MIC of SA. Additionally, SA 
demonstrated synergism with the ionophore gramicidin D, which may 
suggest that SA demonstrates a similar synergistic interaction with SF to 
exert its antibacterial activity. However, this hypothesis still needs to be 
experimentally verified. With the advances in genome sequencing and 
genome mining, this study used platforms such as antiSMASH and GNPS to 
predict and then identify surugamides in S. albus S4 demonstrating the utility 
of such tools. The identification of the compound enabled an informative 
decision to be taken to pursue the compound further. In this genomics era, 
the growing field of genomics-driven natural product discovery hold great 
potential in the activation of silent gene clusters and in the identification and 
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Chapter 5 Assembly line release of surugamides 
Abstract 
Non-ribosomal peptides (NRPs) are a large family of structurally complex 
and diverse natural products, often with remarkable biologically and 
therapeutically relevant activities. However, the structural complexity of 
these peptides can pose significant challenges in their chemical synthesis 
and engineering. NRPs are synthesised by large multifunctional mega 
enzymes called non-ribosomal peptide synthetases (NRPSs) with a modular, 
assembly line-like synthetic logic. In a canonical NRPS system, a terminally 
located cis-acting thioesterase domain is responsible for the hydrolytic 
release or the macrocyclisation of the mature peptide. The surugamide (sur) 
biosynthetic gene cluster includes four NRPS genes (surABCD). SurAD 
specify the biosynthesis of a cyclic octapeptide named surugamide A and 
SurBC specify the biosynthesis of a linear decapeptide named surugamide 
F. Unlike canonical NRPS systems, the terminal NPRSs within the Sur 
pathway (SurC and SurD) lack C-terminal cis-acting TE domains. In this 
study, the assembly-line release of surugamide A and F in Streptomyces 
albus S4 are explored. Understanding alternative release mechanisms is 
important  expanding the synthetic biology toolbox available for engineering 
the biosynthesis of NRPs. The roles of a putative a/b hydrolase (SurF) and a 
putative b-lactamase (SurE) in the synthesis of surugamide A and F were 
characterised in vivo. Gene inactivation studies of surF and surE established 
that SurF was not required for the production of surugamide A and F. 
Reduced production titres of surugamide A and F were observed in the 
absence of SurF. However, SurE was essential for the synthesis of 
surugamide A and F, with the production of both compounds abolished in 
the SurE production mutant. In vitro assays with recombinant SurE and an 
N-acetyl cysteamine thioester mimic of surugamide A further confirmed the 
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5.1 Introduction 
Non-ribosomal peptides (NRPs) are a diverse family of structurally complex 
secondary metabolites, often with a wide range of therapeutically relevant 
activities. Some examples of NRPs include vancomycin (antibacterial), 
cyclosporine (immunosuppressant), bleomycin (antitumor agent) and 
myxothiazol (antifungal) (Figure 5.1). Bacteria and fungi are the most prolific 
producers of NRPs. Genome sequencing and bioinformatics analyses have 
revealed great insight into the distribution of NRPs and their pathways. 
Actinobacteria such as Streptomyces are prolific producers of these 
secondary metabolites (Süssmuth and Mainz, 2017). NRPs can be linear, 
cyclic or branched cyclic in their structure and can further structural 
complexity by modifications such as glycosylation, oxidative cross-linking or 
heterocyclisation (Sieber and Marahiel, 2003; Martínez-Núñez and López, 
2016; Komaki et al., 2018).  
 
NRPs are synthesised by large, multifunctional enzymes called non-
ribosomal peptide synthetases (NRPSs) that have an assembly line like 
synthetic logic (Martínez-Núñez and López, 2016). They are not limited to 
the 20 canonical amino acids, instead they are capable of using different 
monomers such as non-proteinogenic amino acids, fatty acids and α-
hydroxy acids and are able to use both L- and D- versions of the 20 amino 
acids. This in turn, contributes to their structural versatility and most likely 
contributes to their bioactive properties also (Miller and Gulick, 2016; 
Süssmuth and Mainz, 2017). NRPSs are large multimodular enzymes and 
bacterial NRPSs often have their modules spread over many discrete 
























5.2 Modular assembly line like synthetic logic of NRPSs 
Each module in the NRPS is responsible for the incorporation of a specific 
amino acid into the growing peptide chain (Figure 5.2).  NRPSs can encode 
many domains, which include (but is not constrained to) adenylation (A), 
condensation (C), peptidyl carrier protein (PCP) or thiolation (T) and 
thioesterase (TE) domains (Sieber and Marahiel, 2003; Süssmuth and 
Mainz, 2017). The initiation module is the first module of the NRPS and is 
comprised of an A domain and a T domain (Figure 5.2). The initiation 
module is followed by elongation modules which contain C domains as well 
as A and T domains. Elongation continues until it reaches the termination 
module where the final domain of the module is a TE domain (Figure 5.2). A, 
C and T domains are required in each module but a single TE domain can 
terminate peptide synthesis. The order of the modules collinearly 
corresponds to the primary amino acid sequence of the peptide. The typical 
modular organisation of an NRPS system is: A-T-(C-A-T)n-TE with some of 
the modules containing some tailoring domains (Sieber and Marahiel, 2003; 
Süssmuth and Mainz, 2017). 
Figure 5.1 Examples of non-ribosomal peptides 
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NRP synthesis is initiated with the post-translational modification of a 
conserved serine residue in the T domain where a 4’-phosphopantetheinyl 
transferase (PPTase) adds a flexible 4’-phosphopantetheine (PPT) group 
converting the protein from its apo- state to the holo- state (Miller and Gulick, 
2016; Winn et al., 2016). The A domain confers the specificity of the amino 
acid to be incorporated and is responsible for the recognition and activation 
of the amino acid. Following the covalent modification of the T domain, the A 
domain of the initiation module activates the amino acid through adenylation 
using ATP to generate an aminoacyl adenylate intermediate (Sieber and 
Marahiel, 2003; Miller and Gulick, 2016; Süssmuth and Mainz, 2017). The T 
domain then covalently links the activated amino acid to the 4’- PPT arm via 
a thioester bond generating an aminoacyl-S-T intermediate. The A domain of 
the second module similarly activates its cognate amino acid and a T 
domain tethered amino-acyl thioester intermediate is generated. The 
adjacent C domain then catalyses the formation of a peptide bond between 
the two aminoacyl-S-Ts thereby allowing the translocation of the growing 
peptide onto the T domain of the second module (Figure 5.2) (Miller and 
Gulick, 2016; Winn et al., 2016). Additional modification domains such as 
epimerisation (E) domains may also be present. Epimerisation domains can 
change the stereochemistry of amino acids from L- to L- and D- by 
deprotonating and reprotonating the a-carbon of the amino acid when it is 
tethered to a T domain. Elongation continues in an N-terminal to C-terminal 
fashion until it reaches the C-terminally located TE domain (Figure 5.2). The 
peptide is cleaved from the assembly line either by an intramolecular 
reaction with an internal nucleophile, which gives rise to a cyclic peptide with 
or without oligomerisation or by hydrolysis, which results in a linear peptide 



























Figure 5.2 Typical modular organisation of NRPSs (a) and the 
modular assembly line like synthetic logic in NRP biosynthesis 
(b). T domains within NRPSs are post-translationally modified 
where the 4’- PPT group of cofactor CoA is transferred onto a 
conserved serine residue of the T domain. This flexible PPT arm 
allows the shuttle of the tethered intermediates down the assembly 
line. A domain then activates the amino acid, which is then 
covalently linked to the 4’ PPT arm of the primed T domain to form 
the aminoacyl-S-T intermediate. The adjacent C domain then 
catalyses the formation of a peptide bond between two cognate 
aminoacyl-S-Ts. The peptide elongation carries on down the 
assembly line until a terminally located thioesterase domain is 
reached. The mature peptide chain must be released once it 
reaches the end of the assembly line in order to reactivate the 
megasynthetase for the next cycle of synthesis (Winn et al., 2016) 
(b- adapted from (Winn et al., 2016)). 
b) 
a) 
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5.3 Different biosynthetic strategies of NRPs 
The vast majority of NRPSs follow the collinearity rule to catalyse stepwise 
peptide condensation; however, there are systems that deviate from this 
typical biosynthetic strategy (Sieber and Marahiel, 2003; Süssmuth and 
Mainz, 2017). NRPSs can be divided into three major classes: type A, B and 
C (Figure 5.3) (Mootz et al., 2002; Felnagle et al., 2008). Type A NRPSs 
such as the b-lactam precursor L-δ-(a-aminoadipoyl)-L-cysteinyl-D-valine 
(ACV) biosynthetic system strictly follow the collinearity rule where the amino 
acid sequence is determined by the order and number of modules of the 
NRPS (Figure 5.3) (Weber et al., 1994; Mootz and Marahiel, 1997; Byford et 
al., 1997; Felnagle et al., 2008). Each domain is only used once. Peptide 
biosynthesis is initiated at the first module, sometimes referred to as the 
loading module, with elongation occurring down the assembly line until the 
peptide is released from the terminal module. This biosynthetic strategy is 
the simplest and the best characterised (Mootz et al., 2002; Felnagle et al., 
2008).  
 
In type B NRPS systems, the modules and domains are used more than 
once to generate the NRP. In such systems, after the first cycle of synthesis 
is completed, the product remains tethered to the terminal domain while 
another cycle ensues (Figure 5.3) (Mootz et al., 2002; Felnagle et al., 2008). 
Each of the peptide chain remains tethered to the terminal domain until the 
total biosynthesis is complete at which point the final product is released 
from the assembly line (Mootz et al., 2002; Felnagle et al., 2008). An 
example of such a system is the biosynthetic machinery for gramicidin S 
(Figure 5.3) (Krätzschmar et al., 1989; Hoyer et al., 2007). Lastly, type C or 
non-linear NRPSs differ from the typical C-A-T modular arrangement along 
with certain domains functioning more than once in the biosynthesis of the 
peptide such as in the biosynthesis of vibriobactin (Figure 5.3) (Keating et 
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5.4 Canonical assembly line release of NRPs 
Usually located at the C-terminus of the NRPS, the TE domain is the last 
domain to play a role in NRP synthesis, where it can either act as a 
hydrolase or a cyclase and is responsible for the release of the mature 
peptide from the megasynthetase (Figure 5.4) (Miller and Gulick, 2016). TE 
domains are approximately 30 kDa and are homologous to those found in 
fatty acid synthases and polyketide synthases (PKSs) (Challis and Naismith, 
2004; Du and Lou, 2010; Bloudoff and Schmeing, 2017). They belong to the 
α/β hydrolase superfamily, which includes proteases, lipases and esterases. 
They have a defined active site with the catalytic triad Ser, His and Asp 
along with a variable ‘lid’ region that is thought to play a role in their 
substrate specificity (Du and Lou, 2010; Miller and Gulick, 2016).  
 
TE domains catalyse the enzymatic release of the peptide in a two-step 
reaction. First, the His and Asp residues activate the Ser residue as a 
nucleophile through hydrogen bonding (Figure 5.4) (Weissman, 2015; Miller 
and Gulick, 2016). The nucleophilic hydroxyl oxygen group of the active site 
Ser then attacks the carbonyl thioester of the peptidyl-S-TE intermediate to 
form a peptidyl-O-TE intermediate. Thus, the nascent peptide chain is 
transferred from the last T domain onto the hydroxyl group of the active site 
serine to form a peptidyl-O-TE intermediate (Du and Lou, 2010). In the 
second step, this intermediate is released by the cleavage of the ester 
carbonyl through the attack of a nucleophile. The nucleophilic attack can 
occur through water by hydrolysis or through the attack by an intramolecular 
nucleophile (Figure 5.4) (Challis and Naismith, 2004; Du and Lou, 2010). 
TE-catalysed hydrolytic peptide release of the NRP leads to a linear product 
as in the biosynthesis of ACV (Byford et al., 1997; Du and Lou, 2010). The 
other major product release route and the most commonly observed 
mechanism in NRP release is via intramolecular cyclisation, where the 
hydroxyl or amino group of the nascent peptide chain acts as an internal 
nucleophile to result in a cyclic product such as daptomycin (Kopp et al., 
2006; Du and Lou, 2010). The structural restrictions of the cyclic peptide 
plays a role in the enhanced bioactivity observed in NRPs  as well as in 
providing resistance to proteolytic degradation (Du and Lou, 2010; 
Weissman, 2015). 
 





















Insights into the structural information of a TE domain was first obtained 
from the crystal structure of the surfactin (Srf) TE domain excised from the 
NRPS SrfC from Bacillus subtilis (Tseng et al., 2002). Sequence similarity 
shared by Srf-TE with TE domains from other NRPSs suggested it to be a 
prototype for TE domains (Bruner et al., 2002). Srf-TE is a 28 kDa globular 
protein and belongs to the α/β hydrolase superfamily with its characteristic 
fold and the catalytic triad defined by the amino acid residues Ser80, His207 
and Asp107. The lid region of Srf-TE is composed of three α-helices that 
Figure 5.4 TE domain mediated release of a peptide through 
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reach over the active site and adopt two conformations called open and 
closed (Bruner et al., 2002).  The open state allows unobstructed access to 
the active site whereas in the closed state, the lid occludes the active site. 
The closed state was proposed to be the ground state of the enzyme 
(Bruner et al., 2002). Srf-TE also has a distinctive bowl-shaped hydrophobic 
aromatic active site cavity with two cationic amino acid residues (Lys111 and 
Arg120) playing a role in directing the peptide cyclisation (Tseng et al., 2002; 
Bruner et al., 2002). Often, water can act as a competing nucleophile to 
release the peptide through hydrolysis. The mutational change of both 
Lys111 and Arg120 residues to Ala, resulted in an increase in the hydrolytic 
release of the peptide (Tseng et al., 2002). According to the Srf-TE model, 
the terminal T domain bound surfactin peptidyl substrate is directed into the 
active site region where it is transferred onto Ser80, which is activated by the 
His207 and Asp107 residues. The peptidyl-O-TE intermediate 
accommodated in the bowl region is then cyclised to enable the 
macrocyclising chain terminating activity through the intramolecular 
nucleophilic attack by the β-hydroxyl group of the fatty acid on the peptidyl-
O-TE acyl enzyme ester bond, which results in the final lactone product 
(Tseng et al., 2002; Bruner et al., 2002).   
 
Structural information from the TE domain excised from the fengycin 
synthetase (FenB) shed further light on how these domains work (Samel et 
al., 2006). Fen-TE is a 27.5 kDa, globular protein responsible for the regio- 
and stereospecific macrocyclisation and assembly line release of fengycin in 
B. subtilis. It contains a distinctive 6-Å deep, 25-Å long open canyon-like 
active site with the catalytic Ser84 residue found at the bottom of the central 
part of the crevice (Samel et al., 2006). The lid-region of Fen-TE is much 
shorter than that of Srf-TE suggesting access to the catalytic triad is 
unrestricted (Samel et al., 2006). Furthermore, a closed state was not 
observed, at least not under the crystallisation conditions tested, suggesting 
it is unlikely that the lid region plays a crucial role in the recognition of the 
substrate (Samel et al., 2006). It has been proposed that some TE domains 
utilise the open/closed conformations of the lid to control peptide cyclisation, 
perhaps dictated by the presence of more than one suitable nucleophile 
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5.5 N-acetyl cysteamine thioesters (SNACs) 
Given the importance of the compounds produced by NRPS systems, 
biochemical and structural characterisation of these biosynthetic systems 
are areas of great interest (Süssmuth and Mainz, 2017). However, studying 
these systems in vitro is challenging owed to the complexity of these 
assembly lines and the requirement of covalent attachment of the 
intermediates to the T domains before they can be recognised by the 
catalytic domains as substrates (Kittilä and Cryle, 2018). CoA or rather, its 
substructure PPT are important components of NRPS assembly lines (as 
well as PKSs and FASs). The use of CoA in such studies is extremely 
challenging owed to its complex structure which is made up of five 
stereogenic centres and its inherent instability arising from its many 
phosphate linkages (Franke and Hertweck, 2016). Therefore, chemical tools 
to study these systems in vitro are greatly valuable. The truncated N-acetyl 
cysteamine analogue has been found to be a good substitute for CoA and 
related thioesters in such studies. The SNAC moiety is identical to the 
terminal part of 4’-PPT arm and is therefore a good mimic of the natural T 
domain bound peptidyl substrate (Figure 5.5) (Ehmann et al., 2000; Kohli et 
al., 2002; Sieber and Marahiel, 2003). In regards to studying release 
mechanisms, linear peptides synthesised with a SNAC moiety attached at 
the C-terminus can be used to mimic the natural peptidyl-S-T substrate 









Figure 5.5 N-acetyl cysteamine thioesters (SNACs) mimic the 
terminal part of the 4’ PPT arm. SNACs function as good 
biomimetics and represent an important chemical tool set in 
studying specific biosynthetic steps in greater detail (Fig adapted 
























- 94 - 
5.6 Chemoenzymatic cyclisation 
TE domain mediated macrocyclisation of NRPs is the most understood and 
is considered to be the canonical assembly line release mechanism 
(Marahiel et al., 1997). However, the chemical synthesis of NRPs is often 
associated with relatively low yields, is expensive and rather challenging  
(Sieber and Marahiel, 2003). For example, even though cyclisation is 
entropically favoured, the steric repulsion of the residues in the ring structure 
along with the use of protecting groups to achieve proper regiochemistry has 
proven synthetic cyclisation to be incredibly difficult (Kohli et al., 2002; 
Sieber and Marahiel, 2003). As truncated TE domains remain active in vitro, 
there is considerable interest in exploiting them as biocatalysts to generate 
medicinally important cyclic NRPs and to generate new chemical scaffolds 
for testing (Trauger et al., 2000; Sieber and Marahiel, 2003; Grünewald et 
al., 2004). The chemical synthesis of a linear peptide by solid-phase 
synthesis chemistry followed by TE mediate cyclisation that bypasses the 
use of protecting groups and formation of unwanted by-products would be 
highly desirable (Kohli et al., 2002; Sieber and Marahiel, 2003). 
 
Trauger et al., first demonstrated the in vitro cyclisation activity of the 
excised TE from tyrocidine A synthetase (TycC) using a SNAC thioester 
mimic. Incubation of the excised TycC-TE with the tyrocidine decapeptide-
SNAC revealed efficient cyclisation to tyrocidine A with only a minor flux to 
hydrolysis (cyclisation/hydrolysis ratio of 6:1) (Trauger et al., 2000). Further 
experiments with a wide array of peptidyl-SNAC substrates with various 
compositions of amino acids, lengths and stereochemistry revealed that the 
TycC-TE only recognised the C- and N- terminal residues of the substrate, 
depending on its identity and stereochemistry (Trauger et al., 2000). This in 
turn allowed room for the alteration of residues within the peptide backbone 
as well as the investigation of substrates of various lengths. The tyrocidine 
analogue library that was thus created was screened for compounds with 
better or altered activity. Analogues that showed better broad spectrum 
activity towards Gram-positive and Gram-negative bacteria as well as 
reduced human erythrocyte lysis compared to that of tyrocidine A were 
identified demonstrating the potential of TE domains as biocatalysts 
(Trauger et al., 2000; Kohli et al., 2002). A few more examples that 
foreshadow the utility of excised TE domains are described below.  
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Tyc-TE also exhibited activity in vitro towards the SNAC mimic of gramicidin 
S (Trauger et al., 2000). Gramicidin S is a cyclic decapeptide synthesised by 
a type B NRPS. It is formed as result of the dimerization between two 
identical pentapeptides followed by its subsequent cyclisation to form the 
final decapeptide (Figure 5.3) (Krätzschmar et al., 1989; Hoyer et al., 2007). 
Comparison of gramicidin S and tyrocidine A precursors revealed that both 
shared the same two N-terminal amino acid residues (D-Phe-Pro) and three 
C-terminal residues (Val-Orn-Leu) (Trauger et al., 2000). As the Tyc-TE only 
required the conserved C- and N- terminal residues for substrate 
recognition, it was reasoned that the Tyc-TE should be able to both dimerise  
and cyclise a gramicidin S pentapeptide-SNAC. Upon incubation of the 
SNAC substrate with the excised Tyc-TE, production of gramicidin S was 
observed (Trauger et al., 2000). Grünewald et al., showed that the excised 
TE domain from the calcium dependent antibiotic (CDA) NRPS from S. 
coelicolor could be used to make daptomycin derivatives (Grünewald et al., 
2004). Daptomycin and CDA belong to the same family of acidic lipopeptides 
and both possess decapeptide lactones that share 5 amino acids at the 
same positions in the ring. The CDA-TE was shown to have remarkable 
tolerance towards amino acid substitutions in the CDA peptide backbone 
and was able to synthesise daptomycin derivatives that are otherwise not 
accessible via chemical modification of the parent compound (Grünewald et 
al., 2004).   
 
The excised TE domains present an attractive means for the development of 
new or better NRPs. However, even with the use of the excised TEs, the 
yield observed is often much lower than with the natural substrate. 
Additionally, it is hard to draw general conclusions about the substrate 
selectivity of TE domains with substrate specificities ranging from the largely 
permissive TycC-TE to the very restricted specificity of SrfC-TE. 
Improvement of TE domains with increased promiscuity and efficiency is 
therefore a highly attractive area of research (Tseng et al., 2002; Bruner et 
al., 2002; Sieber and Marahiel, 2003; Du and Lou, 2010). Such insights play 
a major role in the rational engineering of biosynthetic pathways to generate 
natural products with desired characteristics to explore and develop new 
drug leads. 
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5.7 Type I and II thioesterases  
There are two types of TEs that have been found to be associated with 
NRPSs: type I and type II. Type I TEs are located at the C-terminal end of 
the termination module of the multimodular NRPS and are thus integrated in 
the NRPS machinery. Srf-TE, Tyc-TE and Fen-TE are all examples of type I 
TEs (Tseng et al., 2002; Samel et al., 2006; Miller and Gulick, 2016). Type II 
TEs on the other hand, are stand-alone discrete hydrolytic enzymes that are 
not covalently liked to the megasynthetase. Unlike type I TEs, type II TEs do 
not appear to have an essential role in the NRP synthesis, rather they are 
involved in the housekeeping functions (Schwarzer et al., 2002; Du and Lou, 
2010). Disruption of type I TEs results in the loss of production, whereas 
disruption of type II TEs decreases yield by ~30–95%, but do not abolish the 
synthesis of the product (Challis and Naismith, 2004; Yeh et al., 2004; 
Claxton et al., 2009).  
 
The trans-acting type II TEs are present in several NRPS gene clusters and 
is exemplified by the type II TE in the surfactin biosynthetic gene cluster 
(BGC). Type II TEs act as proofreading enzymes and clear misloaded T 
domains and aberrant intermediates (Schwarzer et al., 2002). These 
mistakes can arise from PPTase accidentally post-translationally installing 
an acyl-CoA instead of CoA or when an incorrect amino acid is adenylated 
and loaded onto the T domain (Schwarzer et al., 2002). The type II TEs are 
able to hydrolyse the incorrectly loaded acyl or peptidyl groups and restore 
the activity of the NRPS (Schneider and Marahiel, 1998; Schwarzer et al., 
2002). These enzymes must be capable of recognising all the T-domains 
that are misprimed and hydrolyse any incorrect addition while having a low 
specificity for the correctly growing peptide chain. In studies conducted by 
Claxton et al., (2009) on RifR, a type II TE from the hybrid NRPS/PKS 
rifamycin BGC, it was revealed that RifR possessed a broad substrate 
specificity with a greater affinity for carrier proteins that were misacylated 
over the natural rifamycin building blocks (Claxton et al., 2009).  
 
Structural studies of type II TEs have revealed them to adopt an α/β 
hydrolase fold similar to type I TEs (Linne et al., 2004). Comparison of the 
two types of TEs in the surfactin BGC revealed that the type II TE had a 
catalytic triad similar to that of the type I TE consisting of Ser86, Asp190 and 
His216 (Linne et al., 2004). The Asp163 residue was found to be critical for 
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the structural stability of the protein, as the mutant was structurally unstable 
even though it was active (Linne et al., 2004). The Srf type II TE was also 
observed to have a shorter lid, which only partially obstructed the active site 
cavity. It also had a shallower active site cavity that is more easily accessible 
than the type I TE and can only tolerate small acyl substituents on the 4’-
PPT arm (Koglin et al., 2008).  
 
Although TE domain mediated peptide release is the most common release 
mechanism, there are examples of NRPS systems that lack a terminally 
located TE domain especially in fungal NRPS biosynthetic systems. In such 
cases, there are examples of other terminally located domains such as a 
reductase (R) domain or a condensation like (CT) domain, which have been 
shown to perform the same function (Weissman, 2015).  
5.8 Other termination domains 
5.8.1 Reductase domains 
R domains are sometimes found in the terminal NRPS modules in place of a 
TE domain especially in fungi and are responsible for the NRP release from 
the assembly line (Du and Lou, 2010). These R domains share sequence 
similarity with the short chain dehydrogenase/reductase (SDR) superfamily 
and adopts the Rossmann-fold structure  (Kavanagh et al., 2008; Manavalan 
et al., 2010).  R domains typically require NAD(P)H as a cofactor for the 
reductive cleavage of the thioester bond between the nascent peptide chain 
and the T domain (Manavalan et al., 2010). A stable macrocyclic imine is 
then formed by the attack of either a side chain or the N-terminal amino 
group by the C-terminal alcohol or aldehyde group of the freed peptide chain 
(Ehmann et al., 1999; Keating et al., 2001; Manavalan et al., 2010).  
 
The best studied reductive release mechanism of an NRPS system is of 
lysine in Saccharomyces cerevisiae with the Lys2 protein which has an A-T-
R domain arrangement (Ehmann et al., 1999). The terminally located R 
domain is responsible for the release of the T domain bound α-aminoadipate 
by the regiospecific reduction of its C6 carboxylate to its aminoadipate 
semialdehyde, which is in turn reductively transaminated to lysine. The 
reductive release of lysine is carried out by the protein pair Lys2/Lys5 
(Ehmann et al., 1999). The PPTase Lys5 is responsible for the conversion of 
the T domain from its apo- state to the holo- state. The holo-Lys2 is then 
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able to activate the aminoadipate and generate the aminoadipoyl-S-T-acyl 
intermediate just like a canonical A-T domain pair (Ehmann et al., 1999). 
The R domain then utilises NADPH to reduce the thioester bond of the 
aminoadipoyl-S-T-peptidyl intermediate to a hemithioaminal linkage, which 
spontaneously decomposes to form the C6 aldehyde product. The 
semialdehyde then condenses with glutamate to form saccharopine, which is 
in turn hydrolysed to form the final products lysine and a-ketoglutarate 
(Ehmann et al., 1999; Keating et al., 2001; Du and Lou, 2010).  
 
An example of reductive release of a bacterial NRP is in the biosynthesis of 
the linear pentadecapeptide gramicidin A in Bacillus brevis. Two reductases, 
an integrated R domain and a discrete reductase are required for the 
formation of the final product (Kessler et al., 2004; Schracke et al., 2005). 
The BGC for gramicidin A synthesis comprises of four NRPSs, LgrA, LgrB, 
LgrC and LgrD with an R domain found at the C-terminus of LgrD. The LgrD 
R domain is responsible for the release of the peptidyl thioester from the 
NRPS in an NAD(P)H dependent reduction step generating an aldehyde 
intermediate (Kessler et al., 2004). This intermediate is then further reduced 
by a discrete NADPH dependent aldoreductase (LgrE) to generate the final 
product gramicidin A (Kessler et al., 2004; Schracke et al., 2005).   
 
While TE domain mediated release mechanism utilises oxoester chemistry, 
the R domain mediated release mechanisms uses thioester chemistry (Du 
and Lou, 2010) In TE mediated release, the thioester chemistry is switched 
to oxoester chemistry when the peptidyl chain is transferred from the 4’-PPT 
of the T domain to the hydroxyl group of the active site serine for the product 
release by hydrolysis or cyclisation. Although not completely understood, in 
R-domain mediated release, it is most probable that the peptidyl chain is not 
transferred from the T domain to R domain, rather the R domain yields a 
thiohemiacetal that is still bound to the 4’-PPT via the transfer of a hydride 
from NAD(P)H to the thioester. The 4’-PPT of the T domain is then 
regenerated following the release of the aldehyde (Du and Lou, 2010). 
 
5.8.2 Condensation-like domains 
In addition to R domains, some NRPS systems, especially those that release 
cyclic NRPs in fungi, utilise condensation like domains (CT) for the assembly 
line release (Gao et al., 2015). For example, the in vitro re-constitution and 
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biochemical characterisation of the 450 kDa NRPS tryptoquialanine 
synthetase (TqaA) involved in the biosynthesis of the fumiquinazoline F in 
Penicillium aethiopicum revealed that its terminal  CT domain was 
responsible for the formation of 10-membered macrocycle, which then 
underwent a spontaneous intramolecular cyclisation to form the final product 
(Gao et al., 2015; Zhang et al., 2016). Crystal studies of the TqaA-CT 
domains revealed that as with typical C domains, TqaA-CT also adopted a 
pseudo-dimeric open sandwich (V-shaped) structure (Zhang et al., 2016). 
However, the CT domain possessed a distinctive a1 helix and a shorter a2 
helix atypical to that of canonical C domains. This in turn results in the 
obstruction of the acceptor site and solvent channel, which promotes 
cyclisation by averting the nucleophilic attack by the solvent (Zhang et al., 
2016).  
 
CT and TE domains possess distinctly different folds and use different 
mechanisms to release the final products (Gao et al., 2015; Zhang et al., 
2016). In the two-step TE mediated release, the peptidyl chain is transferred 
to the active site serine on the TE, which is followed by an intramolecular 
nucleophilic attack to cleave the ester carbonyl to result in a cyclic product. 
However, as with typical C domains, no covalent adduct with the enzyme is 
expected to be formed during the CT domain mediated cyclisation 
(Fischbach and Walsh, 2006; Gao et al., 2015).  The catalytic histidine is 
instead responsible for the deprotonation of the amine nucleophile enabling 
its attack on the thioester carbonyl which enables cyclisation and release in 
one step (Gao et al., 2015). Additionally, while TE domains can use both 
peptidyl-SNACs and peptidyl-T domains as substrates, studies with the 
TqaA-CT domain, revealed that it required the natural T domain partner for 
the cyclization reaction (Ehmann et al., 2000; Kohli et al., 2002; Gao et al., 
2015). Only the T domain-tethered peptide substrates were recognised by 
the CT domain while the peptidyl-SNAC or peptidyl-CoA substrates were not. 
This contrasts with most TE domains studied, which could accept the mimics 
of the peptidyl-thioesters (Sieber et al., 2003; Bloudoff and Schmeing, 2017). 
Fengycin TE is an exception, which required interaction with the T domain 
for the cyclisation (Sieber et al., 2003; Sieber et al., 2004).  
 
Another example of C domain catalysed chain release is observed in the 
biosynthesis of the enediyene-C1027 chromophore in Streptomyces 
globisporus (Lin et al., 2009). The chromophore comprises of an enediyne 
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core, a deoxy aminosugar, a benzoxazolinate moiety and a b-amino acid. 
The BGC encoding the enediyne antitumor antibiotic C-1027 has an NRPS 
mechanism for the incorporation of the (S)-3-chloro-5-hydroxy-b-tyrosine 
moiety (Van Lanen and Shen, 2008). The A domain (SgcC1), T domain 
(SgcC2) and the C domain (SgcC5) of the minimal NRPS system act as free 
standing proteins (Lin et al., 2009). SgcC5 was able to catalyse the 
condensation reaction to catalyse an ester bond formation between a mimic 
of the enediyne core ((R)-1-phenyl-1,2-ethanediol) and the SgcC2 bound 
(S)-3-chloro-5-hydroxy-b-tyrosine leading to a C-domain mediated release 
(Lin et al., 2009). SgcC5 required the T domain-tethered molecule as its 
substrate. Additionally, SgcC5 was also able to catalyse an amide bond 
formation between the SgcC2-tethered b amino acid and an enediyne core 
mimic with an amine as a nucleophile at the C-2 position (R)-2-amino-1-
phenyl-1-ethanol). SgcC2 was the first C domain shown to be able to 
catalyse both amide and ester bonds (Lin et al., 2009; Chang et al., 2018).  
5.9 Assembly line release of surugamides 
Surugamides are a group of NRPs that were first identified from the marine 
Streptomyces sp. JAMM992 (Takada et al., 2013). The surugamide (sur) 
BGC consists of four successive NRPS genes surA, surB, surC and surD 
(Figure 5.6). Surugamides A-E (SA-SE) are cyclic octapeptides encoded by 
surA and surD (Figure 5.6). SA is the major product with SB-SE thought to 
be formed as a result of the permissive substrate specificity of the A 
domains (Takada et al., 2013). SA contains four isoleucine residues, 
whereas one of the isoleucine residues is replaced by a valine at different 
positions in SB-SE (Takada et al., 2013). Genes surB  and surC encode the 
production of an unrelated linear decapeptide named surugamide F (SF) 
(Figure 5.6) (Ninomiya et al., 2016). The surugamides were recently also 
identified in S. albus J1074 (Mohimani et al., 2016; Xu et al., 2017). Through 
work carried out in this study, the surugamide BGC was identified in S. albus 
S4 with the production of SA and SF verified using LC-HRMS (see Chapter 
4). Since the initial discovery of surugamides, the corresponding BGC has 
been found to be widespread among streptomycete strains closely related to 
S. albus J1074 (Ryan Seipke, unpublished work). 
 
In the surugamide BGC, genes surABCD are organised in an operon with 
the four genes presumably transcribed at the same time and SA and SF 
both co-produced (Figure 5.6). Genes surA/surD are responsible for the 
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biosynthesis of the cyclic compound SA and surB/surC are responsible for 
the biosynthesis of SF (Figure 5.6) (Ninomiya et al., 2016). Following the 
canonical NRPS assembly line logic, a TE domain is expected to be found at 
the C-terminal end of both SurD and SurC for the release of SA and SF, 
respectively. However, intriguingly, both SurD and SurC lack terminally 
located TE domains (Figure 5.6). Neither do they end in an alternate 
termination domain such as an R domain or a C domain (Figure 5.6). 
Bioinformatic tools such as antiSMASH, NRPS-PKS and Pfam are 
consistent with both SurD and SurC ending in an E domain at the C-
terminus end (Figure 5.6, Appendix Figure A3.1) (Ansari et al., 2004; 
Medema et al., 2011). 
 
To investigate the possibility of a trans-acting release factor(s), other genes 
predicted to be encoded within the antiSMASH defined boundaries of the sur 
BGC were considered (Figure A3.2). While there are additional hypothetical 
proteins predicted to be encoded by genes within the BGC, BLAST and 
InterPro analyses predicted proteins are listed in Table 5.1 (and Figure 
A3.2). Examination of the bioinformatically predicted proteins revealed most 
of them to be regulators (e.g. Sur4, Sur12), transporters (e.g. Sur10, Sur11) 
or proteins involved in the folate pathway (e.g. Sur18, Sur19).  Two genes of 
particular interest were surF and surE. Gene surF is predicted to encode a 
protein with an α/β hydrolase fold (InterPro Family IPR029058). As TEs also 
typically contain an α/β hydrolase fold, surF was chosen to be investigated 
further for a potential role in the release of either or both SA and SF.  
 
Gene surE is predicted to encode a protein belonging to the b-lactamase 
superfamily (InterPro Family IPR012338). SurE is very different to and much 
larger than canonical TE domains such as Srf-TE and Fen-TE and lack the 
catalytic triad found in typical TEs (A3.3). While b-lactamases are not known 
to act as trans-acting release factors in NRPS systems, stand-alone metallo-
b-lactamases have been shown to be responsible for the release of some 
fungal PKs. The absence of a TE domain in the PK asperthecin biosynthetic 
pathway in Aspergillus nidulans and the presence of an essential gene 
encoding a b-lactamase (aptB) in the asperthecin BGC led to the proposal 
that the b-lactamase may function as a trans-acting release factor in fungal 
PKS systems (Szewczyk et al., 2008; Li et al., 2011). 





















surF surE surA surDsurB surC
A T C A T TC AE TTC A C AE
A TC T EA TC C AE
SurA
SurD
L-Ile D-Ala L-Ile D-Ile L-Lys
L-Ile D-Phe D-Leu
AA T C TT C AE TC A
EAC T T C ATC A TC A TC A E C A T E
SurB
SurC
L-Trp D-Leu L-Val L-Thr
R-AMPA D-Leu L-Val D-Ala L-Val D-Ala
Figure 5.6. Schematic representation of the surugamide BGC, the 
modular organisation of the NRPSs and their respective 
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Biochemical evidence for this hypothesis was provided from work on the 
Aspergillus terreus PKS atrochrysone carboxylic acid synthase (ACAS) 
responsible for the biosynthesis of atrochrysone. This biosynthetic system 
also lacks a terminal TE domain or an alternate termination domain. The 
assembly line release mechanism in turn was shown to be via the metallo-b-
lactamase ACTE (Awakawa et al., 2009; Li et al., 2011; Chooi and Tang, 
2012). While PKs and NRPs have distinct structures, their biosynthetic 
strategies are very similar. Both NRPSs and PKSs follow an assembly line 
like synthetic logic, use carrier proteins (acyl carrier protein or ACP instead 
of T domains in PKSs) and both systems use the 4’-PPT moiety for 
precursor activation. A TE domain located in the terminal module is 
responsible for release of the PK in a canonical PKS system as well (Du and 
Lou, 2010; Weissman, 2015). Though, the b-lactamases reported with TE 
activity are from PKS systems and in fact, in all cases thus far, from fungi, it 
may be possible for such a system to exist in bacteria too. Additionally, in 
the BGC encoding the cyclic lipoglycopeptide mannopeptimycin, the NRPS 
system lacks a terminal TE domain and it was suggested that MppK, an 
essential protein in the synthesis of mannopeptimycin, which belongs to the 
β-lactamase superfamily may function as the termination/cyclisation protein 
(Magarvey et al., 2006). SurE shares 39% homology with MppK. 
 






SurF α/β hydrolase fold containing protein 
Sur1 NADH-quinone oxidoreductase subunit D/H family 
protein 
Sur2 Predicted membrane protein 
Sur3a/3b Two-component system 
Sur4 ArsR family transcriptional regulator 
Sur5 Aldehyde dehydrogenase family protein 
Table 5.1. Putative proteins encoded by the surugamide biosynthetic 
gene cluster 
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Sur6 MbtH-like protein 
Sur7 ABC transporter permease 
Sur8 ABC transporter ATP binding protein 
Sur9 GntR family transcriptional regulator 
Sur10 MFS transporter 
Sur11 Major facilitator transporter 
Sur12 TetR family transcriptional regulator 
Sur13 MFS transporter 
Sur14 ABC transporter substrate binding protein 
Sur15 ABC transporter permease 
Sur16 ABC transporter permease 
Sur17 ABC transporter ATP binding protein 
Sur18 Dihydropteroate synthase  
Sur19 Dihydroneopterin aldolase 
Sur20 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine 
diphosphokinase 
Sur21 GTP cyclohydrolase 1 Fol E 
Sur22 FtsH family protein 
Sur23 Hypoxanthine phosphoribosyl transferase family 
protein 
Sur24  tRNA (Ile)- lysidine synthetase 
Sur25 Zinicin-like metallopeptidase type 2 
 
5.10 Aims and Objectives 
In the absence of an obvious cis-acting release mechanism for SA and SF, 
two gene candidates (surE and surF) were chosen to be investigated as 
potential trans-acting release factors. To investigate the potential roles of 
SurE and SurF in the synthesis of SA and SF, this study aimed to:  
• Use gene inactivation and complementation studies coupled with LC-
HRMS to investigate the production titre of SA and SF in S. albus S4 
DsurE and DsurF null mutants 
• Carry out an in vitro investigation using purified protein and a SNAC 
thioester mimic of SA 
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5.11 Results 
5.11.1 Deletion of surF in S. albus S4 lowers the titre of SA and SF 
The Redirect recombineering protocol was used to generate S. albus S4 
DsurF (Figure 5.7) in order to examine the role of the α/β hydrolase fold 
containing SurF in the synthesis of SA and SF. Chemical extracts prepared 
from S. albus S4 wild type (WT) and S. albus S4 DsurF were analysed by 
LC-HRMS to check for the presence of SA and SF (Figure 5.8). Deletion of 
surF did not abolish the production of SA or SF. However, the titre of SA and 
SF were both reduced compared to the WT levels. A 62% reduction in the 
titre of SA and 17% reduction in the titre of SF was observed (Figure 5.8). To 
examine whether the production level would return to WT levels with a 
functional copy of the gene, the complementation strain S4 ∆surF attB 
φBT1::pIJ10257-surF was constructed (Figure A3.4) and ethyl acetate 
extracts were prepared for chemical analysis.  Upon complementation, 
production of both SA and SF were restored, with production of SA to near 
WT levels and SF titre exceeding that of the WT strain levels (Figure 5.8). 
Compared to the 62% loss in the titre of SA to the WT titre, upon 
complementation, the loss was only 16% in comparison to the WT titre of 
SA. With SF, interestingly, the titre upon complementation was even greater 
than that of WT with a 57% increase compared to the titre of SF in the WT 
strain (Figure 5.8).  
 
Figure 5.7 PCR verification of S. albus S4 DsurF. a) Verification using 
primer set DT171 and DT172. If Apra cassette has replaced surF, 
then EPL: 1649 bp; if not, 1084 bp. b) Verification using primer set 
RFS96 and RFS97 to check for loss of kanamycin cassette. A 
double crossover event to generate S4 DsurF would result in the 
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Figure 5.8 Deletion of surF results in a lower titre of surugamide A 
(SA) and surugamide F (SF). The EICs corresponding to the 
[M+H]+ ions are shown for SA (C48H81N9O8) and SF 
(C52H85N11O12). The y-axis intensity scale for SA is set to a max 6 
x 106 and the scale for SF is set to 2 x 105. The peak area of SA 
and SF in the WT are 57254844 and 628891, respectively and in 
S4 DsurF, the peak area for both SA and SF were reduced to 
21537268 and 524318 demonstrating a 62% and 17% decrease 
respectively. Upon complementation, in S4 ∆surF attB 
φBT1::pIJ10257-surF, the production of SA and SF returned to 
almost/greater than WT levels. The peak area of SA in the 
complemented strain was 48279612 and SF was 987327, which 
corresponds to only a 16% loss of SA compared to that of WT SA 
titre and an increase in SF titre by 57% compared to that of the 
WT SF titre. 
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5.11.2 Deletion of surE in S. albus S4 abolishes the production of 
SA and SF 
To investigate the role of the predicted b-lactamase family protein encoded 
by surE, the mutant strain S. albus S4 DsurE was generated following the 
Redirect recombineering protocol (Figure 5.9). As with S. albus S4 DsurF, 
chemical extracts prepared from S. albus S4 WT and S. albus S4 DsurE 
were analysed by LC-HRMS to examine the effect of the deletion of surE on 
the production of SA and SF. The deletion of surE completely abolished the 
production of both SA and SF (Figure 5.10). Upon complementation of the 
mutant with a functional copy of the gene, the strain S. albus S4 ∆surF attB 
φBT1::pIJ10257-surF was generated (Figure A3.5). Chemical analyses 
confirmed that production of both SA and SF was restored in the 
complemented strain confirming that surE is essential in the biosynthesis of 









Figure 5.9 PCR verification of S. albus S4 DsurE. a) Verification using 
primer set DT163a and DT64a checking for an internal fragment of 
surE. If surE is present, EPL: 953 bp. b) Verification using primer set 
RFS96 and RFS97 to check for loss of kanamycin cassette. A double 
crossover event to generate S4 DsurE would result in the loss of the 













































5.11.3 Purification trials of SurE 
As the in vivo results showed that SurE was essential for the production of 
SA and SF, SurE was desired to be purified to reconstitute the results in 
vitro. The in vitro reconstitution of the results would confirm that SurE is 
solely able to release the peptides and is responsible for the effect observed. 
However, the purification of SurE proved to be rather challenging. It was 
after many failed attempts that SurE was successfully purified (section 
5.11.4). In the initial expression trial, C- and N- terminal 6x His tagged SurE 
were trialled. However, hardly any production of recombinant SurE was seen 
(Figure A3.6). Expression trials revealed SurE to be in the insoluble fraction 
under most conditions tested. The conditions tested are described briefly in 
the following paragraphs. 
10 12 14 16 18 20 22 24
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SA
10 12 14 16 18 20 22 24
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Figure 5.10 SurE is essential for the production of surugamide A (SA) 
and surugamide F (SF). The EICs corresponding to the [M+H]+ ions 
are shown for SA (C48H81N9O8) and SF (C52H85N11O12). The y axis 
scale for SA is set to a max 6 x 106 and the scale for SF is set to 2 x 
105. Upon deletion of surE, production of both SA and SF were 
abolished. Upon complementation, in S4 ∆surE attB φBT1::pIJ10257-
surE, production of both SA and SF were restored. 
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In the initial trial, BL21(DE3)-pET28a-surE/pET30a-surE cells were 
cultivated using LB at 37 °C until OD600 ~0.6 at which point, the cells were 
induced with IPTG (final concentration 1 mM) and grown overnight at 16 °C. 
Following the incubation period, cells were pelleted and resuspended in 10 
times the volume of the weight of the pellet in the lysis buffer. The pellets 
were then lysed by sonication and the soluble fraction was collected and 
samples were analysed on an SDS-PAGE gel. However, hardly any 
production of recombinant SurE was seen (Figure A3.6). Quick induction 
trials were attempted with 0.5 mM and 1 mM IPTG concentrations by 
growing the cells at 37 °C, inducing the cells at OD600 ~0.6 and a further 4 h 
incubation at 37 °C before harvesting the cells and collecting the soluble 
fraction. However, SurE was still found in the insoluble fraction (Figure 
A3.7). An expression trial at 16 °C overnight in autoinduction media also 
yielded SurE in the insoluble fraction (Figure A3.7). In an effort to make SurE 
more soluble, surE was cloned into the vector pDB-His-MBP. However, a 
quick induction trial in LB revealed His6-MBP-SurE to still be in the insoluble 
fraction (Figure A3.8). To consider alternate lysis methods, lysis via a cell 
disruptor was also explored. Cell disruption with the flow through option at 
20 kpsi still yielded His6-MBP-SurE in the insoluble fraction (Figure A3.9). 
BL21(DE3)-pDB-His-MBP-surE cells grown in autoinduction media (Terrific 
broth) for 2 days at 16 °C and cells from a quick induction trial with 
BL21(DE3)-pET28a-surE were harvested and lysed with the cell disruptor 
using the OneShot option at 27 kpsi and the samples were analysed on a 
gel. However SurE was still found in the insoluble fraction (Figure A3.10). 
 
Whilst this work was being carried out, another group successfully showed 
that SurE was responsible for the offloading of SB in vitro, and in the 
process had purified the Streptomyces albidoflavus NBRC12854 SurE 
homologue (Kuranaga et al., 2018). However, the methodology reported in 
their study (Kuranaga et al., 2018) did not yield soluble SurE in my hands 
(Figure A3.11). To explore the possibility of using a SurE homologue, S. 
albus J1074 surE was cloned into pDB-His-MBP. However, quick expression 
trials revealed His6-MBP-J1074 SurE to be in the insoluble fraction still 
(Figure A3.12). The possibility of denaturing the protein to solubilise SurE (to 
then refold it later was investigated) with surE expressed from pET28a (with 
Dr Justin Clarke). Following harvesting after a quick induction trial, addition 
of 7 M urea containing lysis buffer followed by sonication yielded SurE in the 
soluble fraction (Figure A3.13). The soluble fraction was collected and 
- 110 - 
loaded on to the AKTA equipped with an HisTrap FF Crude column (1 mL 
column). The AKTA was used to purify SurE by refolding it using a gradient 
of washes (100% 7 M urea, 0% imidazole to 0% urea 100% 500 mM 
imidazole containing buffers).  However, almost all of the SurE was lost in 
the flow through (Figure A3.14). A cell free protein expression kit was also 
tried to produce SurE. However, SurE failed to be synthesised in vitro and 
only the positive control protein was successfully synthesised.  
 
5.11.4 Purification of SurE and protein identification 
SurE was successfully produced from BL21(DE3)-pET28a-surE cells grown 
in autoinduction media in the conditions described in Chapter 2 (2.5.2.) His6-
SurE is predicted to be 49764.13 Da and a band consistent with this was 
seen on the gel (Figure 5.11). The purification of SurE was done together 
















Figure 5.11 Purification of His6-SurE. His6-SurE is expected to be 
49764.13 Da and a band consistent with this was observed 
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The protein elution samples were concentrated and desalted for further 
analysis. To verify that the band seen on the gel was in fact His6-SurE, the 
protein sample was analysed by the University of Leeds mass spectrometry 
facility (Figure A3.15). N-terminal methionine excision is a very common post 
translational modification in proteins and is often critical for the function and 
stability of the protein. Mass shifts of -131 corresponds to the loss of a 
methionine (Giglione et al., 2004; Bonissone et al., 2013). His6-SurE is 
predicted to be 49764.13 Da and His6-SurE without the N-terminal 
methionine is predicted to 49632.93 Da. The mass observed in the protein 
mass spectrum data for His6-SurE is 49630.52 + 4.08. The mass of His6-
SurE minus the N-terminal methionine falls into the error range of the 
observed mass further confirming that the protein purified is indeed His6-
SurE.  
 
5.11.5 Analysis of the in vitro activity of SurE on SA-SNAC   
The purified His6-SurE was used in in vitro assays with a SNAC thioester 
mimic to recapitulate the in vivo results and to verify the chain releasing 
activity of SurE. The SNAC used in this study was kindly made by Dr Daniel 
Francis. Although Dr Francis arduously attempted to make both SA and SF 
SNACs, he was only successful in making the SA-SNAC with adequate 
purity. Synthesis of SF-SNAC was particularly challenging due to its 
hydrophobic nature and the presence of the non-proteinogenic amino acid 
R-AMPA (3-amino-2-methylpropionic acid). Therefore, the assay was only 
performed with SA-SNAC. If SurE is active in vitro and is responsible for the 
release of SA by its macrolactamisation, then the enzyme should be able to 
produce SA from the SA-SNAC. 
 
The assay revealed that His6-SurE was indeed active and that it was able to 
act on the SA-SNAC to generate the final cyclic product SA (Figure 5.12). As 
expected there was no SA or SA-SNAC present in the buffer or the His6-
SurE reaction controls (Figure 5.12). In the SA-SNAC only control, a very 
low amount of SNAC less SA was present (probably left over from the 
synthesis and purification of SA-SNAC). To account for this small amount of 
SA, the area under the peak was calculated for SA in the SA-SNAC only 
control and this was subtracted from the peak area of SA in the actual 
reaction (Figure 5.12). In the presence of His6-SurE and SA-SNAC, 
conversion of the SA-SNAC to SA was seen, however the SA-SNAC was 
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not completely converted to SA even after prolonged incubation. Comparing 
the area underneath the curve, 63.8% of the SA-SNAC was converted to SA 
and in regard to the total amount of material, 92.6% of the SA-SNAC was 























Figure 5.12 SurE is able to convert the surugamide A-SNAC to 
surugamide A.  The EICs corresponding to the [M+H]+ ions are 
shown for SA-SNAC (C52H90N10O9S) and SA (C48H81N9O8). Neither 
SA-SNAC nor SA are seen in control reactions. In the presence of 
SurE and SA-SNAC, SurE is able to convert the SA-SNAC to SA  
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5.12 Discussion 
As observed usually with type II TEs associated with NRPSs, the deletion of 
surF resulted in a reduction in the titre of the final products SA and SF 
(Figure 5.8). Sequence alignment of SurE with the type II TEs SrfTEII and 
RifR revealed the conserved catalytic triad of Ser, His and Asp, typical of the 
α/β hydrolase fold superfamily (A3.16).  Bioinformatically, SurF is predicted 
to belong to IPR029058, while type II TEs usually belong to IPR012223. 
Additionally, type II TEs normally have the hydrolase motif GHSMG (A3.16) 
while SurF possess the GXSXG motif (A3.16). However, the observed 
reduction in the titre of SA and SF is consistent with SurF being a type II TE. 
Though, the tire of both SA and SF were reduced, titre of SA (62%) was 
reduced more than that of SF (16%) (Figure 5.8). The genes encoding the 
production of SA and SF are co-transcribed, however, the titre of SA in the 
WT strain is greater than that of SF under the growth conditions tested (titre 
of SA is ~91 times greater than that of SF in the WT). To speculate, it maybe 
that because the rate of synthesis of SA is greater than that of SF, SurF has 
a greater observable impact on the titre of SA. It may also be that SurF is 
one of the rate limiting factors in the production of SF, where the available 
SurF may work competitively on SA synthesis. SF also requires the non-
proteinogenic amino acid R-AMPA. The availability of AMPA could be 
another limiting factor in SF synthesis.  
 
Surprisingly, in the complementation strain, while the titre of SA was almost 
back to WT levels, the titre of SF was greater than that is seen in the WT by 
57%. In the complemented strain surF is overexpressed from the ermE* 
promoter. It may be that with a stronger expression of surF compared to that 
of the native promoter, the increase in the availability of SurF has a directly 
positive impact on the synthesis SF. In the picromycin/methymcyin PKS 
biosynthetic system, while the deletion of its associated type II TE had no 
effect on the PK production levels, its coexpression in the heterologous host 
Streptomyces lividans increased the production of the PK up to sevenfold 
(Tang et al., 1999; Chen et al., 2001). It is unclear why only certain NRPS 
and PKS systems possess type II TES and why their deletion is only fully 
detrimental to some. However, the role they play in efficiency of these 
megasynthetases is important (Kotowska and Pawlik, 2014). The results 
obtained in this study suggest that SurF has a similar role to that of type II 
TEs.  
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SurE, however, is essential for the synthesis of both the cyclic SA and linear 
SF (Figure 5.10). Deletion of surE abolished the production of both SA and 
SF (Figure 5.10) and the production was restored in the complementation 
strain (Figure 5.10). Additionally, the purified SurE was active in vitro and 
was able to utilise the SA-SNAC thioester mimic to produce the final 
compound SA (Figure 5.12). These results support the hypothesis that SurE 
is a trans-acting release factor. It is especially interesting that SurE seems to 
be responsible for the release of both SA and SF, a cyclic and a linear 
product, respectively. SA is probably released by the off-loading of the linear 
peptidyl-S-thioester intermediate followed by a head to tail cyclisation 
whereas SF is probably released via a hydrolytic route with the release of 
the peptidyl-S-thioester intermediate. 
 
b-lactamases can be classified into Classes A-D depending on their amino 
acid sequence similarity (Bush and Jacoby, 2010). Classes A, C and D 
function via serine ester hydrolysis mechanisms while class B comprises of 
metallo b-lactamases (Bush and Jacoby, 2010; Öztürk et al., 2015). Metallo- 
b-lactamases can be further subdivided into B1, B2 and B3 subclasses 
(Bush and Jacoby, 2010). SurE, lacks the conserved metal binding residues 
found in canonical metallo-b-lactamases and therefore is unlikely to be a 
metallo-b-lactamase (A3.17 and A3.18). Instead, SurE shares the active site 
serine (SXXK) with Class A, C and D b-lactamases (A3.19). b-lactamases 
are believed to have evolved from the bacterial cell wall biosynthetic 
enzymes penicillin binding proteins (PBPs) and most members of both 
families possess a catalytic serine in their active site (Massova and 
Mobashery, 1998). PBPs are divided into three major groups: Class A, B 
and C. Classes A and B comprise of high molecular weight (HMW) PBPs 
and Class C consists of low molecular weight (LMW) PBPs. Class A HMW 
PBPs are bifunctional proteins that are capable of transglycosylase and 
transpeptidase activities while Class B PBPs are mono-functional proteins 
with transpeptidase activity. Class C LMW PBPs comprises of D, D 
carboxypeptidases and/or D, D endopeptidases (Massova and Mobashery, 
1998). Sequence alignment of SurE with Class A, B and C PBPs (A3.20) 
revealed that SurE had the catalytic residues arranged in a similar fashion to 
that of LMW Class C PBPs (A3.20.3). The Class C LMW PBPs can be 
further subdivided into subclasses namely A, B and C based on their 
sequence similarity. The subclass B LMW PBPs have a similar active site 
composition to Class C b-lactamases. Sequence alignment of SurE with the 
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subclass B LMW PBP and Class C b-lactamases (A3.21), revealed that 
SurE behaves the same way and shares most catalytic sites with the Class 
C b-lactamases (the conserved H residue is replaced by a K residue in 
Class C b-lactamases). These analyses show that SurE shares all the 
catalytic residues characteristic of subclass B LMW PBPs that share 
similarities with Class C-b-lactamases.  
 
Whilst this study was being carried out, Kuranaga et al., demonstrated that 
SurE was responsible for the release of SB using a SNAC thioester mimic of 
SB (Kuranaga et al., 2018). The study showed that the recombinant SurE 
was able to use the linear SB-SNAC to produce the mature SB. They chose 
to work on SB instead of SA (or SC-E) as the synthesis of SB does not 
require the rare amino acid D-Ileu. The total chemical synthesis of SB in 
their study revealed additional insight into the synthesis of these cyclic 
peptides (Kuranaga et al., 2018). SurE was unable to cyclise the peptidyl 
SNAC of SB with the C-terminal D-Leu replaced with an L-Leu. The data 
collected suggested that SurE has specificity for D-amino acids at the C-
terminus of its substrate (Kuranaga et al., 2018). The last of A domain of 
SurD encodes a D-Leu and of SurC encodes a D-Ala. PBPs or DD 
peptidases also generally recognise D-amino acids (D-Ala-D-Ala in most 
cases), SurE being similar to the PBPs likely also cyclises SA by recognising 
the terminal D amino acid of the SA intermediate (Massova and Mobashery, 
1998; Öztürk et al., 2015; Kuranaga et al., 2018).  
5.13 Conclusions 
From this study, SurF was found to function as a type II thioesterase and 
together with the results presented by Kuranaga et al., this is the first report 
of a PBP homologue, which has been shown to responsible for an NRPS 
assembly line release (Kuranaga et al., 2018).  SurE is especially interesting 
in that it is able to release the cyclic peptide via macrolactamisation and the 
presumably the linear peptide most likely through a hydrolytic route. This 
work contributes to the understanding of how NRPs are off loaded from the 
megasynthetases. With the wealth of knowledge now available through 
genome sequencing and genome mining, this study contributes to expand 
the understanding of how NRPs may be off loaded in some existing and ‘to 
be discovered’ NRPS systems. With the pharmaceutical potential that many 
NRPs possess, industrially producing NRPs, to synthesise derivatives or to 
chemically synthesise NRPs are longstanding goals of the NRPS field. 
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Understanding alternative release mechanisms will expand the synthetic 
biology toolbox available for engineering the biosynthesis of NRPs and will 
provide an opportunity to increase the chemical space of important NRP 
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Chapter 6 General discussion and conclusions  
Since their discovery, antibiotics have revolutionised human medicine. The 
discovery of penicillin in 1928, followed by the use of sulphonamides and 
later the development of streptomycin, tetracycline and chloramphenicol 
ushered in the Golden Age of antibiotic discovery (Clardy et al., 2009). As a 
result, huge progress was made in managing many highly infectious 
diseases (Renwick et al., 2015). Without the treatments that we have in 
place through antibiotics, many of the medical achievements that we take for 
granted today would not be possible (Renwick et al., 2015; Katz and Baltz, 
2016). However, the rise in antibiotic resistance combined with the decline in 
antibiotic discovery has put antibiotic therapy in great jeopardy. Diseases 
and the microbial agents responsible, which were previously thought to be 
controlled by antibiotics are returning with the emergence of multi-drug 
resistance. Consequently, this has placed a significant burden on healthcare 
globally (Wright, 2010; Livermore, 2011; Silver, 2011). Therefore, continued 
discovery and development of new antibiotics is crucial.  
 
Most antibiotics used in the clinic are derived from natural products or 
secondary metabolites obtained predominantly from actinomycetes (Barka et 
al., 2016). Within the Actinobacteria phylum, the soil-dwelling 
streptomycetes are responsible for two-thirds of all the antibiotics used in the 
clinic (Clardy et al., 2006; Barka et al., 2016). Owed to their biochemical 
diversity, potency and selectivity, secondary metabolites remain the lead 
molecules for the development of antibiotics. Even though it was suggested 
that soil might be an exhausted source of antibiotics, genome sequencing 
and genome mining has revealed the untapped wealth of secondary 
metabolites encoded in the genomes of actinomycetes (Challis, 2008b; 
Wright, 2010; Ziemert et al., 2016). Activation of these silent BGCs along 
with understanding the biosynthesis of these compounds will be key in 
tapping into their chemical potential (Wilkinson and Micklefield, 2007).  
 
Chapter 3 describes the generation of a new heterologous host, 
Streptomyces albus S4 D5. Heterologous expression is a cluster-specific 
approach where the BGC of interest is expressed in a genetically amenable 
surrogate host (Zhang et al., 2011; Ongley et al., 2013). It can be a powerful 
tool in isolating the secondary metabolite that is predicted to be encoded by 
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a BGC identified through genome mining. Heterologous expression also 
provides a means to characterise the biosynthetic pathway in a genetically 
tractable host as well as a means to refactor the pathway to generate new 
variants of the compound (Zhang et al., 2011; Ongley et al., 2013). It can 
also aid in optimising the production of a desired compound (Ongley et al., 
2013). Therefore, heterologous hosts represent a valuable tool in antibiotic 
discovery and development efforts.  
 
Five BGCs were rationally targeted and mutated in S. albus S4 to generate 
S. albus S4 D5. S. albus S4 is a relatively fast growing, genetically tractable 
strain with the capability to produce a diverse array of secondary 
metabolites. The BGCs that were mutated encoded the production of two 
antifungal compounds (antimycin and candicidin; (Seipke, Barke, et al., 
2011)) and three previously known antibacterial compounds, which are not 
produced by S. albus S4 under standard laboratory conditions (surugamide, 
albaflavenone and fredericamycin (Seipke, 2015)). The resultant strain, S. 
albus S4 D5 did not exhibit any antifungal or antibacterial activity. The 
abolishment of the production of these compounds will aid in minimising 
rediscovery when bioactivity is observed. With the deletion of these BGCs, a 
significantly less complex chromatographic profile was obtained from the 
chemical extracts, which will ease detection of heterologously produced 
compounds in S. albus S4 D5. The cinnamycin BGC was successfully 
heterologously expressed in S. albus D5, demonstrating its potential as a 
heterologous host. Therefore, in this study (in a multiparty effort with Dr 
Ryan Seipke and Ellie Harris), a new heterologous host was generated, 
which is hoped to be used as a tool that will aid in the discovery and 
development of new and useful chemical entities. 
 
Chapter 4 describes the activation of a silent BGC, which led to the 
identification of surugamides in S. albus S4. The pleiotropic approach of 
varying growth conditions resulted in the production of an antibacterial 
compound(s) in S. albus S4 when grown on mannitol minimal medium (MM) 
agar. Submission of the MSMS data from obtained from the ethyl acetate 
extracts prepared from S. albus S4 grown on MM to the GNPS (Global 
Natural Products Social molecular networking; (Mohimani et al., 2016; Wang 
et al., 2016)) platform revealed the presence of the surugamide A (SA) and 
D within the chemical extract. Surugamides are a group of non-ribosomal 
peptides (NRPs) that were originally isolated from a marine Streptomyces 
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sp. (Takada et al., 2013). The sur BGC encodes the production of the cyclic 
octapeptides surugamides A-E as well as a linear decapeptide named 
surugamide F (SF) (Takada et al., 2013; Ninomiya et al., 2016). SA was 
previously reported to have antibacterial activity against Staphylococcus 
aureus (Wang et al., 2014). In this study, gene inactivation studies were 
used to successfully match surugamides to its BGC in S. albus S4. The 
antibacterial activity seen on MM agar still remained even in the SA 
production mutant. Pleiotropic approaches bring about global changes in the 
cell and as a result, can activate more than one BGC. While pleiotropic 
strategies are high throughput, they offer less control making identification of 
compounds challenging (Rutledge and Challis, 2015). 
 
However, as the bioactivity profile and mechanism of action of SA was 
unknown, it was chosen to be further explored and was therefore 
commercially synthesised. SA did not exhibit any bioactivity against Candida 
albicans or Escherichia coli. The MIC (minimum inhibitory concentration) of 
SA against S. aureus was previously reported to be 9.1223 µg/mL. However, 
in this study the MIC of SA against S. aureus was approximately 28 times 
greater (256 µg/mL) than the reported MIC. In the previous report, SA was 
purified from the microbe itself. The purification process of natural products 
is a challenging and laborious process.  Natural products exist as complex 
matrices and therefore, isolation of specific compounds can be extremely 
challenging (Xiao et al., 2013). As a result, it can sometimes be 
contaminated with other compounds from within the crude chemical extract. 
It is possible that such a contaminant might be responsible for the lower MIC 
of SA that was previously observed. The sur BGC also encodes the 
production of the linear peptide, SF. We therefore hypothesised that SA and 
SF may work synergistically to exert their antibacterial activity. As 
synthesised or purified SF was not available, this hypothesis was tested with 
the structurally similar linear peptide antibiotic gramicidin D. SA and the 
membrane damaging antibiotic gramicidin D did in fact exhibit synergism 
while SA did not demonstrate synergism with either of control compounds 
(CTAB and erythromycin). These results suggest that SA may work 
synergistically with SF. However, this hypothesis still needs to be verified 
with SA and SF themselves. If they do in fact exhibit synergism, to my 
knowledge, this will be the first report of two compounds that are produced 
from the same biosynthetic locus exhibiting such a phenomenon to exert 
their bioactivity. 
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Chapter 5 explores the biosynthetic assembly line release of SA and SF. In 
a canonical non-ribosomal peptide synthetase (NRPS) system, a terminally 
located thioesterase (TE) domain is responsible for the release of the mature 
peptide from the assembly line (Du and Lou, 2010; Süssmuth and Mainz, 
2017). In the absence of a TE domain, a reductase (R) domain or a 
condensation (C) domain has also sometimes been shown to be able to 
release the peptides (Du and Lou, 2010). In the sur BGC, surAD encodes 
the production of the cyclic octapeptides SA-E and surBC encodes the 
production of the linear decapeptide SF (Ninomiya et al., 2016). However, 
both SurD and SurC lack a C-terminally located TE, C or R domains 
(Ninomiya et al., 2016). In this study, two proteins, SurE and SurF were 
investigated for their roles in releasing SA and SF from the biosynthetic 
assembly line.  
 
The gene surE encodes the production of a putative b-lactamase and SurF 
encodes the production of a putative a/b fold containing protein. In this 
study, it was found that SurE was required for the production of both SA and 
SF and that recombinant SurE was able to produce SA from the SA-SNAC 
further confirming its trans-acting assembly line release activity. This study 
also supports the findings of Kuranaga et. al., where SurE was shown to be 
responsible for the release of SB using its SNAC thioester mimic (Kuranaga 
et al., 2018). SurE shares the catalytic residues with penicillin binding 
proteins (PBPs). Together with the findings of Kuranaga et al., this is this the 
first report of a PBP homologue acting as trans-acting release factor in an 
NRPS system. Additionally, in this study, SurF acted similarly to a Type II 
TE, where the production titres of SA and SF were reduced in the absence 
of SurF. NRPs constitute a major class of natural products with diverse 
activities ranging from antibacterials to immunosuppressants (Du and Lou, 
2010; Butler et al., 2013). In the chemical synthesis of NRPs, the cyclisation 
of these peptides pose various challenges. A key bottleneck and one that is 
poorly understood is the substrate fidelity of the C-terminal cis-acting 
thioesterase domains that release the mature peptide from the assembly 
line. Therefore, understanding alternate release mechanisms will provide 
valuable insights for the industrial production of NRPs as well as to 
chemically synthesise derivatives (Sieber and Marahiel, 2003). This study is 
hoped to contribute to the expanding understanding of assembly line release 
mechanisms of NRPs.  
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Actinomycetes, particularly streptomycetes, have long been known to be 
prolific producers of complex secondary metabolites. The genomics era has 
further revealed their chemical potential with the wealth of secondary 
metabolite chemistry that remain to be mined (Nett et al., 2009). With the 
rise in antimicrobial resistance combined with the decline in the antibiotic 
discovery pipeline, there is an urgent need for new antibiotics. The work in 
this thesis is hoped to be a stepping stone in the discovery efforts for new 
antibiotics and to further the understanding of the biosynthesis of some of 
these compounds.  
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Appendices 
Appendix A1 - Primers 
Table A1 List of primers used in this study 
Primer 
name 
Sequence (5’- 3’) Description 
EHP39 caccaggacttcttcacg Verification of S4 
ΔantΔcanΔsurA 
EHP40 gagggagaagaagttgtcgtgg Verification of S4 
ΔantΔcanΔsurA 
EHP35 gtcgtgaatctcctgatcg Verification of S4 
ΔantΔcanΔsurAΔalb 
EHP36 tacggctacctctacatcgacc Verification of S4 
ΔantΔcanΔsurAΔalb 
EHS9 acgc cacctcacgcggcaccggga Protospacer sequence 
for pCRISPomyces-2-
sur 
EHS10 aaac tcccggtgccgcgtgaggtg Protospacer sequence 
for pCRISPomyces-2-
sur 
EHS4 aaac tttctcgcggcggcccggca Protospacer sequence 
for pCRISPomyces-2-
alb 





EHS7 acgc gtacgcctgctccatggaga Protospacer sequence 
for pCRISPomyces-2-
fdm 















Downstream HDR arms 
for pCRISPomyces-2-
sur 
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EHP28  cggcctttttacggttcctggcctctccttcaccgactt
cagc 
Downstream HDR arms 
for pCRISPomyces-2-
sur 
EHP7 tgccgccgggcgttttttatgtgtactggttccgctc Upstream HDR arms for 
pCRISPomyces-2-alb 



























Downstream HDR arms 
for pCRISPomyces-2-
fdm 
DT159 aacgtgtttcacctgggctc surF cosmid screen 
DT160 acggccgaaaagaagggcaa surF cosmid screen 
RFS184 ccattattatcatgacattaa Cos994 insert-end 
sequencing  








REDIRECT primers for 
deleting surE 
DT163a agctggtcatgcagttcgtct Verification of S4 ΔsurE  
DT164a atcgtgggtcaccatcagctc Verification of S4 ΔsurE  
DT167 cggatcacgcgggacggccgaaaagaagggca
agttgtgattccggggatccgtcgacc 




REDIRECT primer for 
deleting surF 
DT169 tcgtcatggtgatgggctcc Verification of S4 ΔsurF  
DT170 gtacagcggggtcagcacg Verification of S4 ΔsurF  
- 149 - 
DT171 acttcctcaaccacaccacg Verification of S4 ΔsurF 
DT172 cggttcaacgtgtttcacct Verification of S4 ΔsurF 
RFS115 cattcttcgcatcccgcct Apramycin resistance 
cassette 










DT208 atcacatatggtgccgatcgaacgcatcaa construction of 
pIJ10257-surF   
DT209 atctaagctttcaggcgcgctgcgcgaaga construction of 
pIJ10257-surF   
DT210 atcacatatggtgggtgccgagggggcgga construction of 
pIJ10257-surE 
DT211 atctaagctttcagagccggtgcatggccc construction of 
pIJ10257-surE   
DT045 tgaccgggaacaccgtgctcac Hygromycin resistance 
cassette 
DT046 cggaaggcgttgagatgcagtt Hygromycin resistance 
cassette 
RFS582 agcccgacccgagcacg pIJ10257 insert 
sequencing primer 
DT206 atctcatatggtgggtgccgagggggcgga Construction of pet28a-
surE, pDB-His-MBP-
surE and pet30a-surE 
DT207 atcactcgaggagccggtgcatggccc Construction of pet30a-
surE 
DT213 atcactcgagtcagagccggtgcatggccc Construction of pet28a-
surE and pDB-His-MBP-
surE 
Restriction endonuclease sites are underlined and Redirect cassette 
sequences are bolded. Sequences in red represent the overlap sequences 
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Figure A2.1 Whole cell bioassays of S. albus S4 against S. aureus 
SH1000 under different cultivation parameters. a) S. albus S4 
grown on MM agar containing 10 mM N-acetylglucosamine. b) S. 
albus S4 grown on MS agar containing 10 mM sodium butyrate. c) S. 
albus S4 grown on MM agar containing 10 mM sodium butyrate. 
Antibacterial activity is seen on MM agar + 10 mM N-acetyl 
glucosamine while the addition of 10 mM sodium butyrate to the MM 
media suppresses the production of the antibacterial compound(s). 
On MS agar containing 10 mM sodium butyrate, no antibacterial 








Figure A2.2 Chemical extracts prepared from S. albus S4 grown on 
MM retained antibacterial activity against S. aureus SH1000. 1: 
Methanol control; 2: Chemical extract prepared from S. albus S4 MM 
agar plates. 

























Figure A2.3 Surugamides A and D were identified by the GNPS 
server in the MSMS data from the chemical extracts of S. 





Figure A2.4 The alignment of the fragmentation pattern of 
surugamide A from the MSMS data of S. albus S4 WT 
chemical extract and SA in the GNPS database 









































Figure A2.5 PCR verification of S. albus S4 DantDcanDsurA. a) 
Verification using primer set EH_P39 and EH_P40. If the region of 
interest is successfully deleted, EPL: 1302 bp, if WT, EPL: 3161 bp. 
b) Checking for the loss of the pCRISPOmyces plasmid by 
checking for the absence apramycin resistance encoding assette. If 
the plasmid is successfully lost, then no product should be seen. If 



















Figure A2.6 Production of surugamide F in ISP2 media compared to 
MM media agar. Production of SF by S. albus S4 is greater in ISP2 
liquid cultures than on MM agar. 
 














































































































Figure A3.2 A schematic arrangement of the surugamide biosynthetic 
gene cluster in S. albus S4. (Genes encoding hypothetical proteins 
are not named) 
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A3.3  
A3.3 Sequence alignment of SurE with FenTE and SurfTE 
 
SurE       VGAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFP 60 
SrfTE      ------------------------------------------------------------ 0 
FenTE      ------------------------------------------------------------ 0 
                                                                        
 
SurE       FGSVTKFLTAELVMQFVCDGDLDLDDPLAGLLPDLGRAADPALGTATVRQLLSHTAGVVD 120 
SrfTE      ------------------------------------------GG----------SDGLQD 8 
FenTE      -----------------------------------AR---SQLS----------AAGEQH 12 
                                                      .          : *  . 
 
SurE       SIEYDEMRGPSYRRFASACARQPALFPPGLAFSYSNTGY--------CLLG-AVIEAASG 171 
SrfTE      VTIMNQDQ-----------EQIIFAFPPVLGYGLMYQNLSSRLPS-YKLCAFDFIEEEDR 56 
FenTE      VIQLNQQG-----------GKNLFCFPPISGFGIYFKDLALQLNHKAAVYGFHFIEEDSR 61 
               ::              :    ***  .:.    .          : .  .**  .  
 
SurE       MDWWTAMDSCLLRPLGIEPAFLHDPRPGQGGATRPVAEGHALRAGGERAERVDHMASLSL 231 
SrfTE      LDR--------------------------------------------------------- 59 
FenTE      IEQ--------------------------------------------------------- 64 
           ::                                                           
 
SurE       AAAGGLVGSATDLVTAARPHLADRKTFAQHDLLPEDAVLAMRTCVPDAEPFGLADGWGLG 291 
SrfTE      ------------------------------------------------------------ 59 
FenTE      ------------------------------------------------------------ 64 
                                                                        
 
SurE       LMRHGTGDGAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLPEAGL 351 
SrfTE      ------------------------------------------------------------ 59 
FenTE      ------------------------------------------------------------ 64 
                                                                        
 
SurE       DVGHYALPVPDSAPLAPDAGHLGTYANGDLELMVTHDAAGDLFLTRESYSDYRLSLHEDD 411 
SrfTE      ------------------------------------------------------------ 59 
FenTE      ------------------------------------------------------------ 64 
                                                                        
 
SurE       LFVARSGEPGALPITGRFVREHPAGPVALLQYGGRAMHRL-------------------- 451 
SrfTE      -------------YADLIQKLQPEGPLTLFGYSAGCSLAFEAAKKLEEQGRIVQRIIMVD 106 
FenTE      -------------YVSRITEIQPEGPYVLLGYSAGGNLAFEVVQAMEQKGLEVSDFIIVD 111 
                         .. : . :* ** .*: *..     :                     
 
SurE       ------------------------------------------------------------ 451 
SrfTE      SYKKQGVSDLDGRTVESDVEALMNVNRDNEALNSEAVKHGLKQKTHAFYSYYVNLISTGQ 166 
FenTE      AYKKDQSITADTE------------NDDSAAYLPEAVRETVMQKKRCYQEYWAQLINEGR 159 
                                                                        
 
SurE       ------------------------------------------------------------ 451 
SrfTE      VKADIDLLTSGADFDM--PEWLASWEEATTGVYRVKRGFGTHAEMLQGETLDRNAEILLE 224 
FenTE      IKSNIHFIEAGIQTETSGAMVLQKWQDAAEEGYAEYTGYGAHKDMLEGEFAEKNANIILN 219 
                                                                        
 
SurE       ------ 451 
SrfTE      FLNTQT 230 
















































Figure A3.4 PCR verification of S4 DsurF-pIJ10257-surF. a) Verification 
using primer set DT169 and 170 checking for an internal fragment of 




















Figure A3.5 PCR verification of S4 DsurE-pIJ10257-surE. a) Verification 
using primer set DT163a and 164a checking for an internal fragment of 
surE. If surE present, EPL: 953 bp 
 










Figure A3.6. Initial expression trial of SurE from pET28a and pET30a 
vectors. SurE expressed from pET28a (a) is predicted to 49764.13 Da 
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3.7 









































































3.7. Expression trial of SurE from
 pET28a and pET30a in autoinduction m
edia and in LB
































































































































































































































































































































              Figure A
3.8 
Figure A
3.8. Expression of SurE from





P vectors in LB







































































































































































































































































































Figure A3.9 Lysis using cell disruptor with the flow through option at 
20 kpsi. His6-MBP-SurE was still present in the insoluble fraction, 
only His6-MBP was found in the soluble fraction. SurE expressed from 
pET28a is expected to be 49764.13 Da, SurE expressed from pDB-
His-MBP is expected to be 91075.76 Da and His6-MBP is expected to 















































Figure A3.10 Lysis using cell disruptor with the OneShot option 
at 27 kpsi. (TP- total protein, IS- insoluble fraction, S- soluble 
fraction). SurE expressed from pET28a is expected to be 
49764.13 Da, His6-MBP-SurE is expected to be 91075.76 Da and 
His6-MBP is expected to be 47550.77 Da. His6-MBP-SurE is 
quite hard to see, but a band of the approximate size can be 
seen in the insoluble fraction. His6-SurE was still present in the 
insoluble fraction, only His6-MBP was found in the soluble 
fraction. 
 















































Figure A3.11 Expression trial of SurE from pET28a and pET30a 
vectors in 2xYT media. SurE expressed from pET28a is 
expected to be 49764.13 Da and SurE expressed from pET30a 
is expected to be 48665.80 Da. SurE expressed from pET28a 
was found in the insoluble fraction. SurE was not expressed 
well from pET30a. 
 






























Figure A3.12. Expression trial of S. albus J1074 SurE 
homologue from pDB-His-MBP from LB quick induction 
media. (TP: total protein, IS- insoluble fraction, S- soluble 
fraction). His6-MBP-J1074-SurE is expected to be 91029.78. 


















































Figure A3.13 7M urea containing lysis buffer yields SurE in the 
soluble fraction. (TP- total protein, IS- insoluble fraction, S- 
soluble fraction). Recombinant His6-SurE is expected to be 
49764.13 Da.  
 



































Figure A3.14. Purification trial of His6-SurE yielded from the 7M 
urea lysis by refolding on the AKTA. Most of the recombinant 
SurE was lost in the FT. His6-SurE is expected to be 49764.13 
Da (IS: insoluble fraction, S: soluble fraction, FT: flow through). 
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   Figure A
3.15 
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A3.16 
A3.16. Sequence alignment of SurF with SrfTEII (PDB: 2RON) and 
RifR (GenBank: AAG5299) The catalytic residues of SrfTEII and 
RifR are bolded in red and is found to be conserved in SurF. The 
hydrolase signature sequence is highlighted. 
 
SurF         VPIERINGIRLHYEESGSGEPVVMVMGSGAGGRSWHLHQVPALRAAGYRVVTFDNRGIPP 60 
RifR         MHRPEAEKWLRRFERAPDAR-ARLVCLPHAGGSASFFFPLAKALAPAVEVLAVQYPGRQ- 58 
SrfTEII      -----MSQLFKSFD--ASEK-TQLICFPFAGGYSASFRPLHAFLQGECEMLAAEPPGHG- 51 
                   .     ::   . . . ::    *** :  :  :        .::: :  *    
 
SurF         TDACAEGFTVDDMVADT---AGLIEHLGLGPCRLVGTSLGAHVAQELCLARPE--LVSQV 115 
RifR         --DRRHEPPVDSIGGLTNRLLEVLRPFGDRPLALFGHSMGAIIGYELALRMPEAGLPAPV 116 
SrfTEII      --TNQ-TSAIEDLEELTDLYKQELNLRPDRPFVLFGHSMGGMITFRLAQKLEREGIFPQA 108 
                      ::.:   *      :.     *  *.* *:*. :  .*.    .  :   . 
 
SurF         ALLATRG------RDDAMRRA-QSRAEREFHDAGGVLTPLYGATVRALQNLSPATLRSEK 168 
RifR         HLFASGRRAPSRYRDDDVRGASDERLVAELRKLGGSD----------------AAMLADP 160 
SrfTEII      VIIS--AIQPPHIQRKKVSHLPDDQFLDHIIQLGGMP----------------AELVENK 150 
              :::         : . :    :.:   .: . **                  * :  :  
 
SurF         EIQDWLDIFEMAPLSGAPGHRAQLGIDMTADRLPAYRRITTPCLVVGFADDLILPAHLGR 228 
RifR         ELLAMV----------LPAIRSDYR-AVETYRHEPGRRVDCPVTVFTGDHDPRVSVGEAR 209 
SrfTEII      EVMSFF----------LPSFRSDYR-ALEQFELYDLAQIQSPVHVFNGLDDKK-CIRDAE 198 
             *:   .           *. *::    :   .     ::  *  *.   .*       .. 
 
SurF         EVADAIPGARYVEVADAGHYGYLERPDQVNNALLDFFAQRA--------- 269 
RifR         AWEEHTTGPADLRVLPGGHFFLVDQAAPMIATMTEKLAGPALTGSTGGNS 259 
SrfTEII      GWKKWAKD-ITFHQFDGGHMFLLSQTEEVAERIFAILNQHPIIQP----- 242 
                .   .   ..   .**   :.:   :   :   :              
A3.17 
A3.17. Sequence alignment of SurE with ACTE (active site residues 
of ACTE are bolded in red) 
 
SurE      GAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFPF 60 
ACTE      ----------------------------------------------------MKRGGYR- 7 
                                                                * *:   
 
SurE      GSVTKFLTAELVMQFVCDGDLDLDDPLAGLLPDLGRAADPALGTATVRQLLSHTAGVVDS 120 
ACTE      -QINKALNISA---F--ENYLDIQH---DHLPKLNDVEQ--L-SPRVLRVLGQNAG---- 51 
           .:.* *. .    *  :. **::.   . **.*. . :  * :  * ::*.:.**     
 
SurE      IEYDEMRGPSYRRFASACARQPALFPPGLAFSYSNTGYC-----LLGAVIEAASGMDWWT 175 
ACTE      -----------------------------KFTLQGTNTYIVGTGRERLIIDTGQGIPEWT 82 
                                        *: ..*.           :*::..*:  ** 
 
SurE      AMDSCLLRPLGIEPA-----------------------------FLHDPRPGQGGATRPV 206 
ACTE      DLISSTLRDSAITLSHVLLTHWHGDHTGGVPDLIRLYPHLSNSIFKHSSSN----GQQPI 138 
           : *. **  .*  :                             * *.       . :*: 
 
SurE      AEGHALRAGGERAE-------RVDHMASLSLAAAGGLVGSATDLVTAARPHLADRKTFAQ 259 
ACTE      IDGQVFHVEGATVRAMHSPGHSHDHMCFILEE---------------------------E 171 
           :*:.::. *  ..         ***. :                              : 
 
SurE      HDLLPEDAVLAMRTCVPDAEPFGLADGWGLGLMRHGTGDGAWYGHDGAVGGASCNLRIHP 319 
ACTE      NAMFTGDNVLGHGT-----SAVEL--------------LGIWMASLRLMQSSGCRVGYPA 212 
          : ::  * **.  *     . . *               * * .    : .:.*.:     
 
SurE      DRSLALALTAN------------------------------STAGPKLWEALVARLPEAG 349 
ACTE      HGAVIADLLAKIAGELDQKARREARVVRTLARNKREEQSKGRSKGSMTVQELVTAMHGKG 272 
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          . ::   * *:                               : *    : **: :   * 
 
SurE      LDVGHYALPVPDSAPLAPDAGHLGTYANGDLELMVTHDAAGDLFLTRESYSDYRLSLHED 409 
ACTE      LDDQVRTMA------LE-------PFINEVL-----GKLAGD------GCVAFEVRRGEK 308 
          **    ::       *         : *  *      . ***      .   :.:   *. 
 
SurE      DLFVARSGEPGALPITGRFVREHPAGPVALLQYGGRAMHRL* 450 
ACTE      RWFIVNDV---------------TSSP--------------- 320 
            *:...                 :.*                
 
 
A3.18 Sequence alignment of SurE with metallo-b-
lactamases. (Bolded in black are the histidine metal binding 
site and in red are the cysteine metal binding sites). 
 
A3.18.1 Sequence alignment of SurE with BcII (a B1 class of 
metallo-b-lactamase, PDB ID: 2BFZ) 
 
SurE      VGAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFP 60 
BcII      ------------------------------------------------------------ 0 
                                                                       
 
SurE      FGSVTKFLTAELVMQFVCDGDLDLDDPLAGLLPDLGRAADPALGTATVRQLLSHTAGVVD 120 
BcII      ------MKKNTLLKVGLCVGLLGTIQFVST----IS---SVQASQKVEKTVIKNETGTIS 47 
                : .  *:   :* * *.  : ::     :.   .   .  . : ::.: :*.:. 
 
SurE      SIEYDEMRGPSYRRFASACARQPALFPPGLAFSYSNTGYCLLGAVIEAASGMDWWTAMDS 180 
BcII      ---ISQLNKNVWVHTELGSFNGEAVPSNGLVLN-TSKGLVLV--------DSSWDDKLTK 95 
              .::.   : :   .. .  *:   **.:. :..*  *:        . .*   : . 
 
SurE      CLLRPLGIEPAFLHDPRPGQGGATRPVAEGHALRAGGERAERVDHMAS------LSLAAA 234 
BcII      ELIEMV--EKKFQK------RVTDVIITHAHADRIGGIKTLKERGIKAHSTALTAELAKK 147 
           *:. :  *  * :        :   ::..** * ** :: :   : :       .**   
 
SurE      GGLVGSATDLVTAARPHLADRKTFAQHDLLPEDAVLAMRTCVPDAEPFGLADGWGLGLMR 294 
BcII      NGYEEPLGDLQTVTNLKFGNM----------------------KVETFYPGKG------H 179 
          .*      ** *.:. ::.:                       ..* *  ..*      : 
 
SurE      HGTGDGAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLPEAGLDVG 354 
BcII      TEDNIVVWLPQYNILVG-GCLVKSTSAKDLGN----VADAYVNEWSTSIENVLKR----- 229 
             .  .*  : . : * .* ::    :.*.      : *  : *.: : .: :       
 
SurE      HYALPVPDSAPLAPDAGHLGTYANGDLELMVTHDAAGDLFLTRESYSDYRLSLHEDDLFV 414 
BcII      -----YRNINAVVPGHGEVGD---------------------------KGLLLHTLDLLK 257 
                 :   :.*. *.:*                              * **  **:  
 
SurE      ARSGEPGALPITGRFVREHPAGPVALLQYGGRAMHRL 451 
BcII      ------------------------------------- 257 
 
 
A3.18.2 Sequence alignment of SurE with CphA (a B2 class of 
metallo-b-lactamase, PDB ID: 1X8G) 
 
SurE      VGAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFP 60 
CphA      -----------------MM----------------------------------------- 2 
                           ::                                          
 
SurE      FGSVTKFLTAELVMQFVCDGDLDLDDPLAGLLPDLGRAADPALGTATVRQLLSHTAGVV- 119 
CphA      ----KGWMKCGL------AGAVVL--------------------------MASFWGGSVR 26 
              . ::.. *       * : *                          : *. .* *  
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SurE      -DSIEYDEMRGPSYRRFASACARQPALFPPGLAFSYSNTGYCLLGAVIEAASGMDWWTAM 178 
CphA      AAGMSLTQVSGPVYVVEDNYY--------------VQENSMVYFGAKGVTVVGATWTPDT 72 
            .:.  :: ** *    .                 .:..   :**   :. *  *     
 
SurE      DSCLL---RPLGIEPAFLHDPRPGQGGATRPVAEGHALRAGGERAERVDHMASLSLAAAG 235 
CphA      ARELHKLIKRVSRK----------------PVLEV------------------------- 91 
             *    : :. :                ** *                           
 
SurE      GLVGSATDLVTAARPHLADRKTFAQHDLLPEDAVLAMRTCVPDAEPFGLADGWGLGLMRH 295 
CphA      ------------------------------------------------------------ 91 
                                                                       
 
SurE      GTGDGAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLPEAGLD--- 352 
CphA      ----------------------------INTNYHTDRAGGNAYWKSIGAKVVSTRQTRDL 123 
                                      :     :: :.*   *::: *:: .:       
 
SurE      -V---------GHYALP-VPDSAPLAPDAGHLGTYANG--DLELMV---THDAAGDLFLT 396 
CphA      MKSDWAEIVAFTRKGLPEYPDLPLVLPNVVHDGDFTLQEGKVRAFYAGPAHTPDGIFVYF 183 
                      : .**  **   : *:. * * ::    .:. :    :*   * :.   
 
SurE      RE---SYSDYRLSLHEDDL-FVARSGEPG--------ALPITGRFVR--EHPAGPVALLQ 442 
CphA      PDEQVLYGNCILKEKLGNLSFADVKAYPQTLERLKAMKLPIKTVIGGHDSPLHGPELIDH 243 
           :    *.:  *. : .:* *.  .. *          ***.  :    .   **  : : 
 
SurE      YGGRAMHRL-- 451 
CphA      YEALIKAAPQS 254 
 
A3.18.3 Sequence alignment of SurE with FEZ1 (a B3 class of 
metallo-b-lactamase, PDB ID: 1K07) 
 
SurE      VGAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFP 60 
FEZ1      ------------------------------------------------------------ 0 
                                                                       
 
SurE      FGSVTKFLTAELVMQFVCDGDLDLDDPLAGLLPDLGRAADP-ALGTATVRQLLSHTAGVV 119 
FEZ1      ---MKKVLSLTALMMVLNHS--SFAYPMPNPFPPFRIAGNLYYVGTDDLASYLIVT---- 51 
             :.*.*:   :* .: ..  .:  *: . :* :  *.:   :**  : . *  *     
 
SurE      DSIEYDEMRGPSYRRFASA-CARQPAL--FPPGLAFSYSNTGYCLLGA-VIEAASGMDWW 175 
FEZ1      -------PRGNIL--INSDLEANVPMIKASIKKLGFKFSDTKILLISHAHFDHAAGSE-- 100 
                  **     : *   *. * :      *.*.:*:*   *:.   :: *:* :   
 
SurE      TAMDSCLLRPLGIEPAFLHDPRPGQGGATRPVAEGHALRAGGERAERVDHMASLSLAAAG 235 
FEZ1      ------LI-------------------------------KQQTKAKYMVMDEDVSVILSG 123 
                *:                                   :*: :    .:*:  :* 
 
SurE      GLVGSATDLVTAARPHLADRKTF-AQH---DLLPEDAVLAMRTCV-P---DAEPFGLADG 287 
FEZ1      G----KSDFHYAN-----DSSTYFTQSTVDKVLHDGERVELGGTVLTAHLTPGHTRGCTT 174 
          *     :*:  *      * .*: :*    .:* :.  : :   *            .   
 
SurE      WGLGLMRHGTGDGAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLP 347 
FEZ1      WTMKLKDHGKQYQAVI-----IGS----IGVNPGYKLVDNI-----TYPKIAE------- 213 
          * : *  **.   *       :*.    : ::*. .*.  :     : **: *        
 
SurE      EAGLDVGHYALPVPDSAPLA-PDAGHLGTYANGDLELMVTHDAAGDLFLTRESYSDYRLS 406 
FEZ1      ----DYKHS-IKVLESMRCDIFLGSHAGMFDLKNKYV-LLQKGQNNPFVDPTGCKNYIE- 266 
              *  *  : * :*       ..* * :   :  : : :.. .: *:   . .:*    
 
SurE      LHEDDLFVARSGEPGALPITGRFVREHPAGPVALLQYGGRAMHRL 451 
FEZ1      QKANDFYTELKKQETA----------------------------- 282 
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A3.19 
A3.19 Sequence alignment of SurE with Class A (TEM-I and 
PSE4), Class C  (AmpC and CMY2) and Class D (OXA2 and 
OXA10) b-lactamases. The catalytic residues SXXK are 
highlighted in red. (PDB IDs: TEM-I- 1BTL, PSE4- 4ID4, AmpC- 
1KE4, CMY2- 1ZC2, OXA2- 1K38, OXA10- 1E3U). 
 
OXA2       -----------MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFS----EFQAKGTIV 45 
OXA10      -------------MKTFAAYVIIACLSS-TALAGSITENTSWNKEFS----AEAVNGVFV 42 
TEMI       MSIQHFRVALIPFFAAFCLP-------VFAHPETL----VKVKDAEDQLG---ARVGYIE 46 
PSE4       ----------MKFLLAFSLLIPS---VVFASSSKFQQVEQDVKAIEVSLS---ARIGVSV 44 
SurE       --------------------------------GAEGAERDAVGALFEELVREHRVTGAQL 28 
AmpC       -----------MFKTTLCALLITASCSTFAA---PQQINDIVHRTITPLIEQQKIPGMAV 46 
CMY2       ----------MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAV 50 
                                                                   *    
 
OXA2       VADERQAD--------RAMLVFDPVRSKKRYSPASTFKIPH---TLFALDAGAVRDEFQI 94 
OXA10      LCKSSS----------KSCATNDLARASKEYLPASTFKIPN---AIIGLETGVIKNEHQV 89 
TEMI       L-DLNSGKI------------LESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGR-- 91 
PSE4       L-DTQNGEY------------W-DYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNPNS-- 88 
SurE       A-VYRDGALSEYATGLASVRTGEPVTPRTGFPFGSVTKFLT------------------- 68 
AmpC       A-VIYQGKPYYFTWGYADIAKKQPVTQQTLFELGSVSKTFT------------------- 86 
CMY2       A-VIYQGKPYYFTWGKADIANNHPVTQQTLFELGSVSKTFN------------------- 90 
                .                        :   *. *                       
 
OXA2       FRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTS 154 
OXA10      FKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGG 149 
TEMI       ---------------RIHYSQNDLVEYSPV---TEKHLTDGMT---VRELCSAAITMSDN 130 
PSE4       ---------------TVEIKKADLVTYSPV---IEKQVGQAIT---LDDACFATMTTSDN 127 
SurE       ---------------------------------------AELV---MQFVCDGDLDLDDP 86 
AmpC       ---------------------------------------GVLG---GDAIARGEIKLSDP 104 
CMY2       ---------------------------------------GVLG---GDAIARGEIKLSDP 108 
                                                               .    .   
 
OXA2       NGDYWIEGSLAISAQ-----------------------------EQIAFLRKL------Y 179 
OXA10      IDKFWLEGQLRISAV-----------------------------NQVEFLESL------Y 174 
TEMI       TAANL------------------------------LLTTIGGPKELTAFLHNMGDHVTRL 160 
PSE4       TAANI------------------------------ILSAVGGPKGVTDFLRQIGDKETRL 157 
SurE       LAGLLPDLGRAADPALGTATVRQLLSHTAGVVDSIEYDEMRGP-S---YRRFAS----AC 138 
AmpC       TTKYWPELTAKQWNGIT---LLHLATYTAGGLPLQVPDEVKSSSD---LLRF-------Y 151 
CMY2       VTKYWPELTGKQWQGIR---LLHLATYTAGGLPLQIPDDVRDKAA---LLHF-------Y 155 
                                                             .          
 
OXA2       RNELP-FRVEHQRLVKDLMIVEAGRNWILRAKTGWEG-------RMGWWVGWVEW-PTGS 230 
OXA10      LNKLS-ASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEK-ETEV 232 
TEMI       DRWEPELNEAIPNDERDTTMPA---AMATTLRKLLTGELLTLASRQQLIDWMEADKVAGP 217 
PSE4       DRIEPDLNEGKLGDLRDTTTPK---AIASTLNKFLFGSALSEMNQKKLESWMVNNQVTGN 214 
SurE       ARQPALFPPGLAFSY-------------SNTGYCLLGAVIEAASGMDWWTAMDS-----C 180 
AmpC       QNWQPAWAPGTQRLY-------------ANSSIGLFGALAVKPSGLSFEQAMQT-----R 193 
CMY2       QNWQPQWTPGAKRLY-------------ANSSIGLFGALAVKPSGMSYEEAMTR-----R 197 
            .                                  *                        
 
OXA2       VFFAL------NIDTPNRMDDL-------------------------------------- 246 
OXA10      YFFAF------NMDIDNESKLP-------------------------------------- 248 
TEMI       LLRS-ALPAGWFIADKSGAGER--GSRGIIAALGPDGKPSRIV---VIYTT--------- 262 
PSE4       LLRS-VLPAGWNIADRSGAGGF--GARSITAVVWSEHQAPIIV---SIYLA--------- 259 
SurE       LLRPLGIEPAFLHDPRPGQGGATRPVAEGHALRAGGERAERVDHMASLSLAAAGGLVGSA 240 
AmpC       VFQPLKLNHTWINVPPAEEKNYAWGYREGKAVHVSPGALD----------AEAYGVKSTI 243 
CMY2       VLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLD----------AEAYGVKSSV 247 
            :                                                           
 
OXA2       ------------------------------------------------------------ 246 
OXA10      ------------------------------------------------------------ 248 
TEMI       ----------------GSQATM-------------------------------------- 268 
PSE4       ----------------QTQASM-------------------------------------- 265 
SurE       TDLVTAARPHLADRKTFAQHDLLPEDAVLAMRTCVPDAEPFGLADGWGLGLMRHGTG--- 297 
AmpC       ED-----------MARWVQSNLKPLDIN---EKTLQQGIQLAQSRYWQTGDMYQGLGWEM 289 
CMY2       ID-----------MARWVQANMDASHVQ---EKTLQQGIALAQSRYWRIGDMYQGLGWEM 293 
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OXA2       ----FKRE--------AIVRAILRSIEALPPNPAVNSDAAR------------------- 275 
OXA10      ----LRK---------SIPTKIMESEGIIGG----------------------------- 266 
TEMI       --------------------------------------------------------DERN 272 
PSE4       --------------------------------------------------------EERN 269 
SurE       -----------------------------------DGAWYGHDGAVGGASCNLRIHPDRS 322 
AmpC       LDWPVNPDSIINGSDNKIALAARPVKAITPPTPAVRASWVHKTGATGGFGSYVAFIPEKE 349 
CMY2       LNWPLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKN 353 
                                                                        
 
OXA2       ------------------------------------------------------------ 275 
OXA10      ------------------------------------------------------------ 266 
TEMI       RQIAEIGASLI-------KHW--------------------------------------- 286 
PSE4       DAIVKIGHSIF-------DVYTSQSR---------------------------------- 288 
SurE       LALALTANSTAG-----PKLWEALVARLPEAGLDVGHYALPVPDSAPLAPDAGHLGTYAN 377 
AmpC       LGIVMLANKNYPNPARVDAAWQILNALQ-------------------------------- 377 
CMY2       LGIVMLANKSYPNPVRVEAAWRILEKLQ-------------------------------- 381 
                                                                        
 
OXA2       ------------------------------------------------------------ 275 
OXA10      ------------------------------------------------------------ 266 
TEMI       ------------------------------------------------------------ 286 
PSE4       ------------------------------------------------------------ 288 
SurE       GDLELMVTHDAAGDLFLTRESYSDYRLSLHEDDLFVARSGEPGALPITGRFVREHPAGPV 437 
AmpC       ------------------------------------------------------------ 377 
CMY2       ------------------------------------------------------------ 381 
                                                                        
 
OXA2       ------------- 275 
OXA10      ------------- 266 
TEMI       ------------- 286 
PSE4       ------------- 288 
SurE       ALLQYGGRAMHRL 450 
AmpC       ------------- 377 
CMY2       ------------- 381 
 
A3.20 Sequence alignment of SurE with Class A and B high 
molecular weight PBPS and class C low molecular 
weight PBPs 
 
A3.20.1 Sequence alignment of SurE with HMW Class A PBPs: 
PBP2 and PBP1b (PBP2- S. aureus, GenBank X62288, PBP1b-  
PDB ID 3FWL) 
 
SurE       ------------------------------------------------------------ 0 
PBP1b      MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRK-GKGKG--KGR 57 
PBP2       ------------------------------------MTEN-KGSSQPKKNGNNGGKSNSK 23 
                                                                        
 
SurE       ------------------------------------------------------------ 0 
PBP1b      KPRGKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDM 117 
PBP2       KNRNVKRTIIKIIGFMIIAFFVVLLLGILL-------FAYYAWKAPAFTEAKLQDPIPA- 75 
                                                                        
 
SurE       ------------------------------------------------------------ 0 
PBP1b      TISKNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDG 177 
PBP2       ------------------------------------------------------------ 75 
                                                                        
 
SurE       ------------------------------------------------------------ 0 
PBP1b      DHLATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHF 237 
PBP2       ---------------KIYDKNGELV--KTLDNGQRHEHVNLKDVPKSMKDAVLATEDNRF 118 
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SurE       -----------------------GAEGAE---RDAVGALFEELVREHRVTG-----AQLA 29 
PBP1b      YEHDGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFL---SSERSYWRKANEAYMA 294 
PBP2       YEHGALDYKRLFGAIGKNLTGGFGSEGASTLTQQVVKDAFL---SQHKSIGRKAQEAYLS 175 
                                    :**.   :: *   *     ..:        * :: 
 
SurE       V-----Y-RDGALSEYATGLASVRTGEPVTPRTGFPFGSVTKFLTAELVMQFVCDGDLDL 83 
PBP1b      LIMDARYSKDRILELYMNEVYLGQSG--DNEIRGFPLASLYYFGRP------VEELSLDQ 346 
PBP2       YRLEQEYSKDDIFQVYLNKIYYSD------GVTGIKAAAKYYFNKD------LKDLNLAE 223 
                 * :*  :. * . :             *:  .:   *         : : .*   
 
SurE       DDPLAGLLPDLG---RAADPA--LGTATVRQLLSHTAGVVDSIEYDEMRG---------- 128 
PBP1b      QALLVGMVKGASIYNPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQ---- 402 
PBP2       EAYLAGLPQVPNNYNIYDHPKAAEDRKNTVLYLMHYHKRITDKQWEDAKKIDLKANLVNR 283 
           :  *.*:    .      .*       .    * :    : .  ::               
 
SurE       ----------------PSYRRFASACARQPALFPPGLAFSYSNTGYCLLGAVIEAASGMD 172 
PBP1b      ---PRGGV----ISPQPAFMQLVRQE------LQAKLGDKV------------KDLSGVK 437 
PBP2       TAEERQNIDTNQDSEYNSYVNFVKSE------LMNNKAFKDENLG-------NVLQSGIK 330 
                            :: .:.         :    . .                **:. 
 
SurE       WWTAMDSCLLRPLGIEP---AF-L------HDPRPG------QGGATRPVAEGHALRAGG 216 
PBP1b      IFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRFSGEVRAMVGGSEPQFAG 497 
PBP2       IYTNMDKDVQKTLQNDVDNGSFYK-----NKDQQVGATILDSKTGGLVAISGGRDFKDVV 385 
            :* :*.                        * . .        *    :  *   :    
 
SurE       ERAERVDHMASLSLAAAGGLVGSATDLVTAARPHLADRKTFAQHDLLPEDAVLAMR-TCV 275 
PBP1b      YN------RAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAP------IALR---Q 542 
PBP2       NR------NQATDPHPTGSSLKPFLAY----GP-AIENMKWATNHA------IQDESSYQ 428 
            .               *.             *      .:  .        :  .     
 
SurE       PDAEPFGLADGWGLGLMRHGTGDGAWYGHDGAVGGASCNLR--IHPDR--SLALALTANS 331 
PBP1b      PNGQVWSP------------QNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLP--- 587 
PBP2       VDGSTF----------------RNYDTKSHGTVSIYDALRQSFNIPALKAWQSVKQNAGN 472 
            :.. :                 .      * *   ..  :    *      ::       
 
SurE       TAGPKLWEALVARLP-----EAGLDVGHYALPVPDSAPLAPDAGHLGTYANGD-LELMVT 385 
PBP1b      -AVTETWIKLGVPK-DQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIA 645 
PBP2       DAPKKFAAKLGLNYEGDIGPSEVLGGSASEFSPTQLASAFAAIANGGTYNNAHSIQKVVT 532 
            *  :    *             :  .   :   : *      .  *.      :. ::: 
 
SurE       HDA--------------------------------------------------AGDLFLT 395 
PBP1b      EDGKVLYQSFPQAERAVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTG----- 700 
PBP2       RDGETIEYDHTSH-KAMSDYTAYMLAE-MLKGTFKPYGSAYGHGVSGVNMGAKTGTGTYG 590 
           .*.                                                  :*      
 
SurE       RESYSDYRLSLHED-DLFV-A--------------------RSGEPGALP----ITGRFV 429 
PBP1b      ---------TTNNNVDTWFAGIDGSTVTITWVGRDNNQPTKLYGASGAMS----IYQRYL 747 
PBP2       AETYSQYNLPDNAAKDVWINGFTPQYTMSVWMGFSKVK---QYGENSFVGHSQQEYPQFL 647 
                      :   * :. .                      *  . :        ::: 
 
SurE       REHPAGPVALLQ---------------------------------------YGGRAMHRL 450 
PBP1b      ANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGMRILPVWTSDPQSLCQQ-----SEMQQQ 802 
PBP2       YENVMSKIS-------SRDGEDFKRPSSVSGSIPSINVSGSQDNNTTNRSTHGGSDTSAN 700 
            ::    :                                                     
 
SurE       ------------------------------------------ 450 
PBP1b      PSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDMFGSN 844 
PBP2       SSGTAQSNNN--------TRSQQS------------------ 716 
                                                      
 
A3.20.2 Sequence alignment of SurE with HMW Class B PBPs: 
PBP2 and PBP2b (PBP2- N. meningitidis, X59628 GenBank,  
PBP2B- UniProtKB Q07868)              
 
SurE      ------------------------------------------------------------ 0 
PBP2B     -MI-------QMPKKNKF---M--NRGAAILSICFALFFFVILGRMAYIQITGKANGEVL 47 
PBP2      MLIKSEYKPRMLPKEEQVKKPMTSNGRISFVLMAIAVLFAGLIARGLYLQTVT---YNFL 57 
                                                                       
 
SurE      ------------------------------------------------------------ 0 
PBP2B     ATKATEQHEKKRTIEASRGSILDRKGKVIAEDTATYKLIAILDKKMTTDVKHPQHVVNKE 107 
PBP2      KEQGDNRIVRTQTLPATRGTVSDRNGAVLALSAPTESLFAVPKEMKEM---------PSA 108 
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SurE      ------------------------------------------------------------ 0 
PBP2B     KTAEALSKVINLDKADILDILNKDAKQVEFGSAGRDITYSQKQKIEKMKLPGISFLRDTK 167 
PBP2      AQLERLSELVDVPVDVLRNKLEQKG--KSFIWIKRQLDPKVAEEVKALGLENFVFEKELK 166 
                                                                       
 
SurE      ----------------GAEGAERDAVGALFEELVREHRVTGAQLAVYRDGALSEYATGLA 44 
PBP2B     RYYPNGVFASNLIGYAEVDEETNEISGAMGLEKVLDKYLKER------DGYVTYESDK-S 220 
PBP2      RHYPMGNLFAHVIGFTNIDGKGQ-----EGLELSREDSLRGE------DGAKVVLRDN-K 214 
                            :   .        *   :. :         **           
 
SurE      SVRTGEPVTPRTGFPFGSVTKFLTAELVMQFVCDGDL--------------DLDDPLAGL 90 
PBP2B     GW-ELPNSKNKITAPKNGDNVYLTIDQKIQTFLEDSMTKVAQKYNPKKIMAAVVDPKTGK 279 
PBP2      GNIVDSLDSPRNSVPKNGQDMILSLDQRIQTLAYDELNKAVAYHKAKAGAVVVLDAQTGE 274 
          .       . :   * ..    *: :  :* .  ..:               : *  :*  
 
SurE      LPDLGRAADPALGTATVRQLLSHTAGVVDSIEYDEMRGPSYRRFASACARQ--------- 141 
PBP2B     VLAMGQR--PSFDPNKR-DVTN---YYNDLISYAYEPGSTMKIFTLAAAMQENVFNANEK 333 
PBP2      ILALVNS--PAYDPNQP-GQANSEQRRNRAVTDMIEPGSAMKPFTIAKALDSGKVDATDT 331 
          :  : .   *: .        .        :      * : : *: * * :          
 
SurE      -----------------------PALFPPGLAFSYSNTGYCLLGAV-------------- 164 
PBP2B     YKSGTFEVGGAPVKDHNNGVGWGPTTYHDGVL-RSSNVAFAKLAKEKLGYDRLNQYLHKF 392 
PBP2      FNTLPYKIGPATVQDTHVY----PTLDVRGIMQKSSNVGTSKLSA-------MFTPKEMY 380 
                                 *:    *:    **.. . *.                 
 
SurE      -----------------IEAASGMDWWTA---MDSCLLRPLGIEPAFLHDPRPGQGGATR 204 
PBP2B     NFYQKTGI------DLPGEVSSKINFKYE---FDKAST-------------AYGQASAVT 430 
PBP2      DFYHDLGVGVRMHSGFPGETAGLLRSWRRWQKIEQATM-------------SFGYGLQLS 427 
                            *.:. :        ::..                 * .     
 
SurE      PVAEGHALRAGGERAERVDHMASLSLAAAGGLVGSATDLVTAARPHLADRKTFAQHDLLP 264 
PBP2B     PIQQIQAA---------------TAIANDGKMM----------------KPYVIDHIVDP 459 
PBP2      LLQLARAY---------------TVLTHDGELL----------------PVSFEKQAVVP 456 
           :   :*                  ::  * ::                   . .: : * 
 
SurE      EDA-------------VLA------MR----TCVPD---AEPFGLADGWGLGLMRHGTGD 298 
PBP2B     DKDKTIYQNKPESAGTPISASTAKKVRDILGEVVTSKIGTGQAYKIEGFDVAGK---TGT 516 
PBP2      K------------GKRVIKASTAKKVRELMVS-VTEAGGTGTAGAVDGFDVGAK---TGT 500 
          .                :       :*      * .   :      :*:.:.     **  
 
SurE      GAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLPEAGLDVGHYALP 358 
PBP2B     AQIAGKGGYLDGTDN--------YIFSFMGMAPKDDPELLIYVAVQQPQL---KAGQSSS 565 
PBP2      ARKLVNGRYVDNK----------HVATFIGFAPAKNPRVIVAVTIDEPTA---NGYY-GG 546 
          .    :.  :..            :   :      .*.:   :.   *      .      
 
SurE      VPDSAPLAPDAGHLGTYANGDLELMV--------------------------------TH 386 
PBP2B     DPVSEIFNPTMKNSLHYLNIEPTEKSDSDKEETKAQTMPDLTDQTVAAAQKKAKEENLTP 625 
PBP2      VVTGPPFKKIMGGSLNILGVSPTKPLTAAAVKTPS------------------------- 581 
             .  :           . .                                        
 
SurE      DAAGDLFLTRESYSDYRL-SLHEDDLFVARSGEPGALPITGRFVREHPAGPVALLQYGGR 445 
PBP2B     IVIGSDVAVKEQYPKADEEVLTNQKVFLKTGGKIKMPDMTGWS-------RREVLQYGEL 678 
PBP2      ------------------------------------------------------------ 581 
                                                                       
 
SurE      AMHRL--------------------------------- 450 
PBP2B     AGIHIEVSGQGYAVSQSVKKDKEIKDKTVIKVKFKNPD 716 
PBP2      -------------------------------------- 581 
                                                 
 
 
A3.20.3. Sequence alignment of SurE with Class C LMW PBPs: 
PBP4*, R61 and ADP (the catalytic residues are bolded in red; 
PDB IDs: PBP4*- 1TVF , R61 D-alanyl-D-alanine 
carboxypeptidase- 1IKI, ADP- 4Y7P) 
 
SurE       ---------------------------------------------VGAEGAERDAVGALF 15 
PBP4*      -----------------------------------------------MKQNKRKHLQTLF 13 
R61        --------------MVSGTVGRGTALGAVLLALLAVPAQAGTAAAADLPAPDDTGLQAVL 46 
ADP        MKTRSQITCASLALLIAGS---SLLYTTQTLIVKAEPTQSVSSSVQTSTQRDRNSVKQAV 57 
                                                              .   :   . 
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SurE       EELVREHRVTGAQLAVYRDGALSEYATGLASVRTGEPVTPRTGFPFGSVTKFLTAELVMQ 75 
PBP4*      ETLGEKHQFNGTVLAAEGGDILYHHSFGYAEMTEKRPLKTNSLFELASLSKPFTALGIIL 73 
R61        HT-ALSQGAPGAMVRVDDNGTIHQLSEGVADRATGRAITTTDRFRVGSVTKSFSAVVLLQ 105 
ADP        RD-TLQLGFPGILAKTSEGGKTWSYAAGVANLSSKKPMKTDFRFRIGSVTKTFTATVVLQ 116 
           .    .    *    .  ..     : * *.    . :.    * ..*::* ::*  ::  
 
SurE       FVCDGDLDLDDPLAGLLPDLGRAADPALGTATVRQLLSHTAGVVDSIEYDEMR------- 128 
PBP4*      LEEKGILGYEDKVDRWLPGFP------YQGVTIRHLLNHTSGLPDYMGWFFANWDS---- 123 
R61        LVDEGKLDLDASVNTYLPGLLP-----DDRITVRQVMSHRSGLYDYTNDMFAQTVPGFES 160 
ADP        LAEENRLNLDDSIEKWLPGVIQGNGYDDKQITIRQLLNHTSGIAEYTRSKSFDLMD---- 172 
           :  .. *. :  :   **..           *:*:::.* :*: :                
 
SurE       --GP--SYRRFASAC--ARQPALFPPGLAFSYSNTGYCLLGAVIEAASGMDWWTAMDSCL 182 
PBP4*      --HKIAVNQDIVDMLMNEGLSGYFEPNEGWMYSNTGYVLLAVIIEKASGMSYADFIKTSI 181 
R61        VRNKVFSYQDLITLSLK--HGVTNAPGAAYSYSNTNFVVAGMLIEKLTGHSVATEYQNRI 218 
ADP        -TKKSYRAEELVKMGIS--MPPDFAPGKSWSYSNTGYVLLGILIETVTGNSYAEEIENRI 229 
                   . :              *. .: ****.: : . :**  :* .     .. : 
 
SurE       LRPLGIEPAFLHDPRPGQGGATRPV---------AEGHALRAGGERAERVDHMASLSLA- 232 
PBP4*      FLPAGMNETRVYNRR-LSPERIDHYAYGYVYDVHSETYVLPDELEETNY-VVY--LDGIQ 237 
R61        FTPLNLTDTFYVHPDTVIPG--TH----------ANGYLTPDEAGGALVDSTEQTVSWAQ 266 
ADP        IEPLELSNTFLPGNSSVIPG--TK---------HARGYIQLDGASE-PKDVTYYNPSMGS 277 
           : *  :  :                         :. :                  .    
 
SurE       AAGGLVGSATDLVTAARPHLADRKTFAQHDLLPEDAVLAMRTCVPDAEPFGLADGWGLGL 292 
PBP4*      GDGTVNSVTSDLFRFDQ-------ALYQDDFISKASKESAFSPVRLN--NGETIDYGFGW 288 
R61        SAGAVISSTQDLDTFFS-------ALMSGQLMSAAQLAQMQQWTT----VNSTQGYGLGL 315 
ADP        SAGDMISTADDLNKFFS-------YLLGGKLLKEQQLKQMLTTVPTG--EAALGRYGLGI 328 
           . * : . : **             :   .::           .           :*:*  
 
SurE       MRHGT-GDGAWYGHDGAVGGASCNLRIHPDRSLALALTANSTAGPKLWEALVARLPEAGL 351 
PBP4*      VLQNSPEKGRIVSHSGGWPGYSTMMIRYIDHRKTLIYLSNKEEDTEYEQAI-LKAAEHIL 347 
R61        RRRDLSCGISVYGHTGTVQGYYTYAFASKDGKRSVTALANTSNNVNVLNTM-ARTLESAF 374 
ADP        YETKLPNGVSIWGHGGSIPGFVTFAGGTLGGKHTLAVNLNSLNA-ESPDPF-KNILLAEF 386 
                       .* *   *         .   ::    *.    :  : :  .     : 
 
SurE       DVGHYALPVPDSAPLAPDAGH------------LGTY------------ANGDLELMVTH 387 
PBP4*      FG------QPYDVPERPADKKKKAIDTAIYSRYVGSYLLQDGTAAQVTTENERLYLEIAG 401 
R61        CG------KPTTAKLRSATSSATTVE-----------------------RHEDIAPGIAR 405 
ADP        SK---------------------------------------------------------- 388 
                                                                        
 
SurE       DAAGDLFLTRESYSDYRLSLHEDDLFVARSGEPGALPITGRFVREHPAGPVALLQYGGRA 447 
PBP4*      QLRLELFPSSE----TR-------FFLRA------LSVEVEFTLGEDAAKSFILYEDGSE 444 
R61        D----------------------------------------------------------- 406 
ADP        ------------------------------------------------------------ 388 
                                                                        
 
SurE       MHRL--- 451 
PBP4*      EEAVRTK 451 
R61        ------- 406 
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A3.21 
A3.21 Sequence alignment of SurE with Class C (subclass B) 
LMW PBPs and Class B b- lactamases. (LMW PBP subclass B: 
PBP4*, R61; Class B b- lactamases: AmpC, CMY2, conserved 
catalytic residues are bolded in red (the conserved H residue is 
replaced by a K residue in Class C b- lactamases);  (PDB IDs: 
PBP4*- 1TVF , R61 D-alanyl-D-alanine carboxypeptidase- 1IKI, 
AmpC- 1KE4, CMY2- 1ZC2) 
 
PBP4*      ---------------------------------MKQNKRKHLQTLFETLGEKHQFNGTVL 27 
SurE       --------------------------------GAEGAERDAVGALFEELVREHRVTGAQL 28 
R61        MVSGTVGRGTALGAVLLALLAVPAQAGTAAAADLPAP-DDTGLQAVLHTALSQGAPGAMV 59 
AmpC       -----------MFKTTLCALLITASCSTFAA---PQQINDIVHRTITPLIEQQKIPGMAV 46 
CMY2       ----------MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAV 50 
                                                  .     .     .:   *  : 
 
PBP4*      AAEGGDILYHHSFGYAEMTEKRPLKTNSLFELASLSKPFTALGIILLEEKGILGYEDKVD 87 
SurE       AVYRDGALSEYATGLASVRTGEPVTPRTGFPFGSVTKFLTAELVMQFVCDGDLDLDDPLA 88 
R61        RVDDNGTIHQLSEGVADRATGRAITTTDRFRVGSVTKSFSAVVLLQLVDEGKLDLDASVN 119 
AmpC       AVIYQGKPYYFTWGYADIAKKQPVTQQTLFELGSVSKTFTGVLGGDAIARGEIKLSDPTT 106 
CMY2       AVIYQGKPYYFTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVT 110 
            .   .     : * *.    . :.    * ..*::* :..         * :  .     
 
PBP4*      RWLPGFPYQ------GVTIRHLLNHTSGLPDYMGWFFAN----WDS--HKIAVNQDIVDM 135 
SurE       GLLPDLGRAADPALGTATVRQLLSHTAGVVDSIE---------YDE--MRGPSYRRFASA 137 
R61        TYLPGLLPDD-----RITVRQVMSHRSGLYDYTNDMFAQTVPGFESVRNKVFSYQDLITL 174 
AmpC       KYWPELTAKQ-----WNGITLLH-----LATYTAGGLPLQVP------DEVKSSSDLLRF 150 
CMY2       KYWPELTGKQ-----WQGIRLLH-----LATYTAGGLPLQIP------DDVRDKAALLHF 154 
              * :            :  :      :                           :    
 
PBP4*      LMNEGLSGYFEPNEGWMYSNTGYVLLAVIIEKASGMSYADFIKTSIFLPAGMNETRVYNR 195 
SurE       C--ARQPALFPPGLAFSYSNTGYCLLGAVIEAASGMDWWTAMDSCLLRPLGIEPAFLHDP 195 
R61        S--LKHGVTNAPGAAYSYSNTNFVVAGMLIEKLTGHSVATEYQNRIFTPLNLTDTFYVHP 232 
AmpC       Y--QNWQPAWAPGTQRLYANSSIGLFGALAVKPSGLSFEQAMQTRVFQPLKLNHTWINVP 208 
CMY2       Y--QNWQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVP 212 
                      *.    *:*:.  : . :    :* .        :: *  :  :      
 
PBP4*      RLSPERIDHY----------AYGYVYDVHSETYVLPDELEETNYVVY------LDGIQGD 239 
SurE       RPG--QGGATRPVAEGHALRAGGERAE--RVDHMASLSL-AAAGGLVGSATDLVTAARPH 250 
R61        DTV--IPGTH----------ANGYLTP--DE----------AGGALVDSTEQTVSWAQSA 268 
AmpC       PAE--EKN-Y----------AWGYREG--KAVHVSPGALDAEAYGVKSTIEDMARWVQSN 253 
CMY2       QNE--QKD-Y----------AWGYREG--KPVHVSPGQLDAEAYGVKSSVIDMARWVQAN 257 
                  .            * *                      :           :   
 
PBP4*      GTVNSVTSDLFRFDQALYQDDFISKASKESAFSPVRLNNGETIDYGFGWVLQNSPEK--- 296 
SurE       LADR------KTFAQ---HDLLPEDAVL-AMRTCVPDAEPFGLADGWGLGLMRHGT---- 296 
R61        GAVISSTQDLDTFFSALMSGQLMSAAQLAQMQQW----TTVNSTQGYGLGLRRRDLSCGI 324 
AmpC       LKPL-----------DINEKTLQQGIQLAQSRYW----QTGDMYQGLGWEMLDWPVNPDS 298 
CMY2       MDAS-----------HVQEKTLQQGIALAQSRYW----RIGDMYQGLGWEMLNWPLKADS 302 
                                : .                     * *  :          
 
PBP4*      ---------------------------GRIVSHSGGWPGYSTMMIRYIDHRKTLIYLSNK 329 
SurE       -------------------------GDGAWYGHDGAVGGASCNLRIHPDRSLALALTANS 331 
R61        SVYG----------------------------HTGTVQGYYTYAFASKDGKRSVTALANT 356 
AmpC       IINGSDNKIALAARPVKAITPPTPAVRASWVHKTGATGGFGSYVAFIPEKELGIVMLANK 358 
CMY2       IINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANK 362 
                                           : *   *         :    :   :*. 
 
PBP4*      EEDTEYEQ-AILKAAEHILFGQPYDVPERPADK----KKKAIDTAIYSRYVGSYLLQDGT 384 
SurE       TAGPK-----LWEALVARLPEA----GLDVGH-YALPVPDSAPLAPDAGHLGTYA----- 376 
R61        SNNVNV-LNTMARTLESAFCGKPTTAKLRSATSSATTVERHEDIAPGI------------ 403 
AmpC       NYPNPARVDAAWQILNA----------LQ------------------------------- 377 
CMY2       SYPNPVRVEAAWRILEK----------LQ------------------------------- 381 
                       .                                                
 
PBP4*      AAQVTTENERLYLEIAGQLRLELFPSSETRFFLR-ALSVEVEFTLGEDAAKSFILYEDGS 443 
SurE       ---------------NGDLELMVTHDAAGDLFLTRESYSDYRLSLHED--DLFVA-RSG- 417 
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R61        -----------------------ARD---------------------------------- 406 
AmpC       ------------------------------------------------------------ 377 
CMY2       ------------------------------------------------------------ 381 
                                                                        
 
PBP4*      EEEAV-------RTK------------------ 451 
SurE       EPGALPITGRFVREHPAGPVALLQYGGRAMHRL 450 
R61        --------------------------------- 406 
AmpC       --------------------------------- 377 
CMY2       --------------------------------- 381 
 
 
